US20230348984A1 - Methods for multiplex detection of alleles associated with ophthalmic conditions - Google Patents
Methods for multiplex detection of alleles associated with ophthalmic conditions Download PDFInfo
- Publication number
- US20230348984A1 US20230348984A1 US18/064,444 US202218064444A US2023348984A1 US 20230348984 A1 US20230348984 A1 US 20230348984A1 US 202218064444 A US202218064444 A US 202218064444A US 2023348984 A1 US2023348984 A1 US 2023348984A1
- Authority
- US
- United States
- Prior art keywords
- seq
- sequence
- detection
- months
- amplification primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 114
- 238000001514 detection method Methods 0.000 title claims description 304
- 108700028369 Alleles Proteins 0.000 title abstract description 19
- 239000002773 nucleotide Substances 0.000 claims abstract description 114
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 113
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 112
- 239000000758 substrate Substances 0.000 claims abstract description 69
- 206010011005 corneal dystrophy Diseases 0.000 claims abstract description 66
- 108020004414 DNA Proteins 0.000 claims abstract description 58
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims abstract description 56
- 230000009089 cytolysis Effects 0.000 claims abstract description 56
- 108091092584 GDNA Proteins 0.000 claims abstract 7
- 239000000523 sample Substances 0.000 claims description 348
- 230000035772 mutation Effects 0.000 claims description 82
- 230000003321 amplification Effects 0.000 claims description 78
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 64
- 239000011541 reaction mixture Substances 0.000 claims description 23
- 239000012472 biological sample Substances 0.000 claims description 18
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 9
- 210000002919 epithelial cell Anatomy 0.000 claims description 8
- 230000008826 genomic mutation Effects 0.000 claims description 2
- 238000013019 agitation Methods 0.000 abstract description 12
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 77
- 239000002751 oligonucleotide probe Substances 0.000 description 77
- 150000007523 nucleic acids Chemical group 0.000 description 54
- 239000000243 solution Substances 0.000 description 51
- 102000039446 nucleic acids Human genes 0.000 description 48
- 108020004707 nucleic acids Proteins 0.000 description 48
- 238000003753 real-time PCR Methods 0.000 description 41
- 239000003153 chemical reaction reagent Substances 0.000 description 39
- 102200040258 rs121909208 Human genes 0.000 description 34
- 102200040436 rs121909211 Human genes 0.000 description 34
- 102200040434 rs121909210 Human genes 0.000 description 33
- 102200040405 rs121909211 Human genes 0.000 description 33
- 208000028431 granular corneal dystrophy 2 Diseases 0.000 description 32
- 201000004183 granular corneal dystrophy type II Diseases 0.000 description 32
- 102200040253 rs121909209 Human genes 0.000 description 31
- 238000011269 treatment regimen Methods 0.000 description 26
- 230000000875 corresponding effect Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 230000002441 reversible effect Effects 0.000 description 21
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 20
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 17
- 238000000605 extraction Methods 0.000 description 16
- 230000007704 transition Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 201000004889 corneal granular dystrophy Diseases 0.000 description 12
- 208000014706 granular corneal dystrophy Diseases 0.000 description 12
- 108700006666 betaIG-H3 Proteins 0.000 description 11
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 201000004225 Thiel-Behnke corneal dystrophy Diseases 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 239000012139 lysis buffer Substances 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 7
- 208000026350 Inborn Genetic disease Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229920000297 Rayon Polymers 0.000 description 7
- 230000001351 cycling effect Effects 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 239000002964 rayon Substances 0.000 description 7
- 230000004393 visual impairment Effects 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000016361 genetic disease Diseases 0.000 description 6
- 230000007614 genetic variation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- IJSMFQNTEUNRPY-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-5-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(N=C=S)C=C1C([O-])=O IJSMFQNTEUNRPY-UHFFFAOYSA-N 0.000 description 2
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 2
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 2
- ZEKAXIFHLIITGV-UHFFFAOYSA-N 7-methoxycoumarin-4-acetic acid Chemical compound OC(=O)CC1=CC(=O)OC2=CC(OC)=CC=C21 ZEKAXIFHLIITGV-UHFFFAOYSA-N 0.000 description 2
- 208000033931 Blepharophimosis-ptosis-epicanthus inversus syndrome Diseases 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000001826 Marfan syndrome Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 201000011252 Phenylketonuria Diseases 0.000 description 2
- 201000004223 Reis-Bucklers corneal dystrophy Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002430 laser surgery Methods 0.000 description 2
- 208000028485 lattice corneal dystrophy type I Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- AYDAHOIUHVUJHQ-UHFFFAOYSA-N 1-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)pyrrole-2,5-dione Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2N1C(=O)C=CC1=O AYDAHOIUHVUJHQ-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- DAKRRPZULHQSKP-UHFFFAOYSA-N 1-oxospiro[2-benzofuran-3,16'-3-oxa-9,23-diazaheptacyclo[17.7.1.15,9.02,17.04,15.023,27.013,28]octacosa-1(27),2(17),4(15),5(28),13,18-hexaene]-5-carboxylic acid Chemical compound C1CCN2CCCC(C=C3C4(OC(=O)C5=CC=C(C=C54)C(=O)O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 DAKRRPZULHQSKP-UHFFFAOYSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- UMTZYGZMIJRCFG-UHFFFAOYSA-N 3-phenyldioxetane Chemical compound C1OOC1C1=CC=CC=C1 UMTZYGZMIJRCFG-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- GGMFTOCYWNYUSU-UHFFFAOYSA-N 5-(5-aminopentylcarbamoyl)-2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(=O)NCCCCCN)C=C1C([O-])=O GGMFTOCYWNYUSU-UHFFFAOYSA-N 0.000 description 1
- MDGNQWAJTIGWLE-UHFFFAOYSA-N 5-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2NC1=NC(Cl)=NC(Cl)=N1 MDGNQWAJTIGWLE-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- WHCPTFFIERCDSB-UHFFFAOYSA-N 7-(diethylamino)-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=CC(N(CC)CC)=CC=C21 WHCPTFFIERCDSB-UHFFFAOYSA-N 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007918 Cellulitis orbital Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241001608562 Chalazion Species 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010510 Congenital hypothyroidism Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 201000000913 Duane retraction syndrome Diseases 0.000 description 1
- 208000020129 Duane syndrome Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 206010061842 Entropion Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062028 Keratitis bacterial Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000000493 Orbital Cellulitis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 208000019222 Poland syndrome Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000027077 Stickler syndrome Diseases 0.000 description 1
- 208000018434 Stromal corneal dystrophy Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 206010044604 Trichiasis Diseases 0.000 description 1
- 206010068233 Trimethylaminuria Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000007960 WAGR syndrome Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical group OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000003079 ectropion Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000009624 holoprosencephaly Diseases 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- UATCLPJEZJKNHE-UHFFFAOYSA-N n-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)-2-iodoacetamide Chemical compound O1C(=O)C2=CC(NC(=O)CI)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 UATCLPJEZJKNHE-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000007909 oculocutaneous albinism Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 229940021506 stye Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- OVTCUIZCVUGJHS-VQHVLOKHSA-N trans-dipyrrin Chemical compound C=1C=CNC=1/C=C1\C=CC=N1 OVTCUIZCVUGJHS-VQHVLOKHSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- This application generally relates to methods for the isolation and detection of disease-associated genetic alleles.
- this application relates to an improved method for the detection of an Avellino corneal dystrophy associated allele.
- Real-time PCR can be used to detect differences between nucleic acid sequences having substantially identical sequences.
- differentially labeled fluorescent nucleic acid probes for example one that binds to a wild type sequence and one that binds to a mutant sequence, single nucleotide changes in the human genome can be quickly and reliably detected.
- This resolving power has been applied to medical diagnostics, where single nucleotide polymorphisms (SNPs), i.e., single base changes found within the coding and/or non-coding sequence of a protein, are correlated to human disease.
- SNPs single nucleotide polymorphisms
- real-time PCR analysis is highly dependent upon the collection and isolation of high quality samples. Poor sample collection and/or isolation require the use of longer assay conditions and greater amounts of real-time PCR reagents, both of which result in increased costs and reduced productivity. Furthermore, failure of a real-time PCR single nucleotide polymorphism detection assay can result in the need to collect additional samples, causing even greater loss in time and resources.
- Corneal dystrophy can be an autosomal dominant hereditary disease, which initially presents with blurred vision in the center of a patient's cornea. The blurry vision gradually spreads toward the perimeter of cornea, worsening the patient's vision as they age.
- corneal dystrophy There are several types of corneal dystrophy that have been characterized, including Avellino corneal dystrophy, Granular corneal dystrophy, lattice type I corneal dystrophy, Thiel-Behnke, and Reis-bucklers corneal dystrophy.
- Corneal dystrophies are known to be caused, at least in some cases, by mutations in the transforming growth factor beta induced (TGF ⁇ I) gene encoding the ⁇ IG-H3 protein (also known as TGF ⁇ I protein, TGFBI protein, and keratoepithelin).
- TGF ⁇ I transforming growth factor beta induced
- Avellino corneal dystrophy Heterozygous patients suffering from Avellino corneal dystrophy have increasing loss in vision with age, becoming severe in the later years of life. Homozygous patients, in contrast, present with severe to complete loss of vision by six years of age. Avellino corneal dystrophy was first recognized as a distinct type of corneal dystrophy around 1988. Prior to then, it was likely misclassified as Granular corneal dystrophy. Today, Avellino corneal dystrophy is known to be the most common form of stromal corneal dystrophy world-wide. In Korea, Avellino corneal dystrophy is believed to have a prevalence around 1 in 870 people (see Lee, J. H.
- Avellino corneal dystrophy is required to prevent the progression of Avellino corneal dystrophy by LASIK surgery
- diagnosis of Avellino corneal dystrophy is just conducted by microscopic observation (e.g., slit-lamp examination) of corneal opacity and thus often doctors miss latent symptoms of patients to perform LASIK surgery, which results in vision loss. Therefore, rapid and precise genetic diagnosis of corneal dystrophy is desirable.
- the diagnosis of Avellino corneal dystrophy using the DNA chip disadvantageously requires several steps, including a step of amplifying DNA in a sample, a step of hybridizing the amplified DNA with the DNA chip, a step of washing the hybridized DNA chip, and a step of detecting a positive response.
- the present disclosure provides improved methods for the detection of one or more alleles associated with human disease.
- the methods described below decrease the time and cost associated with performing assays that yield medical information about a subject.
- the improved methods allow for same-day detection of a genomic marker associated with Avellino corneal dystrophy, at a reduced cost to the patient.
- the present disclosure provides methods for detecting at least two genomic alleles associated with corneal dystrophy in a sample from a subject, the method comprising: (A) providing epithelial cells of a subject adhered to a tip of a substrate; (B) agitating the tip of the substrate in a lysis solution that lyses cells adhered to the substrate; (C) removing the substrate from the lysis solution upon completion of the agitating (B); (D) incubating the lysis solution after the removing (C); (E) isolating genomic DNA from the lysis solution to form a gDNA solution; and (F) determining an identity of at least two nucleotides present in the TGF ⁇ I gene using at least two oligonucleotide primer pairs and the gDNA solution, wherein the at least two nucleotides are located at respective independent positions of the TGF ⁇ I gene corresponding to respective independent single nucleotide polymorphisms (SNPs) associated with corneal dystrophy.
- SNPs
- the at least two nucleotides present in the TGF ⁇ I gene are separated in the human genome by at least one nucleotide.
- At least one pair of the at least two oligonucleotide primer pairs comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:1 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:2.
- At least one pair of the at least two oligonucleotide primer pairs comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:43 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:44.
- the at least two oligonucleotide primer pairs comprise a first amplification primer pair and a second amplification primer pair.
- the first amplification primer pair comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:1 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:2.
- the second amplification primer pair comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:43 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:44.
- the determining (F) further comprises using: (i) a first wild type detection probe having a nucleotide sequence comprising SEQ ID NO:25 and a first mutant detection probe having a nucleotide sequence comprising SEQ ID NO:26, SEQ ID NO:48, or SEQ ID NO:49; and (ii) a second wild type detection probe having a nucleotide sequence comprising SEQ ID NO:45 or SEQ ID NO:47 and a second mutant detection probe having a nucleotide sequence comprising SEQ ID NO:46 or SEQ ID NO:50.
- the present disclosure provides a method for detecting corneal dystrophy, the method comprising: (A) amplifying at least two TGF ⁇ I gene sequences, including a first TGF ⁇ I gene sequence comprising nucleotides encoding amino acid residue 124 and a second TGF ⁇ I gene sequence comprising nucleotides encoding amino acid residue 555, from a biological sample from a human subject using a reaction mixture comprising at least a first amplification primer pair and at least a second amplification primer pair; (B) hybridizing a first detection probes of a first detection oligonucleotide probe pair to the first TGF ⁇ I gene sequence; (C) hybridizing a second detection probe of a second detection oligonucleotide probe pair to the second TGF ⁇ I gene sequence; and (D) detecting one or more mutations in the first TGF ⁇ I gene sequence and/or the second TGF ⁇ I gene sequence based on a use of at least two detection probe pairs, including the first detection oli
- detecting the one or more mutations in the first TGF ⁇ I gene sequence and/or the second TGF ⁇ I gene sequence includes detecting two or more mutations in the first TGF ⁇ I gene sequence and/or the second TGF ⁇ I gene sequence and the two or more mutations are separated in the human genome by at least one nucleotide.
- the at least first amplification primer pair comprises a first amplification primer and a second amplification primer, wherein the first amplification primer comprises nucleotide sequence SEQ ID NO:1 and wherein the second amplification primer comprises nucleotide sequence SEQ ID NO:2.
- the at least second amplification primer pair comprises a third amplification primer and a fourth amplification primer, wherein the third amplification primer is represented by nucleotide sequence SEQ ID NO:43, and wherein the fourth amplification primer is represented by nucleotide sequence SEQ ID NO:44.
- the first amplification primer pair comprises a first amplification primer and a second amplification primer
- the first amplification primer comprises nucleotide sequence SEQ ID NO:1
- the second amplification primer comprises nucleotide sequence SEQ ID NO:2
- the second amplification primer pair comprises a third amplification primer and a fourth amplification primer
- the third amplification primer comprises nucleotide sequence SEQ ID NO:43
- the fourth amplification primer comprises nucleotide sequence SEQ ID NO:44.
- one of the one or more mutations corresponds to, at amino acid 124, arginine mutated to a cysteine (R124C), arginine mutated to a histidine (R124H), and/or arginine mutated to a leucine (R124L) in the encoded TGFBI protein.
- one of the one or more mutations corresponds to, at amino acid 555, arginine mutated to a tryptophan (R555W) and/or arginine mutated to a glutamine (R555Q) in the encoded TGFBI protein.
- each of the at least two detection oligonucleotide probe pairs individually includes a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe comprise a nucleotide sequence pair individually selected from the group consisting of SEQ ID NOs:25-26, SEQ ID NOs:25 and 48, SEQ ID NOs:25 and 49, SEQ ID NOs:27-28, SEQ ID NOs:29-30, SEQ ID NOs:31-32, SEQ ID NOs:33-34, SEQ ID NOs:35-36, SEQ ID NOs:37-38, SEQ ID NOs:39-40, SEQ ID NOs:41-42, SEQ ID NOs:45-46 and SEQ ID NOs:46-47, SEQ ID NOs: 45 and 50, and SEQ ID NOs: 47 and 50.
- the first detection oligonucleotide probe pair comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:26.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:46.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:46.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:48.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:49.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:50.
- the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:50.
- the first detection probe is coupled with a first label and the second detection probe is coupled to a second label.
- the first label is VIC and the second label is FAM.
- the hybridizing (B) and the hybridizing (C) are performed concurrently in a same solution.
- the hybridizing (B) and the hybridizing (C) are performed concurrently or at different time in a same solution or different solutions.
- the present disclosure provides a reaction mixture for detecting corneal dystrophy in a human subject, the reaction mixture comprising: (A) at least a first amplification primer pair and a second amplification primer pair for amplifying and determining (1) a first TGF ⁇ I gene sequence of at least two TGF ⁇ I gene sequences that comprises nucleotides encoding amino acid residue 124 from a biological sample from the subject and (2) a second TGF ⁇ I gene sequence of the at least two TGF ⁇ I gene sequences that comprises nucleotides encoding amino acid residue 555 from a biological sample from the subject; and (B) at least two detection probe pairs, wherein a detection probe in each of the at least two detection probe pairs hybridizes to at least one of the at least two TGF ⁇ I gene sequences.
- the first amplification primer pair comprises a first amplification primer and a second amplification primer
- the first amplification primer comprises a nucleotide sequence SEQ ID NO:1
- the second amplification primer comprises a nucleotide sequence SEQ ID NO:2.
- the second amplification primer pair comprises a third amplification primer and a fourth amplification primer
- the third amplification primer comprises a nucleotide sequence SEQ ID NO:43
- the fourth amplification primer comprises a nucleotide sequence SEQ ID NO:44.
- At least one of the at least two detection probe pairs is used to detect a mutation that corresponds to, at amino acid 124, arginine mutated to a cysteine (R124C), arginine mutated to a histidine (R124H), and/or arginine mutated to a leucine (R124L) in the encoded TGFBI protein.
- R124C arginine mutated to a cysteine
- R124H arginine mutated to a histidine
- R124L arginine mutated to a leucine
- At least one of the at least two detection probe pairs is used to detect a mutation that corresponds to, at amino acid 555, arginine mutated to a tryptophan (R555W) and/or arginine mutated to a glutamine (R555Q) in the encoded TGFBI protein.
- respective detection probe pairs of the at least two detection probe pairs individually include a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe comprise a nucleotide sequence pair individually selected from the group consisting of SEQ ID NOs:25-26, SEQ ID NOs:25 and 48, SEQ ID NOs:25 and 49, SEQ ID NOs:27-28, SEQ ID NOs:29-30, SEQ ID NOs:31-32, SEQ ID NOs:33-34, SEQ ID NOs:35-36, SEQ ID NOs:37-38, SEQ ID NOs:39-40, SEQ ID NOs:41-42, SEQ ID NOs: 45-46 and SEQ ID NOs: 46-47, SEQ ID NOs: 45 and 50, and SEQ ID NOs: 47 and 50.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:26.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:46.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:46.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:48.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:49.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:50.
- one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:50.
- a first detection probe of the at least two detection probes is coupled with a first label and a second detection probe of the at least two detection probes is coupled to a second label.
- the first label is VIC and the second label is FAM.
- the present disclosure provides a reaction mixture for detecting corneal dystrophy in a human subject, the reaction mixture comprising: (A) at least a first amplification primer pair for amplifying and determining a TGF ⁇ I gene sequence from a biological sample from the subject; and (B) a set of at least three detection probes, wherein one detection probe of the set of at least three detection probes hybridizes to the TGF ⁇ I gene sequence when exposed to the TGF ⁇ I gene sequence.
- the TGF ⁇ I gene sequence comprises nucleotides encoding amino acid residue 124 from the biological sample from the subject.
- the set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- the set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- the set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- the set of at least three detection probes include a first detection probe SEQ ID NO:25 and a second detection probe SEQ ID NO:26.
- the set of at least three detection probes include a third detection probe selected from the group consisting of SEQ ID NO:48 and SEQ ID NO:49.
- the set of at least three detection probes include a fourth detection probe that is distinct from the third detection probe and that is selected from the group consisting of SEQ ID NO:48 and SEQ ID NO:49.
- the set of at least three detection probes include two or more detection probes selected from the group consisting of SEQ ID NOs:26 and 48-49.
- the first amplification primer pair comprises a first amplification primer and a second amplification primer
- the first amplification primer comprises a nucleotide sequence SEQ ID NO:1
- the second amplification primer comprises a nucleotide sequence SEQ ID NO:2.
- the reaction mixture further comprises: (C) at least a second amplification primer pair for amplifying and determining a second TGF ⁇ I gene sequence from the biological sample; and (D) a second set of at least three detection probes, wherein one detection probe of the second set of at least three detection probes hybridizes the second TGF ⁇ I gene sequence when exposed to the second TGF ⁇ I gene sequence.
- the second TGF ⁇ I gene sequence comprises nucleotides encoding amino acid residue 555 from the biological sample from the subject.
- the second set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- the second set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- the second set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- the second set of at least three detection probes include a first detection probe that is SEQ ID NO:45 or SEQ ID NO:47, a second detection probe that is SEQ ID NO:46, and a third detection probe that is SEQ ID NO:50.
- the second amplification primer pair comprises a third amplification primer and a fourth amplification primer
- the third amplification primer comprises a nucleotide sequence SEQ ID NO:43
- the fourth amplification primer comprises a nucleotide sequence SEQ ID NO:44.
- the TGF ⁇ I gene sequence comprises nucleotides encoding amino acid residue 555 from the biological sample from the subject.
- the set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs:45-47 and 50.
- the set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- the set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- the set of at least three detection probes include a first detection probe that is SEQ ID NO:45 or SEQ ID NO:47, a second detection probe that is SEQ ID NO:46, and a third detection probe that is SEQ ID NO:50.
- the present disclosure provides a method for detecting corneal dystrophy comprising: (A-1) amplifying a first TGF ⁇ I gene sequence from a biological sample from a human subject using a reaction mixture comprising at least a first amplification primer pair and a set of at least three detection probes; (B-1) hybridizing a first detection probe of the set of at least three detection probes to the first TGF ⁇ I gene sequence; and (C-1) detecting a mutation in the first TGF ⁇ I gene sequence based on (i) the hybridization of the first detection probe of the set of at least three detection probes to the first TGF ⁇ I gene sequence and (ii) the failure of a second and a third detection probe of the set of at least three detection probes to hybridize to first TGF ⁇ I gene sequence.
- the method further comprises: (A-2) amplifying a second TGF ⁇ I gene sequence from the biological sample using the same reaction mixture, wherein the reaction mixture comprises at least a second amplification primer pair and a second set of at least three detection probes; (B-2) hybridizing a first detection probe of the second set of at least three detection probes to the second TGF ⁇ I gene sequence; and (C-2) detecting a mutation in the second TGF ⁇ I gene sequence based on (i) the hybridization of the first detection probe of the second set of at least three detection probes to the first TGF ⁇ I gene sequence and (ii) and (ii) the failure of a second detection probe and a third detection probe of the second set of at least three detection probes to hybridize to the second TGF ⁇ I gene sequence.
- the amplifying (A-1), the amplifying (A-2), the hybridizing (B-1), the hybridizing (B-2), the detecting (C-1), and the detecting (C-2) are performed with a same aliquot of the biological sample.
- the amplifying the first TGF ⁇ I gene sequence (A-1) and the amplifying the second TGF ⁇ I gene sequence (A-2) are performed concurrently.
- the hybridizing (B-1) and the hybridizing (B-2) are performed concurrently.
- the detecting (C-1) and the detecting (C-2) are performed concurrently.
- the reaction mixture has some of the features described above. For brevity, such details are not repeated herein.
- the present disclosure provides use of a reaction mixture, as recited in any above, for predicting the risk of complication following laser eye surgery in a subject through a detection of heterozygous corneal dystrophy in the human subject.
- the laser eye surgery comprises one of Lasik and Excimer laser surgery.
- the present disclosure provides a method for detecting a genomic mutation associated with corneal dystrophy in a sample from a human subject, the method comprising: (A) providing epithelial cells of a human subject adhered to a tip of a substrate; (B) agitating the tip of the substrate in a lysis solution that lyses cells adhered to the substrate; (C) removing the substrate from the lysis solution upon completion of the agitating (B); (D) incubating the lysis solution after the removing (C); (E) isolating genomic DNA from the lysis solution to form a gDNA solution; and (F) determining an identity of at least a nucleotide present in the TGF ⁇ I gene using at least a first primer pair, a set of at least three detection probes, and the gDNA solution by concurrently exposing the gDNA solution to the at least three detection probes, wherein: the at least a nucleotide is located at a particular position of the TGF ⁇ I gene
- the method further comprises: (G) determining an identity of at least a second nucleotide present in the TGF ⁇ I gene using at least a second primer pair, a second set of at least three detection probes, and the gDNA solution by concurrently exposing the gDNA solution to the set of at least three detection probes and the second set of at least three detection probes, wherein: the at least a second nucleotide is located at a second particular position, independent of the position of the at least a nucleotide, of the TGF ⁇ I gene corresponding to a second single nucleotide polymorphism (SNPs) associated with corneal dystrophy, and at least two detection probes of the second set of the at least three detection probes are configured to detect a respective mutation at the second particular position of the TGF ⁇ I gene.
- SNPs single nucleotide polymorphism
- the determining (F) and the determining (G) are performed concurrently.
- the determining (F) and the determining (G) are performed using the same gDNA solution.
- FIGS. 1 A- 1 B illustrate an improved method 100 for the detection of genomic alleles associated with disease, according to some embodiments.
- FIG. 2 provides a list of sequences for forward and reverse PCR primer pairs (SEQ ID NOs:1-24) useful for real-time PCR detection of a single nucleotide polymorphism associated with Avellino corneal dystrophy, in accordance with some embodiments.
- FIG. 3 provides a list of sequences for wild type and mutant detection probe pairs (SEQ ID NOs:25-42) useful for real-time PCR detection of a single nucleotide polymorphism associated with Avellino corneal dystrophy, in accordance with some embodiments.
- FIG. 4 provides a list of the probe sequences and primers used in the allele detection experiments shown in FIGS. 5 through 8 .
- FIGS. 5 A, 5 B, and 5 C provide experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described in FIG. 4 .
- FIG. 5 A provides an allelic discrimination plot run (left-hand panel) using the indicated reagent mixture and indicated cycling conditions (right-hand panel).
- FIG. 5 B provides the Real-Time PCR plots for the various mutants compared to a normal control.
- FIG. 5 C provides the Real-Time PCR plots for the various mutants compared to a homozygous control.
- FIGS. 6 A, 6 B, and 6 C provide experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described in FIG. 4 .
- FIG. 6 A provides an allelic discrimination plot run (left-hand panel) using the indicated reagent mixture and indicated cycling conditions (right-hand panel).
- FIG. 6 B provides the Real-Time PCR plots for the various mutants compared to a normal control.
- FIG. 6 C provides the Real-Time PCR plots for the various mutants compared to a homozygous control.
- FIG. 7 provides experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described in FIG. 4 .
- FIG. 7 provides an allelic discrimination plot (left-hand panel) run using the indicated reagent mixture and indicated cycling conditions (right-hand panel).
- FIG. 8 provides experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described in FIG. 4 .
- FIG. 8 provides an allelic discrimination plot run using the indicated reagent mixture and indicated cycling conditions (right-hand panel).
- the designation “B” in the allelic discrimination plot (left-hand panel) indicates samples were pre-treated with lysis buffer prior to performing the Real-Time PCR assay.
- the designation “DW-A” in the allelic discrimination plot (left-hand panel) indicates samples were pre-treated with distilled water prior to performing the Real-Time PCR assay.
- the circles surrounding the different sample dots show the two matched samples, “B” and “DW-A” respectively, for each of the alleles detected (see, the left-hand panel); there are two dots within each circle, one for sample “B” and one for sample “DW-A”.
- LASIK is a medical procedure that greatly improves many people's quality of life, for individuals carrying the G/A TGF ⁇ I SNP, it commonly causes a gradual vision impairment over a four to eighteen month period, which may lead to loss of vision. The vision impairment may occur in a longer or shorter period of time. Fortunately, screening can be performed to identify individuals carrying the mutation who should avoid having the LASIK procedure.
- the present disclosure is based at least in part on the discovery of methods that improve sample isolation, preparation, and analysis.
- methods are provided which allow for the re-use of patient samples, for example, when an assay fails or additional follow-up testing needs to be performed.
- these improved methods include gently swirling a substrate (e.g., a rayon-tipped or cotton-tipped applicator) carrying cells sloughed-off the buccal membrane of the patient in a lysis solution at room temperature for 30-45 seconds (rather than extended incubation for 20 minutes at elevated temperature). The lysis solution is then incubated at 45° C. for 30 minutes to improve lysis and increase the yield of genomic sample.
- the rayon-tipped or cotton-tipped applicator can then be stored (e.g., frozen or refrigerated) for re-isolation of genomic DNA used for re-testing.
- the improvements provided herein are provided through the use of lower amounts of genomic DNA template for the real-time PCR detection assays. In some embodiments, this is achieved by increasing the number of real-time PCR cycles performed (e.g., at about 40 cycles) and/or by using 3 second denaturation cycle times at 95° C.
- the amount of sample required is reduced by these methods, so too are the requirements for the real-time PCR reagents. Because many reagents used in diagnostic assays are proprietary, the reagents can be expensive. Reducing the amount of reagent used can also significantly reduce the costs associated with the reagent.
- invention or “present invention” as used herein is not meant to be limiting to any one specific embodiment of the invention but applies generally to any and all embodiments of the invention as described in the claims and specification.
- polymorphism and variants thereof refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals.
- genomic mutation or “genetic variation” and variants thereof include polymorphisms.
- single nucleotide polymorphism refers to a site of one nucleotide that varies between alleles.
- a single nucleotide polymorphism is a single base change or point mutation but also includes the so-called “indel” mutations (insertions or deletions of a nucleotide), resulting in genetic variation between individuals.
- SNPs which make up about 90% of all human genetic variation, occur every 100 to 300 bases along the 3-billion-base human genome. However, SNPs can occur much more frequently in other organisms like viruses. SNPs can occur in coding or non-coding regions of the genome.
- a SNP in the coding region may or may not change the amino acid sequence of a protein product.
- a SNP in a non-coding region can alter promoters or processing sites and may affect gene transcription and/or processing. Knowledge of whether an individual has particular SNPs in a genomic region of interest may provide sufficient information to develop diagnostic, preventive and therapeutic applications for a variety of diseases.
- the present disclosure relates to the detection of a guanine-to-adenine SNP located in exon 4 of the TGF ⁇ I gene associated with Avellino corneal dystrophy.
- primer refers to an oligonucleotide that acts as a point of initiation of DNA synthesis in a PCR reaction.
- a primer is usually about 15 to about 35 nucleotides in length and hybridizes to a region complementary to the target sequence.
- probe and variants thereof (e.g., detection probe) refers to an oligonucleotide that hybridizes to a target nucleic acid in a PCR reaction.
- Target sequence refers to a region of nucleic acid that is to be analyzed and comprises the polymorphic site of interest.
- the disclosure provides improved methods for isolating genomic samples used in real-time PCR single nucleotide polymorphism detection assays.
- the improved method 100 uses a combination of steps outlined in FIG. 1 .
- the method includes providing a sample of cells from a subject.
- the cells are collected by contacting a cellular surface of a patient with a substrate capable of reversibly immobilizing the cells onto a substrate.
- the disclosed methods are applicable to a variety of cell types obtained from a variety of samples.
- the cell type for use with the disclosed methods include but is not limited to epithelial cells, endothelial cells, connective tissue cells, skeletal muscle cells, endocrine cells, cardiac cells, urinary cells, melanocytes, keratinocytes, blood cells, white blood cells, buffy coat, hair cells (including, e.g., hair root cells) and/or salival cells.
- the cells are epithelial cells.
- the cells are subcapsular-perivascular (epithelial type 1); pale (epithelial type 2); intermediate (epithelial type 3); dark (epithelial type 4); undifferentiated (epithelial type 5); and large-medullary (epithelial type 6).
- the cells are buccal epithelial cells (e.g., epithelial cells collected using a buccal swap).
- the sample of cells used in the disclosed methods include any combination of the above identified cell types.
- the method includes providing ( 102 ) a sample of cells from a subject.
- the cells provided are buccal epithelial cells.
- the cell sample is collected by any of a variety of methods which allow for reversible binding of the subjects cells to the substrate.
- the substrate is employed in a physical interaction with the sample containing the subject's cells in order to reversibly bind the cells to the substrate.
- the substrate is employed in a physical interaction with the body of the subject directly in order to reversibly bind the cells to the substrate.
- the sample is a buccal cell sample and the sample of buccal cells is collected by contacting a buccal membrane of the subject (e.g., the inside of their cheek) with a substrate capable of reversibly immobilizing cells that are dislodged from the membrane.
- the swab is rubbed against the inside of the subject's cheek with a force equivalent to brushing a person's teeth (e.g., a light amount of force or pressure).
- a force equivalent to brushing a person's teeth e.g., a light amount of force or pressure.
- the sample is advantageously collected in a non-invasive manner and as such sample collection is accomplished anywhere and by almost anyone.
- the sample is collected at a physician's office, at a subject's home, or at a facility where LASIK surgery is performed or to be performed.
- the patient, the patient's doctor, nurses or a physician's assistant or other clinical personnel collects the sample.
- the substrate is made of any of a variety of materials to which cells are reversibly bound.
- Exemplary substrates include those made of rayon, cotton, silica, an elastomer, a shellac, amber, a natural or synthetic rubber, cellulose, BAKELITE, NYLON, a polystyrene, a polyethylene, a polypropylene, a polyacrylonitrile, or other materials or combinations thereof.
- the substrate is a swab having a rayon tip or a cotton tip.
- the tip of the substrate (e.g., the tip of the rayon swab or cotton swab) is then agitated in a lysis solution from about 10 seconds to 60 seconds (1 minute), or about 20 seconds to 60 seconds, about 20 seconds to about 45 seconds, or about 20 seconds to about 30 seconds, about 15 seconds to about 60 seconds, about 15 seconds to about 45 seconds, or about 15 seconds to about 30 seconds, about 10 seconds to about 60 seconds, about 10 seconds to about 45 seconds, or about 10 seconds to about 30 seconds, about 10 seconds to about 15 seconds or about 10 seconds to about 20 seconds.
- the agitation occurs for about 60 seconds or about 1 minute. In some embodiments, the agitation occurs for less than a minute (e.g., less than 60 seconds).
- the agitation occurs for no more than 15 seconds, 20 seconds, 30 seconds, 45 seconds, 60 seconds, 90 seconds, 120 seconds or more. In some embodiments, the agitation occurs for no more than 45 seconds. In some embodiments, the agitation occurs for no more than 30 seconds. In some embodiments, the agitation occurs for no more than 20 seconds. In some embodiments, the agitation occurs for no more than 15 seconds.
- agitation includes any movement of the substrate in the lysis solution.
- the tip of the substrate e.g., the tip of the rayon swab or cotton swab
- the tip of the substrate is moved gently in the lysis solution, such that a plurality of buccal cells remains affixed to the substrate for isolation at a later time and/or subsequent time.
- Such movement in the lysis solution includes swirling motions, side to side motions, up and down motions and/or dipping motions, or any other movement of the substrate in the lysis solutions that results in a plurality of buccal cell remain affixed to the tip while allowing for some buccal cells to be dispersed into the lysis solution.
- the agitation step is performed at room temperature, for instance, temperatures between about 15° C. and about 30° C., about 18° C. and about 28° C., about 18° C. and about 25° C. or about 20° C. and about 25° C.
- the substrate e.g., a swab with a rayon tip or cotton tip
- the substrate is removed and, in some embodiments, stored for use later, in case re-testing or further (e.g., different or additional) testing is needed.
- the substrate e.g., buccal swab with a rayon tip or cotton tip
- the substrate is placed in a container and stored frozen.
- the substrate e.g., buccal swab with a rayon tip or cotton tip
- the substrate is refrigerated.
- the substrate is stored at any of a variety of temperatures and for any of a variety of times while still remaining useful for one or more additional extractions.
- the substrate containing the sample is stored for 0 weeks, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks or 12 weeks or more. In some embodiments, the substrate containing the sample is stored for and/or is capable of being stored for 0 weeks to 12 weeks, 1 week to 12 weeks, 2 weeks to 12 weeks, 3 weeks to 12 weeks, 4 weeks to 12 weeks, 5 weeks to 12 weeks, 6 weeks to 12 weeks, 7 weeks to 12 weeks, 8 weeks to 12 weeks, 9 weeks, 10 weeks to 12 weeks, or 11 weeks to 12 weeks. In some embodiments, the substrate containing the sample is stored for 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, or 36 months or more.
- the substrate containing the sample is stored for 1 month to 30 months, 2 months to 30 months, 3 months to 30 months, 4 months to 30 months, 5 months to 30 months, 6 months to 30 months, 7 months to 30 months, 8 months to 30 months, 9 months to 30 months, 10 months to 30 months, 12 months to 30 months, 14 months to 30 months, 16 months to 30 months or 18 months to 30 months.
- the substrate containing the sample is stored for 1 month to 22 months, 2 months to 22 months, 3 months to 22 months, 4 months to 22 months, 5 months to 22 months, 6 months to 22 months, 7 months to 22 months, 8 months to 22 months, 9 months to 22 months, 10 months to 22 months, 12 months to 22 months, 14 months to 22 months, 16 months to 22 months, 18 months to 22 months.
- the substrate containing the sample is stored for 1 month to 20 months, 2 months to 20 months, 3 months to 20 months, 4 months to 20 months, 5 months to 20 months, 6 months to 20 months, 7 months to 20 months, 8 to 20 months, 9 to 20 months, 10 months to 20 months, 12 months to 20 months, 14 months to 20 months, 16 months to 20 months, 18 months to 20 months.
- the substrate containing the sample is stored for 1 month to 18 months, 2 months to 18 months, 3 months to 18 months, 4 months to 18 months, 5 months to 18 months, 6 months to 18 months, 7 months to 18 months, 8 months to 18 months, 9 months to 18 months, 10 months to 18 months, 12 months to 18 months, 14 months to 18 months, 16 months to 18 months or 17 months to 18 months.
- the substrate containing the sample is stored for 1 month to 12 months, 2 months to 12 months, 3 months to 12 months, 4 months to 12 months, 5 months to 12 months, 6 months to 12 months, 7 months to 12 months, 8 months to 12 months, 9 months to 12 months, 10 months to 12 months or 11 months to 12 months.
- the substrate containing the sample is stored at about ⁇ 25° C., about ⁇ 24° C., about ⁇ 23° C., about ⁇ 22° C., about ⁇ 21° C., about ⁇ 20° C., about ⁇ 19° C., about ⁇ 18° C., about ⁇ 17° C., about ⁇ 16° C. or about ⁇ 15° C. In some embodiments, the substrate containing the sample is stored at about ⁇ 25° C. to about ⁇ 15° C., about ⁇ 22° C. to about ⁇ 17° C., about ⁇ 20° C. to about ⁇ 15° C. or about ⁇ 25° C. to about ⁇ 20° C.
- the substrate containing the sample is stored at about ⁇ 90° C., about ⁇ 89° C., about ⁇ 88° C., about ⁇ 87° C., about ⁇ 86° C., about ⁇ 85° C., about ⁇ 84° C., about ⁇ 83° C., about ⁇ 82° C., about ⁇ 81° C., about ⁇ 80° C., about ⁇ 79° C., about ⁇ 78° C., about ⁇ 77° C., about ⁇ 76° C., about ⁇ 75° C., about ⁇ 74° C., about ⁇ 73° C., about ⁇ 72° C., about ⁇ 71° C., about ⁇ 70° C., about ⁇ 69° C., about ⁇ 68° C., about ⁇ 67° C., about ⁇ 66° C.
- the substrate containing the sample is freeze-thawed one or more times (e.g., after being frozen, the substrate containing the sample is thawed, used according to the present methods and re-frozen) and or used in the present methods.
- the substrate containing the sample is freeze-thawed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more times.
- the substrate containing the sample is used in the present methods 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more times.
- the increased extraction of nucleic acids of cells is accomplished by performing the extraction incubation for an increased or longer period of time as compared to standard practice.
- the extraction incubation is performed for about 45 minutes, e.g., 45 ⁇ 5, 45 ⁇ 10, 45 ⁇ 15, or 45 ⁇ 20 minutes.
- the extraction incubation is performed for about 25 minutes to about 65 minutes, about 30 minutes to about 60 minutes, about 35 minutes to about 55 minutes, about 45 minutes to about 65 minutes, about 45 minutes to about 55 minutes, or about 40 minutes to about 50 minutes.
- the extraction incubation time is about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes or about 65 minutes.
- the increased the extraction of nucleic acids of cells is accomplished by performing the extraction incubation at an increased or higher temperature as compared to standard practice.
- the extraction incubation is performed at about 45° C., e.g., 45 ⁇ 2° C., 45 ⁇ 5° C., or 45 ⁇ 10° C.
- the extraction incubation temperature is about 35° C. to about 55° C., about 40° C. to about 50° C. or about 43° C. to about 47° C.
- the extraction temperature is about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C. or about 55° C.
- more than one extraction temperature is used.
- standard temperatures are used for a portion of the extraction and an elevated temperature is used for another portion of the extraction.
- substantially small numbers of cells are released from the substrate for subsequent lysis according to the present systems and methods.
- at least 1 cell, at least 2 cells, at least 5 cells, at least 10 cells, at least 15 cells, at least 20 cells, at least 50 cells, at least 75 cells, at least 100 cells, at least 125 cells, at least 150 cells, at least 175 cells, at least 200 cells, at least 250 cells, at least 300 cells, at least 350 cells, at least 400 cells, at least 450 cells, at least 500 cells or more are released from the substrate during agitation.
- lysis solutions have been described and are known to those of skill in the art. Any of these well known lysis solutions can be employed with the present methods in order to isolate nucleic acids from a sample. Exemplary lysis solutions include those commercially available, such as those sold by INVITROGEN®, QIAGEN®, LIFE TECHNOLOGIES® and other manufacturers, as well as those which can be generated by one of skill in a laboratory setting. Lysis buffers have also been well described and a variety of lysis buffers can find use with the disclosed methods, including for example those described in Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013), both of which are incorporated herein by reference for all purposes.
- Cell lysis is a commonly practiced method for the recovery of nucleic acids from within cells.
- the cells are contacted with a lysis solution, commonly an alkaline solution comprising a detergent, or a solution of a lysis enzyme.
- lysis solutions typically contain salts, detergents and buffering agents, as well as other agents that one of skill would understand to use.
- the nucleic acids are recovered from the lysis solution.
- the buffer salt concentration is from about 10 mM to about 200 mM, about 10 mM to about 100 mM or about 20 mM to about 80 mM.
- the buffer further comprises chelating agents such as ethylenediaminetetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).
- EDTA ethylenediaminetetraacetic acid
- EGTA ethylene glycol tetraacetic acid
- the lysis solution further comprises other compounds to assist with nucleic acid release from cells such as polyols, including for example but not limited to sucrose, as well as sugar alcohols such as maltitol, sorbitol, xylitol, erythritol, and/or isomalt.
- polyols are in the range of from about 2% to about 15% w/w, or about 5% to about 15% w/w or about 5% to about 10% w/w.
- the lysis solutions further comprises surfactants, such as for example but not limited to Triton X-100, SDS, CTAB, X-114, CHAPS, DOC, and/or NP-40.
- surfactants such as for example but not limited to Triton X-100, SDS, CTAB, X-114, CHAPS, DOC, and/or NP-40.
- such surfactants are in the range of from about 1% to about 5% w/w, about 1% to about 4% w/w, or about 1% to about 3% w/w.
- the lysis solution further comprises chaotropes, such as for example but not limited to urea, sodium dodecyl sulfate and/or thiourea.
- the chaotrope is used at a concentration in the range of from about 0.5 M to 8 M, about 1 M to about 6 M, about 2 M to about 6 M or about 1 M to 3 M.
- the lysis solution further comprises one or more additional lysis reagents and such lysis reagents are well known in the art.
- such lysis reagents include cell wall lytic enzymes, such as for example but not limited to lysozyme.
- lysis reagents comprise alkaline detergent solutions, such as 0.1 aqueous sodium hydroxide containing 0.5% sodium dodecyl sulphate.
- the lysis solution further comprises aqueous sugar solutions, such as sucrose solution and chelating agents such as EDTA, for example the STET buffer.
- the lysis reagent is prepared by mixing the cell suspension with an equal volume of lysis solution having twice the desired concentration (for example 0.2 sodium hydroxide, 1.0% sodium dodecyl sulphate).
- the mixture comprising lysis solution and lysed cells is contacted with a neutralizing or quenching reagent to adjust the conditions such that the lysis reagent does not adversely affect the desired product.
- the pH is adjusted to a pH of from about 5 to about 9, about 6 to about 8, about 5 to about 7, about 6 to about 7 or about 6.5 to 7.5 to minimize and/or prevent degradation of the cell contents, including for example but not limited to the nucleic acids.
- the neutralizing reagent comprises an acidic buffer, for example an alkali metal acetate/acetic acid buffer.
- lysis conditions such as temperature and composition of the lysis reagent are chosen such that lysis is substantially completed while minimizing degradation of the desired product, including for example but not limited to nucleic acids.
- a first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth or twentieth lysis solution is employed with the methods.
- the volume of lysis buffer used is about 10 ⁇ L, about 20 ⁇ L, about 30 ⁇ L, about 40 ⁇ L, about 50 ⁇ L, about 60 ⁇ L, about 70 ⁇ L, about 80 ⁇ L, about 90 ⁇ L, about 100 ⁇ L, about 120 ⁇ L, about 130 ⁇ L, about 140 ⁇ L, about 150 ⁇ L, 160 ⁇ L, about 170 ⁇ L, about 180 ⁇ L, about 190 ⁇ L, about 200 ⁇ L, about 220 ⁇ L, about 230 ⁇ L, about 240 ⁇ L, about 250 ⁇ L, about 260 ⁇ L, about 270 ⁇ L, about 280 ⁇ L, about 290 ⁇ L, about 300 ⁇ L, about 320 ⁇ L, about
- the lysis buffer is between about 10 ⁇ L and about 1000 ⁇ L, about 10 ⁇ L and about 800 ⁇ L, about 10 ⁇ L and about 600 ⁇ L, about 10 ⁇ L and about 400 ⁇ L, about 20 ⁇ L and about 400 ⁇ L, about 50 ⁇ L and about 300 ⁇ L, about 50 ⁇ L and about 200 ⁇ L, about 50 ⁇ L and about 400 ⁇ L, about 100 ⁇ L and about 400 ⁇ L, about 10 ⁇ L and about 300 ⁇ L or about 100 ⁇ L and about 200 ⁇ L.
- the nucleic acids are isolated from lysis buffer prior to performing subsequent analysis.
- the nucleic acids are isolated from the lysis buffer prior to the performance of additional analyses, such as for example but not limited to real-time PCR analyses.
- additional analyses such as for example but not limited to real-time PCR analyses.
- Any of a variety of methods useful in the isolation of small quantities of nucleic acids are used by various embodiments of the disclosed methods. These include but are not limited to precipitation, gel filtration, density gradients and solid phase binding. Such methods have also been described in for example, Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013), incorporated herein by reference for all purposes.
- Solid phase affinity for nucleic acids according to the disclosed methods can be through any one of a number of means typically used to bind a solute to a substrate. Examples of such means include but are not limited to, ionic interactions (e.g., anion-exchange chromatography) and hydrophobic interactions (e.g., reversed-phase chromatography), pH differentials and changes, salt differentials and changes (e.g., concentration changes, use of chaotropic salts/agents).
- ionic interactions e.g., anion-exchange chromatography
- hydrophobic interactions e.g., reversed-phase chromatography
- pH differentials and changes e.g., sodium bicarbonate
- salt differentials and changes e.g., concentration changes, use of chaotropic salts/agents.
- Exemplary ion exchange based substrates include but are not limited to DEA-SEPHAROSETM, Q-SEPHAROSETM, and DEAE-SEPHADEXTM from PHARMACIA (Piscataway, N.J.), DOWEX® I from The Dow Chemical Company (Midland, Mich.), AMBERLITE® from Rohm & Haas (Philadelphia, Pa.), DUOLITE® from Duolite International, In. (Cleveland, Ohio), DIALON TI and DIALON TII.
- the disclosed methods are used to isolate nucleic acids, such as genomic DNA (gDNA) for a variety of nucleic acid analyses, including genomic analyses.
- genomic DNA gDNA
- genomic analyses including genomic analyses.
- such analysis includes detection of variety of genetic mutations, which include but are not limited to one or more deletions, insertions, transitions and transversions.
- the mutation is a single-nucleotide polymorphism (SNP).
- gDNA genomic DNA
- PCR methods such as real-time PCR analysis, microarray analysis, hybridization analysis and nucleic acid sequence analysis, as well as a variety of other methods where nucleic acid compositions are analyzed and which are known to those of skill in the art. See, for example, Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013).
- Real-time PCR relies on the visual emission of fluorescent dyes conjugated to short polynucleotides (termed “detection probes”) that associate with genomic alleles in a sequence-specific fashion.
- detection probes conjugated to short polynucleotides
- Real-time PCR probes differing by a single nucleotide can be differentiated in a real-time PCR assay by the conjugation and detection of probes that fluoresce at different wavelengths.
- Real-Time PCR finds use in detection applications (diagnostic applications), quantification applications and genotyping applications.
- real-time PCR can result in detection of a variety of gene mutations, including for example but not limited to SNPs.
- detection of SNPs in specific gene candidates is performed using real-time PCR, based on the use of intramolecular quenching of a fluorescent molecule by use of a tethered quenching moiety.
- real-time PCR methods also include the use of molecular beacon technology.
- the molecular beacon technology utilizes hairpin-shaped molecules with an internally-quenched fluorophore whose fluorescence is restored by binding to a DNA target of interest (See, e.g., Kramer, R. et al. Nat. Biotechnol. 14:303-308, 1996).
- increased binding of the molecular beacon probe to the accumulating PCR product is used to specifically detect SNPs present in genomic DNA.
- TAQMAN® allelic discrimination assay One of the many suitable genotyping procedures is the TAQMAN® allelic discrimination assay.
- an oligonucleotide probe labeled with a fluorescent reporter dye at the 5′ end of the probe and a quencher dye at the 3′ end of the probe is utilized. The proximity of the quencher to the intact probe maintains a low fluorescence for the reporter.
- the 5′ nuclease activity of DNA polymerase cleaves the probe, and separates the dye and quencher. This results in an increase in fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye.
- the 5′ nuclease activity of DNA polymerase cleaves the probe between the reporter and the quencher only if the probe hybridizes to the target and is amplified during PCR.
- the probe is designed to straddle a target SNP position and hybridize to the nucleic acid molecule only if a particular SNP allele is present.
- forward and reverse PCR primer pairs SEQ ID NOs:1 to 24 in FIG. 2
- any of the forward and reverse primer pairs disclosed therein are used in the improved methods disclosed herein.
- the forward and reverse primer pair of SEQ ID NO:1 (forward) and SEQ ID NO:2 (reverse) are used in the improved methods provided herein.
- fluorescently labeled real-time PCR probe pairs for the detection of the wild type (“G”) and Avellino corneal dystrophy-associated mutant (“A”) allele having nucleotide sequences according to SEQ ID NOs: 25 to 42, as shown in FIG. 3 were constructed as described in U.S. Patent Publication 2012/0077200.
- any of the wild type and mutant probes are used in the improved methods disclosed herein.
- the wild type and mutant probe pair of SEQ ID NO:25 (wild type) and SEQ ID NO:26 (mutant) are used in the improved methods provided herein.
- the wild type probes were labeled with VIC, and the mutant probes were labeled with FAM.
- the minor groove binder (MGB) was attached to the probe so as to facilitate binding to a complementary gene fragment.
- Real-time PCR methods include a variety of steps or cycles as part of the methods for amplification. These cycles include denaturing double-stranded nucleic acids, annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence and synthesizing (i.e., replicating) second-strand DNA from the annealed forward primer and the reverse primer. This three step process is referred to herein as a cycle.
- about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 cycles are employed. In some embodiments, about 10 to about 60 cycles, about 20 to about 50 or about 30 to about 40 cycles are employed. In some embodiments, 40 cycles are employed.
- the denaturing double-stranded nucleic acids step occurs at a temperature of about 80° C. to 100° C., about 85° C. to about 99° C., about 90° C. to about 95° C. for about 1 second to about 5 seconds, about 2 seconds to about 5 seconds, or about 3 seconds to about 4 seconds. In some embodiments, the denaturing double-stranded nucleic acids step occurs at a temperature of 95° C. for about 3 seconds.
- the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 40° C. to about 80° C., about 50° C. to about 70° C., about 55° C. to about 65° C. for about 15 seconds to about 45 seconds, about 20 seconds to about 40 seconds, about 25 seconds to about 35 seconds. In some embodiments, the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 60° C. for about 30 seconds.
- the synthesizing (i.e., replicating) second-strand DNA from the annealed forward primer and the reverse primer occurs at about 40° C. to about 80° C., about 50° C. to about 70° C., about 55° C. to about 65° C. for about 15 seconds to about 45 seconds, about 20 seconds to about 40 seconds, about 25 seconds to about 35 seconds.
- the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 60° C. for about 30 seconds.
- a genomic DNA sample prepared according to the present methods described herein is combined with only about 0.05 ⁇ L, about 0.10 ⁇ L about 0.15 ⁇ L, about 0.20 ⁇ L, about 0.25 ⁇ L or about 0.25 ⁇ L of a 30 ⁇ , 35 ⁇ , 40 ⁇ , 45 ⁇ , 50 ⁇ or 100 ⁇ real-time PCR assay mix and distilled water to form the PCR master mix.
- the PCR master mix has a final volume of about 5 ⁇ L, about 6 ⁇ L, about 7 ⁇ L, about 8 ⁇ L, about 9 ⁇ L, about 0 ⁇ L, about 11 ⁇ L, about 12 ⁇ L, about 13 ⁇ L, about 14 ⁇ L, about 15 ⁇ L, about 16 ⁇ L, about 17 ⁇ L, about 18 ⁇ L, about 19 ⁇ L or about 20 ⁇ L or more.
- primers are tested and designed in a laboratory setting. In some embodiments, primers are designed by computer based in silico methods. Primer sequences are based on the sequence of the amplicon or target nucleic acid sequence that is to be amplified. Shorter amplicons typically replicate more efficiently and lead to more efficient amplification as compared to longer amplicons.
- T M melting temperature
- Primer specificity is defined by its complete sequence in combination with the 3′ end sequence, which is the portion elongated by Taq polymerase.
- the 3′ end should have at least 5 to 7 unique nucleotides not found anywhere else in the target sequence, in order to help reduce false-priming and creation of incorrect amplification products.
- Forward and reverse primers typically bind with similar efficiency to the target.
- tools such as NCBI BLAST (located on the World Wide Web at ncbi.nlm.nih.gov) are employed to performed alignments and assist in primer design.
- primer complexity or linguistic sequence complexity An additional aspect of primer design is primer complexity or linguistic sequence complexity (see, Kalendar R, et al. ( Genomics, 98(2): 137-144 (2011)). Primers with greater linguistic sequence complexity (e.g., nucleotide arrangement and composition) are typically more efficient.
- the linguistic sequence complexity calculation method is used to search for conserved regions between compared sequences for the detection of low-complexity regions including simple sequence repeats, imperfect direct or inverted repeats, polypurine and polypyrimidine triple-stranded cDNA structures, and four-stranded structures (such as G-quadruplexes).
- linguistic complexity (LC) measurements are performed using the alphabet-capacity L-gram method (see, A. Gabrielian, A.
- these quadruplexes are formed by the intermolecular association of two or four DNA molecules, dimerization of sequences that contain two G-bases, or by the intermolecular folding of a single strand containing four blocks of guanines (see, P. S. Ho, PNAS, 91:9549-9553 (1994); I. A. Il'icheva, V. L. Florent'ev, Russian Journal of Molecular Biology 26:512-531(1992); D. Sen, W. Gilbert, Methods Enzymol. 211:191-199 (1992); P. A. Rachwal, K. R. Fox, Methods 43:291-301 (2007); S. Burge, G. N. Parkinson, P. Hazel, A. K.
- These methods include various bioinformatics tools for pattern analysis in sequences having GC skew, (G ⁇ C)/(G+C), AT skew, (A ⁇ T)/(A+T), CG ⁇ AT skew, (S ⁇ W)/(S+W), or purine-pyrimidine (R ⁇ Y)/(R+Y) skew regarding CG content and melting temperature and provide tools for determining linguistic sequence complexity profiles.
- GC skew in a sliding window of n where n is a positive integer
- bases is calculated with a step of one base, according to the formula, (G ⁇ C)/(G+C), in which G is the total number of guanines and C is the total number of cytosines for all sequences in the windows (Y. Benita, et al., Nucleic Acids Res. 31:e99 (2003)).
- Positive GC-skew values indicated an overabundance of G bases, whereas negative GC-skew values represented an overabundance of C bases.
- other skews are calculated in the sequence.
- Such methods, as well as others, are employed to determine primer complexity in some embodiments.
- real-time PCR is performed using exonuclease primers (TAQMAN® probes).
- the primers utilize the 5′ exonuclease activity of thermostable polymerases such as Taq to cleave dual-labeled probes present in the amplification reaction (See, e.g., Wittwer, C. et al. Biotechniques 22:130-138, 1997).
- thermostable polymerases such as Taq to cleave dual-labeled probes present in the amplification reaction
- the primer probes used in this assay are distinct from the PCR primer and are dually-labeled with both a molecule capable of fluorescence and a molecule capable of quenching fluorescence.
- fluorescent probes When the probes are intact, intramolecular quenching of the fluorescent signal within the DNA probe leads to little signal. When the fluorescent molecule is liberated by the exonuclease activity of Taq during amplification, the quenching is greatly reduced leading to increased fluorescent signal.
- fluorescent probes include the 6-carboxy-floruescein moiety and the like.
- Exemplary quenchers include Black Hole Quencher 1 moiety and the like.
- PCR primers can find use with the disclosed methods. Exemplary primers include but are not limited to those described herein. Primers for use in the disclosed methods are also found in U.S. Patent Publication No. 20120077200, which is hereby incorporated by reference for all purposes. In some embodiments, the PCR primers for use in the methods of the present disclosure include but are not limited to the following listed in Table 1 and find use in the detection of the TGF ⁇ I gene. Tables 2 and 3 provide biophysical parameters for each primer, as calculated using the World Wide Web at primerdigital.com/tools/PrimerAnalyser.html.
- the real-time PCR primers for use with the disclosed methods have a linguistic sequence complexity of at least 70%, at least 72%, at least 75%, at least 77%, at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 97% or at least 99%.
- detection probes can find use with the disclosed methods and are employed for genotyping and or for quantification.
- Detection probes commonly employed by those of skill in the art include but are not limited to hydrolysis probes (also known as TAQMAN® probes, 5′ nuclease probes or dual-labeled probes), hybridization probes, and Scorpion primers (which combine primer and detection probe in one molecule).
- detection probe design is determined by one of skill in the art based on the desired probe target such that the probe is compatible with the PCR primers employed (e.g., primers and probes should not interfere with one another's functions in the real-time PCR assay).
- probes are designed to have higher T m 's than the primers in order to promote efficient signal production.
- T m 's are calculated using any of a variety of methods known in the art and those of skill would readily understand such various methods for calculating T m ; such methods include for example those available in online tools such as the calculators available on the World Wide Web at promega.com/techserv/tools/biomath/calc11.htm.
- the increased T m of the detection probe provides that the detection probe has bound before the primers are elongated by the polymerase.
- detection probes contain various modifications.
- detection probes include modified nucleic acid residues, such as but not limited to 2′-O-methyl ribonucleotide modifications, phosphorothioate backbone modifications, phosphorodithioate backbone modifications, phosphoramidate backbone modifications, methylphosphonate backbone modifications, 3′ terminal phosphate modifications and/or 3′ alkyl substitutions.
- the detection probe has increased affinity for a target sequence due to modifications.
- detection probes include detection probes with increased length, as well as detection probes containing chemical modifications.
- modifications include but are not limited to 2′-fluoro (2′-deoxy-2′-fluoro-nucleosides) modifications, LNAs (locked nucleic acids), PNAs (peptide nucleic acids), ZNAs (zip nucleic acids), morpholinos, methylphosphonates, phosphoramidates, polycationic conjugates and 2′-pyrene modifications.
- the detector probes contains one or more modifications including 2′ fluoro modifications (aka, 2′-Deoxy-2′-fluoro-nucleosides), LNAs (locked nucleic acids), PNAs (peptide nucleic acids), ZNAs (zip nucleic acids), morpholinos, methylphosphonates, phosphoramidates, and/or polycationic conjugates.
- 2′ fluoro modifications aka, 2′-Deoxy-2′-fluoro-nucleosides
- LNAs locked nucleic acids
- PNAs peptide nucleic acids
- ZNAs zip nucleic acids
- morpholinos methylphosphonates
- phosphoramidates phosphoramidates
- the detection probes contain detectable moieties, such as those described herein as well as any detectable moieties known to those of skill in the art.
- detectable moieties include for example but are not limited to fluorescent labels and chemiluminescent labels. Examples of such detectable moieties can also include members of FRET pairs.
- the detection probe contains a detectable entity.
- fluorescent labels include but are not limited to AMCA, DEAC (7-Diethylaminocoumarin-3-carboxylic acid); 7-Hydroxy-4-methylcoumarin-3; 7-Hydroxycoumarin-3; MCA (7-Methoxycoumarin-4-acetic acid); 7-Methoxycoumarin-3; AMF (4′-(Aminomethyl)fluorescein); 5-DTAF (5-(4,6-Dichlorotriazinyl)aminofluorescein); 6-DTAF (6-(4,6-Dichlorotriazinyl)aminofluorescein); 6-FAM (6-Carboxyfluorescein; aka FAM; including TAQMAN® FAMTM); TAQMAN VIC®; 5(6)-FAM cadaverine; 5-FAM cadaverine; 5(6)-FAM ethylenediamme; 5-FAM ethylenediamme; 5-FITC (FITC Isomer I; fluorescein-5-isothiocyanate); 5-FITC cada
- chemiluminescent labels include but are not limited to those labels used with Southern Blot and Western Blot protocols (see, for e.g., Sambrook and Russell, Molecular Cloning: A Laboratory Manual, (3rd ed.) (2001); incorporated by reference herein in its entirety). Examples include but are not limited to -(2′-spiroadamantane)-4-methoxy-4-(3′′-phosphoryloxy)phenyl-1,2-dioxetane (AMPPD); acridinium esters and adamantyl-stabilized 1,2-dioxetanes, and derivatives thereof.
- AMPPD -(2′-spiroadamantane)-4-methoxy-4-(3′′-phosphoryloxy)phenyl-1,2-dioxetane
- AMPPD acridinium esters and adamantyl-stabilized 1,2-dioxetanes, and derivatives thereof.
- the labeling of probes is known in the art.
- the labeled probes are used to hybridize within the amplified region during amplification.
- the probes are modified so as to avoid them from acting as primers for amplification.
- the detection probe is labeled with two fluorescent dyes, one capable of quenching the fluorescence of the other dye.
- One dye is attached to the 5′ terminus of the probe and the other is attached to an internal site, so that quenching occurs when the probe is in a non-hybridized state.
- real-time PCR probes consist of a pair of dyes (a reporter dye and an acceptor dye) that are involved in fluorescence resonance energy transfer (FRET), whereby the acceptor dye quenches the emission of the reporter dye.
- FRET fluorescence resonance energy transfer
- the fluorescence-labeled probes increase the specificity of amplicon quantification.
- Real-time PCR that are used in some embodiments of the disclosed methods also include the use of one or more hybridization probes (i.e., detection probes), as determined by those skilled in the art, in view of this disclosure.
- hybridization probes include but are not limited to one or more of those provided in the described methods.
- Exemplary probes, such as the HEX channel and/or FAM channel probes, are understood by one skilled in the art.
- detection probes and primers are conveniently selected e.g., using an in silico analysis using primer design software and cross-referencing against the available nucleotide database of genes and genomes deposited at the National Center for Biotechnology Information (NCBI).
- NCBI National Center for Biotechnology Information
- the primers and probes are selected such that they are close together, but not overlapping.
- the primers may have the same (or close T M ) (e.g., between about 58° C. and about 60° C.).
- the T M of the probe is approximately 10° C. higher than that selected for the T M of the primers.
- the length of the probes and primers is selected to be between about 17 and 39 base pairs, etc.
- Probes for use in the methods of the present invention include but are not limited to the following exemplary probes listed in Table 4.
- Probe Sequence Normal probe 1 SEQ ID NO: 25 VIC-CAC GGA CCG CAC GGA-NFQ (15 bp) Mutant probe 1 SEQ ID NO: 26 FAM-CAC GGA CCA CAC GGA-NFQ Normal probe 2 SEQ ID NO: 27 VIC-ACA CGG ACC GCA CG-NFQ Mutant probe 2 SEQ ID NO: 28 FAM-ACA CGG ACC ACA CG-NFQ (14 bp) Normal probe 3 SEQ ID NO: 29 VIC-TAC ACG GAC CGC A-NFQ Mutant probe 3 SEQ ID NO: 30 FAM-TAC ACG GAC CAC A-NFQ (13 bp) Normal probe 4 SEQ ID NO: 31 VIC-CTG TAC ACG GAC CGC ACG-NFQ Mutant probe 4 SEQ ID NO: 32 FAM-CTG TAC ACG GAC CAC ACG-NFQ (18 bp) Normal probe 5 SEQ ID NO:
- diagnostic testing is employed to determine one or more genetic conditions by detection of any of a variety of mutations. In some embodiments, diagnostic testing is used to confirm a diagnosis when a particular condition is suspected based on for example physical manifestations, signs and/or symptoms as well as family history information. In some embodiments, the results of a diagnostic test assist those of skill in the medical arts in determining an appropriate treatment regimen for a given patient and allow for more personalized and more effective treatment regimens. In some embodiments, a treatment regimen include any of a variety of pharmaceutical treatments, surgical treatments, lifestyles changes or a combination thereof as determined by one of skill in the art.
- the nucleic acids obtained by the disclosed methods are useful in a variety of diagnostic tests, including tests for detecting mutations such as deletions, insertions, transversions and transitions.
- diagnostics are useful for identifying unaffected individuals who carry one copy of a gene for a disease that requires two copies for the disease to be expressed, identifying unaffected individuals who carry one copy of a gene for a disease in which the information could find use in developing a treatment regimen, preimplantation genetic diagnosis, prenatal diagnostic testing, newborn screening, genealogical DNA test (for genetic genealogy purposes), presymptomatic testing for predicting adult-onset disorders such as Huntington's disease, presymptomatic testing for estimating the risk of developing adult-onset cancers and Alzheimer's disease, confirmational diagnosis of a symptomatic individual, and/or forensic/identity testing.
- the present methods find use in the detection of corneal dystrophy.
- corneal dystrophy is detected for example through detection of Avellino corneal dystrophy-related SNPs, such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/A)C SNP).
- Avellino corneal dystrophy-related SNPs such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/A)C SNP).
- corneal dystrophy is detected for example through detection of granular corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555W mutation caused by a C to T transition at nucleotide 1663 of TGF ⁇ I gene also referred to as a (C/T)GG SNP).
- granular corneal dystrophy-related SNPs such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555W mutation caused by a C to T transition at nucleotide 1663 of TGF ⁇ I gene also referred to as a (C/T)GG SNP).
- corneal dystrophy is detected for example through detection of lattice dystrophy-related SNPs, such as those that result in R124 and/or 626 mutations in the TGF ⁇ I gene (including for example but not limited to an R124C mutation caused by a C to T transition at nucleotide 417 of TGF ⁇ I gene also referred to as a (C/T)GC SNP or a H626P mutation caused by an A to C transition at nucleotide 1924 of TGF ⁇ I gene.
- lattice dystrophy-related SNPs such as those that result in R124 and/or 626 mutations in the TGF ⁇ I gene (including for example but not limited to an R124C mutation caused by a C to T transition at nucleotide 417 of TGF ⁇ I gene also referred to as a (C/T)GC SNP or a H626P mutation caused by an A to C transition at nucleotide 1924 of TGF ⁇ I gene.
- corneal dystrophy is detected for example through detection of Reis-Buckler corneal dystrophy-related SNPs, such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124L mutation caused by a G to T transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/T)C SNP).
- Reis-Buckler corneal dystrophy-related SNPs such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124L mutation caused by a G to T transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/T)C SNP).
- corneal dystrophy is detected for example through detection of Thiel-Behnke corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555Q mutation caused by a G to A transition at nucleotide 1664 of TGF ⁇ I gene also referred to as a C(G/A)G SNP).
- Thiel-Behnke corneal dystrophy-related SNPs such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555Q mutation caused by a G to A transition at nucleotide 1664 of TGF ⁇ I gene also referred to as a C(G/A)G SNP).
- newborn screening includes any genetic screening employed just after birth in order to identify genetic disorders. In some embodiments, newborn screening finds use in the identification of genetic disorders so that a treatment regimen is determined early in life. Such tests include but are not limited to testing infants for phenylketonuria and congenital hypothyroidism.
- carrier testing is employed to identify people who carry a single copy of a gene mutation.
- the mutation when present in two copies, the mutation can cause a genetic disorder.
- one copy is sufficient to cause a genetic disorder.
- the presence of two copies is contra-indicated for a particular treatment regimen, such as the presence of the Avellino mutation and pre-screening prior to performing surgical procedures in order to ensure the appropriate treatment regiment is pursued for a given patient.
- such information is also useful for individual contemplating procreation and assists individuals with making informed decisions as well as assisting those skilled in the medical arts in providing important advice to individual patients as well as patients' relatives.
- predictive and/or presymptomatic types of testing are used to detect gene mutations associated with a variety of disorders. In some cases, these tests are helpful to people who have a family member with a genetic disorder, but who may exhibit no features of the disorder at the time of testing.
- predictive testing identifies mutations that increase a person's chances of developing disorders with a genetic basis, including for example but not limited to certain types of cancer.
- presymptomatic testing is useful in determining whether a person will develop a genetic disorder, before any physical signs or symptoms appear. The results of predictive and presymptomatic testing provides information about a person's risk of developing a specific disorder and help with making decisions about an appropriate medical treatment regimen for a patient as well as for a patient's relatives.
- Predictive testing is also employed, in some embodiments, to detect mutations which are contra-indicated with certain treatment regimens, such as the presence of the Avellino mutation being contra-indicated with performing LASIK surgery and/or other refractive procedures, such as but not limited to Phototherapeutic keratectomy (PTK) and/or Photorefractive keratectomy (PRK).
- LASIK Phototherapeutic keratectomy
- PRK Photorefractive keratectomy
- diagnostic testing also includes pharmacogenomics which includes genetic testing that determines the influence of genetic variation on drug response. Information from such pharmacogenomic analyses finds use in determining and developing an appropriate treatment regimen. Those of skill in the medical arts employ information regarding the presence and/or absence of a genetic variation in designing appropriate treatment regimen.
- diseases whose genetic profiles are determined using the methods of the present disclosure include but are not limited to ophthalmic disorders, cancer, diabetes mellitus, hypertension, schizophrenia, and most common congenital malformations, such as cleft lip, cleft palate, neural tube defects, Achondroplasia, Alpha-1 Antitrypsin Deficiency, Antiphospholipid Syndrome, Autism, Autosomal Dominant Polycystic Kidney Disease, Charcot-Marie-Tooth, Colon cancer, Cri du chat, Crohn's Disease, Cystic fibrosis, Dercum Disease, Down Syndrome, Duane Syndrome, Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia, Familial Hypercholesterolemia, Familial Mediterranean Fever, Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia, Holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis
- Ophthalmic disorders and/or disorders that include an ophthalmic component include but are not limited to chalazion, stye, trichiasis, entropion, ectropion, lagophthalmos, bleharitis, dacryocystitis, orbital cellulitis, ptergium, pterygiumcorneal dystrophy, conjuctivitis, ophtalmia neonatorum, bacterial corneal ulcer, fungal corneal ulcer, glaucoma, Fuchs Dystrophy, keratoconus, Advanced Macular Degeneration, Retinitis pigmentosa, cataracts, retinal disorecers, macular degeneration, diabetic eye problems (for example, diabetic retinopathy), blepharophimosis-ptosis-epicanthus-inversus syndrome (BPES), oculocutaneous albinism, Marfan syndrome, Stickler syndrome, and CHARGE (coloboma, heart anomalies,
- Corneal dystrophies include but are not limited to Avellino corneal dystrophy, granular corneal dystrophy, lattice type I corneal dystrophy, Fuchs Dystrophy, Thiel-Behnke and Reis-bucklers corneal dystrophy. Cancers include but are not limited to carcinoma, sarcoma, blastoma, lymphoma, leukemia germ cell tumors, and cancers of unknown origin.
- the cancer include but is not limited to head and neck, skin, colon, oral, glioblastoma, breast, laryngeal, esophageal, endothelial, endometrial, ovarian, lung, urogenital, rectal, prostate, kidney, melanoma, renal, pancreatic, gastrointestinal, blood, liver, uterine and brain as well as viral induced cancers such as papilloma virus-induced cancer.
- the present methods find use in development of personalized medicine treatment regimens by providing the genomic DNA which is used in determining the genetic profile for an individual.
- such genetic profile information is employed by those skilled in the art in order determine and/or develop a treatment regimen.
- the presence and/or absence of various genetic variations and mutations identified in nucleic acids isolated by the described methods are used by those of skill in the art as part of a personalized medicine treatment regimen or plan.
- information obtained using the disclosed methods is compared to databases or other established information in order to determine a diagnosis for a specified disease and or determine a treatment regimen.
- the information regarding the presence or absence of a genetic mutation in a particular patient is compared to a database or other standard source of information in order to make a determination regarding a proposed treatment regimen.
- the presence of a genetic mutation indicates pursuing a particular treatment regimen.
- the absence of a genetic mutation indicates not pursuing a particular treatment regimen.
- information regarding the presence and/or absence of a particular genetic mutation is used to determine the treatment efficacy of treatment with the therapeutic entity, as well as to tailor treatment regimens for treatment with therapeutic entity.
- information regarding the presence and/or absence of a genetic mutation is employed to determine whether to pursue a treatment regimen.
- information regarding the presence and/or absence of a genetic mutation is employed to determine whether to continue a treatment regimen.
- the presence and/or absence of a genetic mutation is employed to determine whether to discontinue a treatment regimen.
- the presence and/or absence of a genetic mutation is employed to determine whether to modify a treatment regimen.
- the presence and/or absence of a genetic mutation is used to determine whether to increase or decrease the dosage of a treatment that is being administered as part of a treatment regimen. In other embodiments, the presence and/or absence of a genetic mutation is used to determine whether to change the dosing frequency of a treatment administered as part of a treatment regimen. In some embodiments, the presence and/or absence of a genetic mutation is used to determine whether to change the number of dosages per day, per week, times per day of a treatment. In some embodiments the presence and/or absence of a genetic mutation is used to determine whether to change the dosage amount of a treatment.
- the presence and/or absence of a genetic mutation is determined prior to initiating a treatment regiment and/or after a treatment regimen has begun. In some embodiments, the presence and/or absence of a genetic mutation is determined and compared to predetermined standard information regarding the presence or absence of a genetic mutation.
- a composite of the presence and/or absence of more than one genetic mutation is generated using the disclosed methods and such composite includes any collection of information regarding the presence and/or absence of more than one genetic mutation.
- the presence or absence of 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 20 or more, 30 or more or 40 or more genetic mutations is examined and used for generation of a composite.
- Exemplary information in some embodiments includes nucleic acid or protein information, or a combination of information regarding both nucleic acid and/or protein genetic mutations.
- the composite includes information regarding the presence and/or absence of a genetic mutation. In some embodiments, these composites are used for comparison with predetermined standard information in order to pursue, maintain or discontinue a treatment regimen.
- corneal dystrophy is detected for example through detection of 2, 3, 4 or 5 SNPs selected from but not limited to Avellino corneal dystrophy-related SNPs, granular corneal dystrophy-related SNPs, lattice dystrophy-related SNPs, Reis-Buckler corneal dystrophy-related SNPs, and/or Thiel-Behnke corneal dystrophy-related SNPs.
- SNPs selected from but not limited to Avellino corneal dystrophy-related SNPs, granular corneal dystrophy-related SNPs, lattice dystrophy-related SNPs, Reis-Buckler corneal dystrophy-related SNPs, and/or Thiel-Behnke corneal dystrophy-related SNPs.
- corneal dystrophy is detected for example through detection of an Avellino corneal dystrophy-related SNP, in combination with a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP, a Reis-Buckler corneal dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP.
- Avellino corneal dystrophy-related SNP in combination with a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP, a Reis-Buckler corneal dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP.
- corneal dystrophy is detected for example through detection of a granular corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a lattice dystrophy-related SNPs, a Reis-Buckler corneal dystrophy-related SNPs, and/or a Thiel-Behnke corneal dystrophy-related SNP.
- corneal dystrophy is detected for example through detection of a lattice dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a Reis-Buckler corneal dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP.
- corneal dystrophy is detected for example through detection of a Reis-Buckler corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP.
- corneal dystrophy is detected for example through detection of a Thiel-Behnke corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP and/or a Reis-Buckler corneal dystrophy-related SNP.
- corneal dystrophy is detected for example through detection of 2, 3, 4, 5 and/or 6 SNPs selected from Avellino corneal dystrophy-related SNPs.
- the SNPs include SNPs that result in mutations at positions 124, 555 and/or 626 of the polypeptide encoded by the human TGF ⁇ I gene.
- These mutations include those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/A)C SNP), granular corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555W mutation caused by a C to T transition at nucleotide 1663 of the TGF ⁇ I gene also referred to as a (C/T)GG SNP), lattice dystrophy-related SNPs, such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124C mutation caused by a C to T transition at nucleotide 417 of TGF ⁇ I gene also referred to as a (C/T)GC SNP), Reis-Buckler corneal dystrophy-related SNPs, such as
- corneal dystrophy is detected for example through detection of Avellino corneal dystrophy-related SNPs, such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGF ⁇ I gene also referred to as a C(G/A)C SNP) in combination with a granular corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGF ⁇ I gene (including for example but not limited to an R555W mutation caused by a C to T transition at nucleotide 1663 of TGF ⁇ I gene also referred to as a (C/T)GG SNP).
- Avellino corneal dystrophy-related SNPs such as those that result in R124 mutations in the TGF ⁇ I gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGF ⁇ I gene also referred
- corneal dystrophy is detected for example through detection of Avellino corneal dystrophy-related SNPs, such as those that result in H626P mutations in the TGF ⁇ I gene (including for example but not limited to an H626P mutation caused by an A to C transition at nucleotide 1924 of TGF ⁇ I gene).
- Avellino corneal dystrophy-related SNPs such as those that result in H626P mutations in the TGF ⁇ I gene (including for example but not limited to an H626P mutation caused by an A to C transition at nucleotide 1924 of TGF ⁇ I gene).
- corneal dystrophy is detected for example through detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, corneal dystrophy is detected for example through detection of 2, 3, 4 and/or 5 of R124C, R124H, R124L, R555W, and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R124C in combination with one or more of R124H, R124L, R555W and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R124H in combination with one or more of R124C, R124L, R555W and/or R555Q.
- corneal dystrophy is detected for example through detection of R555W in combination with one or more of R124C, R124H, R124L and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R555Q in combination with one or more of R124C, R124H, R124L and/or R555W. In some embodiments, R124H is detected in combination with R555W. In some embodiments, corneal dystrophy is detected for example through detection of H262P in combination with one or more of R124C, R124H, R124L, R555W and/or R555Q. In some embodiments, R124C, R124H, R124L, R555W and/or R555Q are all detected. In some embodiments, R124C, R124H, R124L, R555W, R555Q and/or H626P are all detected.
- any or all of the reagents described above are packaged into a diagnostic kit.
- kits include any and/or all of the primers, probes, buffers and/or other reagents described herein in any combination.
- the kit includes reagents for detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P.
- the kit includes reagents for detection of 2, 3, 4, and/or 5 of R124C, R124H, R124L, R555W and R555Q.
- the kit includes reagents for detection of R124C, R124H, and R124L.
- the kit includes reagents for detection of R555W and R555Q. In some embodiments, the kit includes reagents for detection of R124C. In some embodiments, the kit includes reagents for detection of R124H. In some embodiments, the kit includes reagents for detection of R124L. In some embodiments, the kit includes reagents for detection of R555W. In some embodiments, the kit includes reagents for detection of R555Q.
- the kit includes primers and probes for detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, the kit includes primers and probes for detection of 2, 3, 4, and/or 5 of R124C, R124H, R124L, R555W and R555Q. In some embodiments, the kit includes primers and probes for detection of R124C, R124H, and R124L. In some embodiments, the kit includes primers and probes for detection of R555W and R555Q. In some embodiments, the kit includes primers and probes for detection of R124C. In some embodiments, the kit includes primers and probes for detection of R124H.
- the kit includes primers and probes for detection of R124L. In some embodiments, the kit includes primers and probes for detection of R555W. In some embodiments, the kit includes primers and probes for detection of R555Q. In some embodiments, the kit includes primers and probes for detection of H626P.
- the reagents in the kit are included as lyophilized powders. In some embodiments, the reagents in the kit are included as lyophilized powders with instructions for reconstitution. In some embodiments, the reagents in the kit are included as liquids. In some embodiments, the reagents are included in plastic and/or glass vials or other appropriate containers. In some embodiments the primers and probes are all contained in individual containers in the kit. In some embodiments, the primers are packaged together in one container, and the probes are packaged together in another container. In some embodiments, the primers and probes are packaged together in a single container.
- the kit further includes control gDNA and/or DNA samples.
- the control DNA sample included is TGFBI R124 normal.
- the control DNA sample included corresponds to the mutation being detected, including R124C, R124H, R124L, R555W, R555Q and/or H626P.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H, R124L, R555W, R555Q and/or H626P are included.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H, R124L, R555W and/or R555Q are included.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H and/or R124L are included.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R555W and/or R555Q are included.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C are included.
- a control DNA sample corresponding to TGFBI R124 normal DNA and a mutant DNA sample corresponding to R124H are included.
- a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124L are included.
- a control DNA sample corresponding to TGFBI R124 normal DNA and a mutant DNA sample corresponding to R555W are included.
- a control DNA sample corresponding to TGFBI R124 normal and mutant DNA sample corresponding to R555Q are included.
- a control DNA sample corresponding to TGFBI R124 normal and mutant DNA sample corresponding to H626P are included.
- the concentration of the control DNA sample is 5 ng/ ⁇ L, 10 ng/ ⁇ L, 20 ng/ ⁇ L, 30 ng/ ⁇ L, 40 ng/ ⁇ L, 50 ng/ ⁇ L, 60 ng/ ⁇ L, 70 ng/ ⁇ L, 80 ng/ ⁇ L, 90 ng/ ⁇ L, 100 ng/ ⁇ L, 110 ng/ ⁇ L, 120 ng/ ⁇ L, 130 ng/ ⁇ L, 140 ng/ ⁇ L, 150 ng/ ⁇ L, 160 ng/ ⁇ L, 170 ng/ ⁇ L, 180 ng/ ⁇ L, 190 ng/ ⁇ L or 200 ng/ ⁇ L.
- the concentration of the control DNA sample is 50 ng/ ⁇ L, 100 ng/ ⁇ L, 150 ng/ ⁇ L or 200 ng/ ⁇ L. In some embodiments, the concentration of the control DNA sample is 100 ng/ ⁇ L. In some embodiments, the control DNA samples have the same concentration. In some embodiments, the control DNA samples have different concentrations.
- the kit can further include buffers, for example, GTXpress TAQMAN® reagent mixture, or any equivalent buffer.
- the buffer includes any buffer described herein.
- the kit can further include reagents for use in cloning, such as vectors (including, e.g., M13 vector).
- reagents for use in cloning such as vectors (including, e.g., M13 vector).
- the kit further includes reagents for use in purification of DNA.
- the kit further includes instructions for using the kit for the detection of corneal dystrophy in a subject. In some embodiments, these instructions include various aspects of the protocols described herein.
- DNA was extracted from oral epithelium or hair root or whole blood as described below and in line with the disclosures provided herein.
- the sample was first pre-treated in 1 ⁇ PBS 300 ⁇ L. Next, 30 ⁇ L Lysis solution was added to tube and the mixture vortexed. The mixture was then incubated at 95° C. for 3 min. Next, 30 ⁇ L of DNA Stabilizing Solution (from Life Technologies/Thermo Scientific, USA) was added and the mixture vortexed. The mixture was then centrifuged at 13,000 RPM for 1 min.
- DNA Stabilizing Solution from Life Technologies/Thermo Scientific, USA
- the sample was first pre-treated in 1 ⁇ PBS 300 ⁇ L starting with 3 ⁇ L of whole blood. Next, 30 ⁇ L of lysis solution was added to tube and the mixture vortexed. The mixture was then incubated at 95° C. for 3 min. Next, 30 ⁇ L of DNA Stabilizing Solution (from Life Technologies/Thermo Scientific, USA) was added and the mixture vortexed. The mixture was then centrifuged at 13,000 RPM for 1 min.
- DNA Stabilizing Solution from Life Technologies/Thermo Scientific, USA
- the DNA concentration was read using a commercially available Tecan® Infinite® 200 PRO NanoQuant.
- 100 ⁇ L of eluents were pipetted into a clear 96 well plate.
- 100 ⁇ L of prepared blank solution was added to well H12. Concentrations were then read using the manufacturer's instructions provided with the NanoQuant.
- Reaction mixtures were prepared using the probes and primers described below in Tables 5 and 6.
- TGFBI 124 F TCC ACC ACC ACT CAG (SEQ ID NO: 1) CTG TA TGFBI 124 R CCA TCT CAG GCC TCA (SEQ ID NO: 2) GCT T TGFBI 555 F ACA CAG TCT TTG CTC (SEQ ID NO: 43) CCA CAA A TGFBI 555 R ACT TAA GTT GGT CTT (SEQ ID NO: 44) TAC CCA AGA GTC T
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Eye Examination Apparatus (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Systems and methods for detecting at least two genomic alleles associated with corneal dystrophy in a sample from a human subject are disclosed in which cells (e.g., epithelial) of the subject are adhered to a tip of a substrate. The tip of the substrate is agitated in a lysis solution that lyses cells adhered to the substrate. The substrate is removed from the lysis solution upon completion of this agitation. The resulting lysis solution is incubated and then genomic DNA from the lysis solution is isolated to form a gDNA solution. From this, identity of at least two nucleotides present in the human TGFβI gene is determined using at least two oligonucleotide primer pairs and the gDNA solution. These at least two nucleotides are located at respective independent positions of the TGFβI gene corresponding to respective independent single nucleotide polymorphisms (SNPs) associated with corneal dystrophy.
Description
- This application is a continuation of U.S. patent application Ser. No. 15/154,895, filed May 13, 2016 (now U.S. Pat. No. 11,525,160), which is a continuation application of International Application No. PCT/US2014/065975, filed Nov. 17, 2014, which claims priority to U.S. Provisional Patent Application Ser. No. 61/905,051, filed Nov. 15, 2013. All of these patent applications are incorporated by reference herein in their entireties.
- The contents of the electronic sequence listing (070335-5007-US01_Sequence_Listing.xml; Size: 101,518 bytes; and Date of Creation: Jul. 20, 2023) is herein incorporated by reference in its entirety.
- This application generally relates to methods for the isolation and detection of disease-associated genetic alleles. In particular, this application relates to an improved method for the detection of an Avellino corneal dystrophy associated allele.
- Real-time PCR can be used to detect differences between nucleic acid sequences having substantially identical sequences. Through the use of differentially labeled fluorescent nucleic acid probes, for example one that binds to a wild type sequence and one that binds to a mutant sequence, single nucleotide changes in the human genome can be quickly and reliably detected. This resolving power has been applied to medical diagnostics, where single nucleotide polymorphisms (SNPs), i.e., single base changes found within the coding and/or non-coding sequence of a protein, are correlated to human disease.
- However, real-time PCR analysis is highly dependent upon the collection and isolation of high quality samples. Poor sample collection and/or isolation require the use of longer assay conditions and greater amounts of real-time PCR reagents, both of which result in increased costs and reduced productivity. Furthermore, failure of a real-time PCR single nucleotide polymorphism detection assay can result in the need to collect additional samples, causing even greater loss in time and resources.
- Accordingly, methods resulting in improved sample collection and isolation, which improve the overall success rate of the assay, reduce the reagents required for the assay, and reduce the need to collect additional samples at later time are highly desirable. Furthermore, methods for performing real-time PCR SNP detection assays with lower amounts of sample material will also reduce the challenges associated with the collection and isolation of high quality samples.
- Corneal dystrophy can be an autosomal dominant hereditary disease, which initially presents with blurred vision in the center of a patient's cornea. The blurry vision gradually spreads toward the perimeter of cornea, worsening the patient's vision as they age. There are several types of corneal dystrophy that have been characterized, including Avellino corneal dystrophy, Granular corneal dystrophy, lattice type I corneal dystrophy, Thiel-Behnke, and Reis-bucklers corneal dystrophy. Corneal dystrophies are known to be caused, at least in some cases, by mutations in the transforming growth factor beta induced (TGFβI) gene encoding the βIG-H3 protein (also known as TGFβI protein, TGFBI protein, and keratoepithelin).
- Heterozygous patients suffering from Avellino corneal dystrophy have increasing loss in vision with age, becoming severe in the later years of life. Homozygous patients, in contrast, present with severe to complete loss of vision by six years of age. Avellino corneal dystrophy was first recognized as a distinct type of corneal dystrophy around 1988. Prior to then, it was likely misclassified as Granular corneal dystrophy. Today, Avellino corneal dystrophy is known to be the most common form of stromal corneal dystrophy world-wide. In Korea, Avellino corneal dystrophy is believed to have a prevalence around 1 in 870 people (see Lee, J. H. et al., Ophthalmic Epidemiol., 17:160, 2010; see also Holland, E. J. et al., Ophthalmology, 99:1564, 1992; Kennedy, S. M. et al., Br. J. Ophthalmol., 80:489, 1996; Dolmetsch, A. M. et al., Can. J. Ophthalmol., 31:29, 1996; Afshari, N. A. et al., Arch. Ophthalmol., 119:16, 2001; Stewart, H. S. Hum. Mutat., 14:126, 1999).
- Previously, it was discovered that heterozygous individuals (e.g., having one wild type βIG-H3 allele and one mutant βIG-H3 allele) were highly susceptible to accelerating loss of vision following LASIK surgery. Notably, two years after surgery increased opacity of the cornea was observed in these patients with increasing aggressiveness, eventually resulting in complete loss of vision (Jun, R. M. et al., Opthalmology, 111:463, 2004). Previously, eye surgery has been performed with an expectation that LASIK or Excimer Laser surgery would get rid of vision blurriness of a patient suffering from corneal dystrophy. For a hypothetical number of three hundred thousand cases of LASIK surgery, 300 people would have lost their vision, based on 1/1000 of minimum estimation of heterozygous patients suffering from Avellino corneal dystrophy. Patients who have undergone LASIK surgery are mainly in their 20's and 30's carrying out productive activities; therefore, their vision loss causes serious troubles in both society and economics.
- In addition, after approval of LASIK surgery in year 2000 in USA, African American patients suffering from Avellino corneal dystrophy who underwent LASIK surgery have been found to lose eye sight, which infers that plenty of similar cases might be occurring throughout the world.
- Therefore, although accurate diagnosis of Avellino corneal dystrophy is required to prevent the progression of Avellino corneal dystrophy by LASIK surgery, the diagnosis of Avellino corneal dystrophy is just conducted by microscopic observation (e.g., slit-lamp examination) of corneal opacity and thus often doctors miss latent symptoms of patients to perform LASIK surgery, which results in vision loss. Therefore, rapid and precise genetic diagnosis of corneal dystrophy is desirable.
- A DNA chip for detecting a mutation in βIG-H3 gene, which is responsible for Avellino corneal dystrophy, was developed (Korean Patent Laid-Open Publication No. 10-2007-0076532). However, the diagnosis of Avellino corneal dystrophy using the DNA chip disadvantageously requires several steps, including a step of amplifying DNA in a sample, a step of hybridizing the amplified DNA with the DNA chip, a step of washing the hybridized DNA chip, and a step of detecting a positive response.
- Given the above background, what is needed in the art are improved methods for detecting multiple mutated alleles associated with corneal dystrophy.
- The present disclosure provides improved methods for the detection of one or more alleles associated with human disease. The methods described below decrease the time and cost associated with performing assays that yield medical information about a subject. For example, in some embodiments, the improved methods allow for same-day detection of a genomic marker associated with Avellino corneal dystrophy, at a reduced cost to the patient.
- In some embodiments, the present disclosure provides methods for detecting at least two genomic alleles associated with corneal dystrophy in a sample from a subject, the method comprising: (A) providing epithelial cells of a subject adhered to a tip of a substrate; (B) agitating the tip of the substrate in a lysis solution that lyses cells adhered to the substrate; (C) removing the substrate from the lysis solution upon completion of the agitating (B); (D) incubating the lysis solution after the removing (C); (E) isolating genomic DNA from the lysis solution to form a gDNA solution; and (F) determining an identity of at least two nucleotides present in the TGFβI gene using at least two oligonucleotide primer pairs and the gDNA solution, wherein the at least two nucleotides are located at respective independent positions of the TGFβI gene corresponding to respective independent single nucleotide polymorphisms (SNPs) associated with corneal dystrophy.
- In some embodiments, the at least two nucleotides present in the TGFβI gene are separated in the human genome by at least one nucleotide.
- In some embodiments, at least one pair of the at least two oligonucleotide primer pairs comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:1 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:2.
- In some embodiments, at least one pair of the at least two oligonucleotide primer pairs comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:43 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:44.
- In some embodiments, the at least two oligonucleotide primer pairs comprise a first amplification primer pair and a second amplification primer pair. The first amplification primer pair comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:1 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:2. The second amplification primer pair comprises a forward PCR primer having a nucleotide sequence comprising SEQ ID NO:43 and a reverse PCR primer having a nucleotide sequence comprising SEQ ID NO:44.
- In some embodiments, the determining (F) further comprises using: (i) a first wild type detection probe having a nucleotide sequence comprising SEQ ID NO:25 and a first mutant detection probe having a nucleotide sequence comprising SEQ ID NO:26, SEQ ID NO:48, or SEQ ID NO:49; and (ii) a second wild type detection probe having a nucleotide sequence comprising SEQ ID NO:45 or SEQ ID NO:47 and a second mutant detection probe having a nucleotide sequence comprising SEQ ID NO:46 or SEQ ID NO:50.
- In some embodiments, the present disclosure provides a method for detecting corneal dystrophy, the method comprising: (A) amplifying at least two TGFβI gene sequences, including a first TGFβI gene sequence comprising nucleotides encoding
amino acid residue 124 and a second TGFβI gene sequence comprising nucleotides encodingamino acid residue 555, from a biological sample from a human subject using a reaction mixture comprising at least a first amplification primer pair and at least a second amplification primer pair; (B) hybridizing a first detection probes of a first detection oligonucleotide probe pair to the first TGFβI gene sequence; (C) hybridizing a second detection probe of a second detection oligonucleotide probe pair to the second TGFβI gene sequence; and (D) detecting one or more mutations in the first TGFβI gene sequence and/or the second TGFβI gene sequence based on a use of at least two detection probe pairs, including the first detection oligonucleotide probe pair and the second detection oligonucleotide probe pair. - In some embodiments, detecting the one or more mutations in the first TGFβI gene sequence and/or the second TGFβI gene sequence includes detecting two or more mutations in the first TGFβI gene sequence and/or the second TGFβI gene sequence and the two or more mutations are separated in the human genome by at least one nucleotide.
- In some embodiments, the at least first amplification primer pair comprises a first amplification primer and a second amplification primer, wherein the first amplification primer comprises nucleotide sequence SEQ ID NO:1 and wherein the second amplification primer comprises nucleotide sequence SEQ ID NO:2.
- In some embodiments, the at least second amplification primer pair comprises a third amplification primer and a fourth amplification primer, wherein the third amplification primer is represented by nucleotide sequence SEQ ID NO:43, and wherein the fourth amplification primer is represented by nucleotide sequence SEQ ID NO:44.
- In some embodiments, the first amplification primer pair comprises a first amplification primer and a second amplification primer, the first amplification primer comprises nucleotide sequence SEQ ID NO:1, the second amplification primer comprises nucleotide sequence SEQ ID NO:2, the second amplification primer pair comprises a third amplification primer and a fourth amplification primer, the third amplification primer comprises nucleotide sequence SEQ ID NO:43, and the fourth amplification primer comprises nucleotide sequence SEQ ID NO:44.
- In some embodiments, one of the one or more mutations corresponds to, at
amino acid 124, arginine mutated to a cysteine (R124C), arginine mutated to a histidine (R124H), and/or arginine mutated to a leucine (R124L) in the encoded TGFBI protein. - In some embodiments, one of the one or more mutations corresponds to, at
amino acid 555, arginine mutated to a tryptophan (R555W) and/or arginine mutated to a glutamine (R555Q) in the encoded TGFBI protein. - In some embodiments, each of the at least two detection oligonucleotide probe pairs individually includes a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe comprise a nucleotide sequence pair individually selected from the group consisting of SEQ ID NOs:25-26, SEQ ID NOs:25 and 48, SEQ ID NOs:25 and 49, SEQ ID NOs:27-28, SEQ ID NOs:29-30, SEQ ID NOs:31-32, SEQ ID NOs:33-34, SEQ ID NOs:35-36, SEQ ID NOs:37-38, SEQ ID NOs:39-40, SEQ ID NOs:41-42, SEQ ID NOs:45-46 and SEQ ID NOs:46-47, SEQ ID NOs: 45 and 50, and SEQ ID NOs: 47 and 50.
- In some embodiments, the first detection oligonucleotide probe pair comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:26.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:46.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:46.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:48.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:49.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:50.
- In some embodiments, the second detection oligonucleotide probe pair comprises a third detection oligonucleotide probe and a fourth detection oligonucleotide probe, wherein the third detection oligonucleotide probe and the fourth detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:50.
- In some embodiments, the first detection probe is coupled with a first label and the second detection probe is coupled to a second label.
- In some embodiments, the first label is VIC and the second label is FAM.
- In some embodiments, the hybridizing (B) and the hybridizing (C) are performed concurrently in a same solution.
- In some embodiments, the hybridizing (B) and the hybridizing (C) are performed concurrently or at different time in a same solution or different solutions.
- In some embodiments, the present disclosure provides a reaction mixture for detecting corneal dystrophy in a human subject, the reaction mixture comprising: (A) at least a first amplification primer pair and a second amplification primer pair for amplifying and determining (1) a first TGFβI gene sequence of at least two TGFβI gene sequences that comprises nucleotides encoding
amino acid residue 124 from a biological sample from the subject and (2) a second TGFβI gene sequence of the at least two TGFβI gene sequences that comprises nucleotides encodingamino acid residue 555 from a biological sample from the subject; and (B) at least two detection probe pairs, wherein a detection probe in each of the at least two detection probe pairs hybridizes to at least one of the at least two TGFβI gene sequences. - In some embodiments, the first amplification primer pair comprises a first amplification primer and a second amplification primer, the first amplification primer comprises a nucleotide sequence SEQ ID NO:1, and the second amplification primer comprises a nucleotide sequence SEQ ID NO:2.
- In some embodiments, the second amplification primer pair comprises a third amplification primer and a fourth amplification primer, the third amplification primer comprises a nucleotide sequence SEQ ID NO:43, and the fourth amplification primer comprises a nucleotide sequence SEQ ID NO:44.
- In some embodiments, at least one of the at least two detection probe pairs is used to detect a mutation that corresponds to, at
amino acid 124, arginine mutated to a cysteine (R124C), arginine mutated to a histidine (R124H), and/or arginine mutated to a leucine (R124L) in the encoded TGFBI protein. - In some embodiments, at least one of the at least two detection probe pairs is used to detect a mutation that corresponds to, at
amino acid 555, arginine mutated to a tryptophan (R555W) and/or arginine mutated to a glutamine (R555Q) in the encoded TGFBI protein. - In some embodiments, respective detection probe pairs of the at least two detection probe pairs individually include a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe comprise a nucleotide sequence pair individually selected from the group consisting of SEQ ID NOs:25-26, SEQ ID NOs:25 and 48, SEQ ID NOs:25 and 49, SEQ ID NOs:27-28, SEQ ID NOs:29-30, SEQ ID NOs:31-32, SEQ ID NOs:33-34, SEQ ID NOs:35-36, SEQ ID NOs:37-38, SEQ ID NOs:39-40, SEQ ID NOs:41-42, SEQ ID NOs: 45-46 and SEQ ID NOs: 46-47, SEQ ID NOs: 45 and 50, and SEQ ID NOs: 47 and 50.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:26.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:46.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:46.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:48.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:25 and SEQ ID NO:49.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:45 and SEQ ID NO:50.
- In some embodiments, one of the at least two detection probe pairs comprises a first detection oligonucleotide probe and a second detection oligonucleotide probe, wherein the first detection oligonucleotide probe and the second detection oligonucleotide probe respectively comprise nucleotide sequence pair SEQ ID NO:47 and SEQ ID NO:50.
- In some embodiments, a first detection probe of the at least two detection probes is coupled with a first label and a second detection probe of the at least two detection probes is coupled to a second label.
- In some embodiments, the first label is VIC and the second label is FAM.
- In some embodiments, the present disclosure provides a reaction mixture for detecting corneal dystrophy in a human subject, the reaction mixture comprising: (A) at least a first amplification primer pair for amplifying and determining a TGFβI gene sequence from a biological sample from the subject; and (B) a set of at least three detection probes, wherein one detection probe of the set of at least three detection probes hybridizes to the TGFβI gene sequence when exposed to the TGFβI gene sequence.
- In some embodiments, the TGFβI gene sequence comprises nucleotides encoding
amino acid residue 124 from the biological sample from the subject. - In some embodiments, the set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- In some embodiments, the set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- In some embodiments, the set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs:25-42 and 48-49.
- In some embodiments, the set of at least three detection probes include a first detection probe SEQ ID NO:25 and a second detection probe SEQ ID NO:26.
- In some embodiments, the set of at least three detection probes include a third detection probe selected from the group consisting of SEQ ID NO:48 and SEQ ID NO:49.
- In some embodiments, the set of at least three detection probes include a fourth detection probe that is distinct from the third detection probe and that is selected from the group consisting of SEQ ID NO:48 and SEQ ID NO:49.
- In some embodiments, the set of at least three detection probes include two or more detection probes selected from the group consisting of SEQ ID NOs:26 and 48-49.
- In some embodiments, the first amplification primer pair comprises a first amplification primer and a second amplification primer, the first amplification primer comprises a nucleotide sequence SEQ ID NO:1, and the second amplification primer comprises a nucleotide sequence SEQ ID NO:2.
- In some embodiments, the reaction mixture further comprises: (C) at least a second amplification primer pair for amplifying and determining a second TGFβI gene sequence from the biological sample; and (D) a second set of at least three detection probes, wherein one detection probe of the second set of at least three detection probes hybridizes the second TGFβI gene sequence when exposed to the second TGFβI gene sequence.
- In some embodiments, the second TGFβI gene sequence comprises nucleotides encoding
amino acid residue 555 from the biological sample from the subject. - In some embodiments, the second set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- In some embodiments, the second set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- In some embodiments, the second set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- In some embodiments, the second set of at least three detection probes include a first detection probe that is SEQ ID NO:45 or SEQ ID NO:47, a second detection probe that is SEQ ID NO:46, and a third detection probe that is SEQ ID NO:50.
- In some embodiments, the second amplification primer pair comprises a third amplification primer and a fourth amplification primer, the third amplification primer comprises a nucleotide sequence SEQ ID NO:43, and the fourth amplification primer comprises a nucleotide sequence SEQ ID NO:44.
- In some embodiments, the TGFβI gene sequence comprises nucleotides encoding
amino acid residue 555 from the biological sample from the subject. - In some embodiments, the set of at least three detection probes include at least one detection probe selected from the group consisting of SEQ ID NOs:45-47 and 50.
- In some embodiments, the set of at least three detection probes include at least two or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- In some embodiments, the set of at least three detection probes include at least three or more detection probes selected from the group consisting of SEQ ID NOs: 45-47 and 50.
- In some embodiments, the set of at least three detection probes include a first detection probe that is SEQ ID NO:45 or SEQ ID NO:47, a second detection probe that is SEQ ID NO:46, and a third detection probe that is SEQ ID NO:50.
- In some embodiments, the present disclosure provides a method for detecting corneal dystrophy comprising: (A-1) amplifying a first TGFβI gene sequence from a biological sample from a human subject using a reaction mixture comprising at least a first amplification primer pair and a set of at least three detection probes; (B-1) hybridizing a first detection probe of the set of at least three detection probes to the first TGFβI gene sequence; and (C-1) detecting a mutation in the first TGFβI gene sequence based on (i) the hybridization of the first detection probe of the set of at least three detection probes to the first TGFβI gene sequence and (ii) the failure of a second and a third detection probe of the set of at least three detection probes to hybridize to first TGFβI gene sequence.
- In some embodiments, the method further comprises: (A-2) amplifying a second TGFβI gene sequence from the biological sample using the same reaction mixture, wherein the reaction mixture comprises at least a second amplification primer pair and a second set of at least three detection probes; (B-2) hybridizing a first detection probe of the second set of at least three detection probes to the second TGFβI gene sequence; and (C-2) detecting a mutation in the second TGFβI gene sequence based on (i) the hybridization of the first detection probe of the second set of at least three detection probes to the first TGFβI gene sequence and (ii) and (ii) the failure of a second detection probe and a third detection probe of the second set of at least three detection probes to hybridize to the second TGFβI gene sequence.
- In some embodiments, the amplifying (A-1), the amplifying (A-2), the hybridizing (B-1), the hybridizing (B-2), the detecting (C-1), and the detecting (C-2) are performed with a same aliquot of the biological sample.
- In some embodiments, the amplifying the first TGFβI gene sequence (A-1) and the amplifying the second TGFβI gene sequence (A-2) are performed concurrently.
- In some embodiments, the hybridizing (B-1) and the hybridizing (B-2) are performed concurrently.
- In some embodiments, the detecting (C-1) and the detecting (C-2) are performed concurrently.
- In some embodiments, the reaction mixture has some of the features described above. For brevity, such details are not repeated herein.
- In some embodiments, the present disclosure provides use of a reaction mixture, as recited in any above, for predicting the risk of complication following laser eye surgery in a subject through a detection of heterozygous corneal dystrophy in the human subject.
- In some embodiments, the laser eye surgery comprises one of Lasik and Excimer laser surgery.
- In some embodiments, the present disclosure provides a method for detecting a genomic mutation associated with corneal dystrophy in a sample from a human subject, the method comprising: (A) providing epithelial cells of a human subject adhered to a tip of a substrate; (B) agitating the tip of the substrate in a lysis solution that lyses cells adhered to the substrate; (C) removing the substrate from the lysis solution upon completion of the agitating (B); (D) incubating the lysis solution after the removing (C); (E) isolating genomic DNA from the lysis solution to form a gDNA solution; and (F) determining an identity of at least a nucleotide present in the TGFβI gene using at least a first primer pair, a set of at least three detection probes, and the gDNA solution by concurrently exposing the gDNA solution to the at least three detection probes, wherein: the at least a nucleotide is located at a particular position of the TGFβI gene corresponding to a single nucleotide polymorphism (SNPs) associated with corneal dystrophy, and each of at least two detection probes of the set of the at least three detection probes is configured to detect a different mutation at the particular position of the TGFβI gene.
- In some embodiments, the method further comprises: (G) determining an identity of at least a second nucleotide present in the TGFβI gene using at least a second primer pair, a second set of at least three detection probes, and the gDNA solution by concurrently exposing the gDNA solution to the set of at least three detection probes and the second set of at least three detection probes, wherein: the at least a second nucleotide is located at a second particular position, independent of the position of the at least a nucleotide, of the TGFβI gene corresponding to a second single nucleotide polymorphism (SNPs) associated with corneal dystrophy, and at least two detection probes of the second set of the at least three detection probes are configured to detect a respective mutation at the second particular position of the TGFβI gene.
- In some embodiments, the determining (F) and the determining (G) are performed concurrently.
- In some embodiments, the determining (F) and the determining (G) are performed using the same gDNA solution.
-
FIGS. 1A-1B illustrate animproved method 100 for the detection of genomic alleles associated with disease, according to some embodiments. -
FIG. 2 provides a list of sequences for forward and reverse PCR primer pairs (SEQ ID NOs:1-24) useful for real-time PCR detection of a single nucleotide polymorphism associated with Avellino corneal dystrophy, in accordance with some embodiments. -
FIG. 3 provides a list of sequences for wild type and mutant detection probe pairs (SEQ ID NOs:25-42) useful for real-time PCR detection of a single nucleotide polymorphism associated with Avellino corneal dystrophy, in accordance with some embodiments. -
FIG. 4 provides a list of the probe sequences and primers used in the allele detection experiments shown inFIGS. 5 through 8 . -
FIGS. 5A, 5B, and 5C provide experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described inFIG. 4 .FIG. 5A provides an allelic discrimination plot run (left-hand panel) using the indicated reagent mixture and indicated cycling conditions (right-hand panel).FIG. 5B provides the Real-Time PCR plots for the various mutants compared to a normal control.FIG. 5C provides the Real-Time PCR plots for the various mutants compared to a homozygous control. -
FIGS. 6A, 6B, and 6C provide experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described inFIG. 4 .FIG. 6A provides an allelic discrimination plot run (left-hand panel) using the indicated reagent mixture and indicated cycling conditions (right-hand panel).FIG. 6B provides the Real-Time PCR plots for the various mutants compared to a normal control.FIG. 6C provides the Real-Time PCR plots for the various mutants compared to a homozygous control. -
FIG. 7 provides experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described inFIG. 4 .FIG. 7 provides an allelic discrimination plot (left-hand panel) run using the indicated reagent mixture and indicated cycling conditions (right-hand panel). -
FIG. 8 provides experimental data regarding detection of the R124C, R124H, R124L, R555W and R555Q mutants using the probes described inFIG. 4 . In particular,FIG. 8 provides an allelic discrimination plot run using the indicated reagent mixture and indicated cycling conditions (right-hand panel). The designation “B” in the allelic discrimination plot (left-hand panel) indicates samples were pre-treated with lysis buffer prior to performing the Real-Time PCR assay. The designation “DW-A” in the allelic discrimination plot (left-hand panel) indicates samples were pre-treated with distilled water prior to performing the Real-Time PCR assay. The circles surrounding the different sample dots show the two matched samples, “B” and “DW-A” respectively, for each of the alleles detected (see, the left-hand panel); there are two dots within each circle, one for sample “B” and one for sample “DW-A”. - I. Introduction
- The detection of disease-related SNPs is an increasingly more important tool for the diagnosis and prognosis of various medical conditions. For example, the presence of a single nucleotide change in
exon 4 of the TGFβI gene is strongly associated with Avellino corneal dystrophy. It was found that individuals heterozygous for this SNP are at high risk for vision loss following LASIK surgery. While LASIK is a medical procedure that greatly improves many people's quality of life, for individuals carrying the G/A TGFβI SNP, it commonly causes a gradual vision impairment over a four to eighteen month period, which may lead to loss of vision. The vision impairment may occur in a longer or shorter period of time. Fortunately, screening can be performed to identify individuals carrying the mutation who should avoid having the LASIK procedure. - The present disclosure is based at least in part on the discovery of methods that improve sample isolation, preparation, and analysis. In some embodiments, methods are provided which allow for the re-use of patient samples, for example, when an assay fails or additional follow-up testing needs to be performed. In some embodiments, these improved methods include gently swirling a substrate (e.g., a rayon-tipped or cotton-tipped applicator) carrying cells sloughed-off the buccal membrane of the patient in a lysis solution at room temperature for 30-45 seconds (rather than extended incubation for 20 minutes at elevated temperature). The lysis solution is then incubated at 45° C. for 30 minutes to improve lysis and increase the yield of genomic sample. Advantageously, the rayon-tipped or cotton-tipped applicator can then be stored (e.g., frozen or refrigerated) for re-isolation of genomic DNA used for re-testing.
- In some embodiments, the improvements provided herein are provided through the use of lower amounts of genomic DNA template for the real-time PCR detection assays. In some embodiments, this is achieved by increasing the number of real-time PCR cycles performed (e.g., at about 40 cycles) and/or by using 3 second denaturation cycle times at 95° C. Advantageously, because the amount of sample required is reduced by these methods, so too are the requirements for the real-time PCR reagents. Because many reagents used in diagnostic assays are proprietary, the reagents can be expensive. Reducing the amount of reagent used can also significantly reduce the costs associated with the reagent.
- It is contemplated that all combinations of specific conditions (e.g., sample handling, incubation temperature, reaction volumes, reaction cycle numbers, reaction cycle times, reaction cycle temperatures) for performing each of these individual steps can be used to perform the methods described herein for detecting disease-related SNPs, such as the Avellino corneal dystrophy-related SNP found in
exon 4 of the TGFβI gene. - II. Select Definitions
- The term “invention” or “present invention” as used herein is not meant to be limiting to any one specific embodiment of the invention but applies generally to any and all embodiments of the invention as described in the claims and specification.
- As used herein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure.
- As used herein, the term “polymorphism” and variants thereof refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. The terms “genetic mutation” or “genetic variation” and variants thereof include polymorphisms.
- As used herein the term “single nucleotide polymorphism” (“SNP”) and variants thereof refers to a site of one nucleotide that varies between alleles. A single nucleotide polymorphism (SNP) is a single base change or point mutation but also includes the so-called “indel” mutations (insertions or deletions of a nucleotide), resulting in genetic variation between individuals. SNPs, which make up about 90% of all human genetic variation, occur every 100 to 300 bases along the 3-billion-base human genome. However, SNPs can occur much more frequently in other organisms like viruses. SNPs can occur in coding or non-coding regions of the genome. A SNP in the coding region may or may not change the amino acid sequence of a protein product. A SNP in a non-coding region can alter promoters or processing sites and may affect gene transcription and/or processing. Knowledge of whether an individual has particular SNPs in a genomic region of interest may provide sufficient information to develop diagnostic, preventive and therapeutic applications for a variety of diseases. In some embodiments, the present disclosure relates to the detection of a guanine-to-adenine SNP located in
exon 4 of the TGFβI gene associated with Avellino corneal dystrophy. - The term “primer” and variants thereof refers to an oligonucleotide that acts as a point of initiation of DNA synthesis in a PCR reaction. A primer is usually about 15 to about 35 nucleotides in length and hybridizes to a region complementary to the target sequence.
- The term “probe” and variants thereof (e.g., detection probe) refers to an oligonucleotide that hybridizes to a target nucleic acid in a PCR reaction. Target sequence refers to a region of nucleic acid that is to be analyzed and comprises the polymorphic site of interest.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, various embodiments of methods and materials are specifically described herein.
- III. Sample Preparation
- In some embodiments, the disclosure provides improved methods for isolating genomic samples used in real-time PCR single nucleotide polymorphism detection assays. In some embodiments, the
improved method 100 uses a combination of steps outlined inFIG. 1 . - In some embodiments, the method includes providing a sample of cells from a subject. In some embodiments, the cells are collected by contacting a cellular surface of a patient with a substrate capable of reversibly immobilizing the cells onto a substrate.
- The disclosed methods are applicable to a variety of cell types obtained from a variety of samples. In some embodiments, the cell type for use with the disclosed methods include but is not limited to epithelial cells, endothelial cells, connective tissue cells, skeletal muscle cells, endocrine cells, cardiac cells, urinary cells, melanocytes, keratinocytes, blood cells, white blood cells, buffy coat, hair cells (including, e.g., hair root cells) and/or salival cells. In some embodiments, the cells are epithelial cells. In some embodiments, the cells are subcapsular-perivascular (epithelial type 1); pale (epithelial type 2); intermediate (epithelial type 3); dark (epithelial type 4); undifferentiated (epithelial type 5); and large-medullary (epithelial type 6). In some embodiments, the cells are buccal epithelial cells (e.g., epithelial cells collected using a buccal swap). In some embodiments, the sample of cells used in the disclosed methods include any combination of the above identified cell types.
- In some embodiments, the method includes providing (102) a sample of cells from a subject. In some embodiments, the cells provided are buccal epithelial cells.
- The cell sample is collected by any of a variety of methods which allow for reversible binding of the subjects cells to the substrate. In some embodiments, the substrate is employed in a physical interaction with the sample containing the subject's cells in order to reversibly bind the cells to the substrate. In some embodiments, the substrate is employed in a physical interaction with the body of the subject directly in order to reversibly bind the cells to the substrate. In some embodiments, the sample is a buccal cell sample and the sample of buccal cells is collected by contacting a buccal membrane of the subject (e.g., the inside of their cheek) with a substrate capable of reversibly immobilizing cells that are dislodged from the membrane. In such embodiments, the swab is rubbed against the inside of the subject's cheek with a force equivalent to brushing a person's teeth (e.g., a light amount of force or pressure). Any method which would allow the subject's cells to be reversibly bound to the substrate is contemplated for use with the disclosed methods.
- In some embodiments, the sample is advantageously collected in a non-invasive manner and as such sample collection is accomplished anywhere and by almost anyone. For example, in some embodiments the sample is collected at a physician's office, at a subject's home, or at a facility where LASIK surgery is performed or to be performed. In some embodiments the patient, the patient's doctor, nurses or a physician's assistant or other clinical personnel collects the sample.
- In some embodiments the substrate is made of any of a variety of materials to which cells are reversibly bound. Exemplary substrates include those made of rayon, cotton, silica, an elastomer, a shellac, amber, a natural or synthetic rubber, cellulose, BAKELITE, NYLON, a polystyrene, a polyethylene, a polypropylene, a polyacrylonitrile, or other materials or combinations thereof. In some embodiments, the substrate is a swab having a rayon tip or a cotton tip.
- The tip of the substrate (e.g., the tip of the rayon swab or cotton swab) is then agitated in a lysis solution from about 10 seconds to 60 seconds (1 minute), or about 20 seconds to 60 seconds, about 20 seconds to about 45 seconds, or about 20 seconds to about 30 seconds, about 15 seconds to about 60 seconds, about 15 seconds to about 45 seconds, or about 15 seconds to about 30 seconds, about 10 seconds to about 60 seconds, about 10 seconds to about 45 seconds, or about 10 seconds to about 30 seconds, about 10 seconds to about 15 seconds or about 10 seconds to about 20 seconds. In some embodiments, the agitation occurs for about 60 seconds or about 1 minute. In some embodiments, the agitation occurs for less than a minute (e.g., less than 60 seconds). In some embodiments, the agitation occurs for no more than 15 seconds, 20 seconds, 30 seconds, 45 seconds, 60 seconds, 90 seconds, 120 seconds or more. In some embodiments, the agitation occurs for no more than 45 seconds. In some embodiments, the agitation occurs for no more than 30 seconds. In some embodiments, the agitation occurs for no more than 20 seconds. In some embodiments, the agitation occurs for no more than 15 seconds.
- In some embodiments, agitation includes any movement of the substrate in the lysis solution. In some embodiments, the tip of the substrate (e.g., the tip of the rayon swab or cotton swab) is moved gently in the lysis solution, such that a plurality of buccal cells remains affixed to the substrate for isolation at a later time and/or subsequent time. Such movement in the lysis solution includes swirling motions, side to side motions, up and down motions and/or dipping motions, or any other movement of the substrate in the lysis solutions that results in a plurality of buccal cell remain affixed to the tip while allowing for some buccal cells to be dispersed into the lysis solution.
- In some embodiments, the agitation step is performed at room temperature, for instance, temperatures between about 15° C. and about 30° C., about 18° C. and about 28° C., about 18° C. and about 25° C. or about 20° C. and about 25° C.
- After agitation, the substrate (e.g., a swab with a rayon tip or cotton tip) is removed and, in some embodiments, stored for use later, in case re-testing or further (e.g., different or additional) testing is needed. In some embodiments, the substrate (e.g., buccal swab with a rayon tip or cotton tip) is placed in a container and stored frozen. In some embodiments, the substrate (e.g., buccal swab with a rayon tip or cotton tip) is refrigerated. In some embodiments, the substrate is stored at any of a variety of temperatures and for any of a variety of times while still remaining useful for one or more additional extractions.
- In some embodiments, the substrate containing the sample is stored for 0 weeks, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks or 12 weeks or more. In some embodiments, the substrate containing the sample is stored for and/or is capable of being stored for 0 weeks to 12 weeks, 1 week to 12 weeks, 2 weeks to 12 weeks, 3 weeks to 12 weeks, 4 weeks to 12 weeks, 5 weeks to 12 weeks, 6 weeks to 12 weeks, 7 weeks to 12 weeks, 8 weeks to 12 weeks, 9 weeks, 10 weeks to 12 weeks, or 11 weeks to 12 weeks. In some embodiments, the substrate containing the sample is stored for 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, or 36 months or more. In some embodiments, the substrate containing the sample is stored for 1 month to 36 months, 2 months to 36 months, 3 months to 36 months, 4 months to 36 months, 5 months to 36 months, 6 months to 36 months, 7 months to 36 months, 8 months to 36 months, 9 months to 36 months, 10 months to 36 months, 12 months to 36 months, 14 months to 36 months, 16 months to 36 months, 18 months to 36 months. In some embodiments, the substrate containing the sample is stored for 1 month to 30 months, 2 months to 30 months, 3 months to 30 months, 4 months to 30 months, 5 months to 30 months, 6 months to 30 months, 7 months to 30 months, 8 months to 30 months, 9 months to 30 months, 10 months to 30 months, 12 months to 30 months, 14 months to 30 months, 16 months to 30 months or 18 months to 30 months. In some embodiments, the substrate containing the sample is stored for 1 month to 24 months, 2 months to 24 months, 3 months to 24 months, 4 months to 24 months, 5 months to 24 months, 6 months to 24 months, 7 months to 24 months, 8 months to 24 months, 9 months to 24 months, 10 months to 24 months, 12 months to 24 months, 14 months to 24 months, 16 months to 24 months, 18 months to 24 months. In some embodiments, the substrate containing the sample is stored for 1 month to 22 months, 2 months to 22 months, 3 months to 22 months, 4 months to 22 months, 5 months to 22 months, 6 months to 22 months, 7 months to 22 months, 8 months to 22 months, 9 months to 22 months, 10 months to 22 months, 12 months to 22 months, 14 months to 22 months, 16 months to 22 months, 18 months to 22 months. In some embodiments, the substrate containing the sample is stored for 1 month to 20 months, 2 months to 20 months, 3 months to 20 months, 4 months to 20 months, 5 months to 20 months, 6 months to 20 months, 7 months to 20 months, 8 to 20 months, 9 to 20 months, 10 months to 20 months, 12 months to 20 months, 14 months to 20 months, 16 months to 20 months, 18 months to 20 months. In some embodiments, the substrate containing the sample is stored for 1 month to 18 months, 2 months to 18 months, 3 months to 18 months, 4 months to 18 months, 5 months to 18 months, 6 months to 18 months, 7 months to 18 months, 8 months to 18 months, 9 months to 18 months, 10 months to 18 months, 12 months to 18 months, 14 months to 18 months, 16 months to 18 months or 17 months to 18 months. In some embodiments, the substrate containing the sample is stored for 1 month to 12 months, 2 months to 12 months, 3 months to 12 months, 4 months to 12 months, 5 months to 12 months, 6 months to 12 months, 7 months to 12 months, 8 months to 12 months, 9 months to 12 months, 10 months to 12 months or 11 months to 12 months.
- In some embodiments, the substrate containing the sample is stored at about 2° C., about 3° C., about 4° C., about 5° C., about 6° C., about 7° C., or about 8° C. In some embodiments, the substrate containing the sample is stored at about 2° C. to about 8° C., about 3° C. to about 8° C., about 4° C. to about 8° C., about 5° C. to about 8° C., about 6° C. to about 8° C. or about 7° C. to about 8° C. In some embodiments, the substrate containing the sample is stored at about −25° C., about −24° C., about −23° C., about −22° C., about −21° C., about −20° C., about −19° C., about −18° C., about −17° C., about −16° C. or about −15° C. In some embodiments, the substrate containing the sample is stored at about −25° C. to about −15° C., about −22° C. to about −17° C., about −20° C. to about −15° C. or about −25° C. to about −20° C. In some embodiments, the substrate containing the sample is stored at about −90° C., about −89° C., about −88° C., about −87° C., about −86° C., about −85° C., about −84° C., about −83° C., about −82° C., about −81° C., about −80° C., about −79° C., about −78° C., about −77° C., about −76° C., about −75° C., about −74° C., about −73° C., about −72° C., about −71° C., about −70° C., about −69° C., about −68° C., about −67° C., about −66° C. or about −65° C. In some embodiments, the substrate containing the sample is stored at about −90° C. to about −65° C., about −85° C. to about −65° C., about −80° C. to about −65° C., about −75° C. to about −65° C. or about −70° C. to about −65° C. In some embodiments, the substrate containing the sample is stored at −90° C. to −65° C.
- In some embodiments, the substrate containing the sample is freeze-thawed one or more times (e.g., after being frozen, the substrate containing the sample is thawed, used according to the present methods and re-frozen) and or used in the present methods. In some embodiments, the substrate containing the sample is freeze-thawed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more times. In some embodiments, the substrate containing the sample is used in the
present methods present methods 1 to 20 times, 2 to 20 times, 3 to 20 times, 4 to 30 times, 5 to 20 times, 6 to 20 times, 7 to 20 times, 8 to 20 times, 9 to 20 times, 10 to 20 times, 11 to 20 times, 12 to 20 times, 13 to 20 times, 14 to 20 times, 15 to 20 times, 16 to 20 times, 17 to 20 times, 18 to 20 times, 19 to 20 times, 5 to 15 times, 5 to 10 times, 1 to 10 times, 1 to 5 times, 1 to 4 times, 1 to 3 times or 1 to 2 times. - In some embodiments, the substrate containing the sample is stored for 1 week at room temperature or about 15° C. to about 30° C. In some embodiments, the sample is stored for about 1, 2 or 3 weeks at about 2° C. to about 8° C. or about 4° C. In some embodiments, the substrate containing the sample is stored for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months at about −25° C. to about −15° C. or about −20° C. In some embodiments, the substrate containing the sample is stored for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months at about −90° C. to about −65° C. or about −80° C.
- Advantageously and surprisingly, it was found that the reduced number of cells extracted from the substrate is countered by increased extraction of nucleic acids from individual cells. In some embodiments, increased extraction is accomplished by incubating the cells for a longer time as compared to standard practices, incubating the cells at an elevated temperature as compared to standard practices, or a combination of both.
- In some embodiments, the increased extraction of nucleic acids of cells is accomplished by performing the extraction incubation for an increased or longer period of time as compared to standard practice. In some embodiments, the extraction incubation is performed for about 45 minutes, e.g., 45±5, 45±10, 45±15, or 45±20 minutes. In some embodiments, the extraction incubation is performed for about 25 minutes to about 65 minutes, about 30 minutes to about 60 minutes, about 35 minutes to about 55 minutes, about 45 minutes to about 65 minutes, about 45 minutes to about 55 minutes, or about 40 minutes to about 50 minutes. In some embodiments, the extraction incubation time is about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes or about 65 minutes.
- In some embodiments, the increased the extraction of nucleic acids of cells is accomplished by performing the extraction incubation at an increased or higher temperature as compared to standard practice. In some embodiments, the extraction incubation is performed at about 45° C., e.g., 45±2° C., 45±5° C., or 45±10° C. In some embodiments, the extraction incubation temperature is about 35° C. to about 55° C., about 40° C. to about 50° C. or about 43° C. to about 47° C. In some embodiments, the extraction temperature is about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C. or about 55° C. In some embodiments, more than one extraction temperature is used. For example in some embodiments, standard temperatures are used for a portion of the extraction and an elevated temperature is used for another portion of the extraction.
- In some embodiments, substantially small numbers of cells are released from the substrate for subsequent lysis according to the present systems and methods. In some embodiments, at least 1 cell, at least 2 cells, at least 5 cells, at least 10 cells, at least 15 cells, at least 20 cells, at least 50 cells, at least 75 cells, at least 100 cells, at least 125 cells, at least 150 cells, at least 175 cells, at least 200 cells, at least 250 cells, at least 300 cells, at least 350 cells, at least 400 cells, at least 450 cells, at least 500 cells or more are released from the substrate during agitation.
- In some embodiments, about 1 ng/μL to about 50 ng/μL, about 1 ng/μL to about 40 ng/μL, about 1 ng/μL to about 30 ng/μL, about 1 ng/μL to about 20 ng/μL, about 1 ng/μL to about 10 ng/μL, about 1 ng/μL to about 5 ng/μL, about 1 ng/μL to about 4 ng/μL, about 1 ng/μL to about 3 ng/μL or about 1 ng/μL to about 2 ng/μL of nucleic acid with a purity of about 0.55 to 2.00, about 0.6 to about 2.00, about 0.7 to about 2.00 about 0.8 to about 2.00, about 0.9 to about 2.00, about 1.0 to about 2.00 about 1.1 to about 2.00, about 1.2 to about 2.00, about 1.3 to about 2.00, about 1.4 to about 2.00, about 1.5 to about 2.00 about 1.6 to about 2.00 about 1.7 to about 2.00 about 1.8 to about 2.00 or about 1.9 to about 2.00 is employed (obtained) from a single subject with the described methods. In some embodiments, 1 ng/μL to 50 ng/μL with a purity of about 0.55 to 2.00 is employed (obtained) from a single subject with the described methods.
- IV. Lysis Solutions
- A variety of lysis solutions have been described and are known to those of skill in the art. Any of these well known lysis solutions can be employed with the present methods in order to isolate nucleic acids from a sample. Exemplary lysis solutions include those commercially available, such as those sold by INVITROGEN®, QIAGEN®, LIFE TECHNOLOGIES® and other manufacturers, as well as those which can be generated by one of skill in a laboratory setting. Lysis buffers have also been well described and a variety of lysis buffers can find use with the disclosed methods, including for example those described in Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013), both of which are incorporated herein by reference for all purposes.
- Cell lysis is a commonly practiced method for the recovery of nucleic acids from within cells. In many cases, the cells are contacted with a lysis solution, commonly an alkaline solution comprising a detergent, or a solution of a lysis enzyme. Such lysis solutions typically contain salts, detergents and buffering agents, as well as other agents that one of skill would understand to use. After full and/or partial lysis, the nucleic acids are recovered from the lysis solution.
- In some embodiments, cells are resuspended in an aqueous buffer, with a pH in the range of from about
pH 4 to about 10, about 5 to about 9, about 6 to about 8 or about 7 to about 9. - In some embodiments, the buffer salt concentration is from about 10 mM to about 200 mM, about 10 mM to about 100 mM or about 20 mM to about 80 mM.
- In some embodiments, the buffer further comprises chelating agents such as ethylenediaminetetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).
- In some embodiments, the lysis solution further comprises other compounds to assist with nucleic acid release from cells such as polyols, including for example but not limited to sucrose, as well as sugar alcohols such as maltitol, sorbitol, xylitol, erythritol, and/or isomalt. In some embodiments, polyols are in the range of from about 2% to about 15% w/w, or about 5% to about 15% w/w or about 5% to about 10% w/w.
- In some embodiments, the lysis solutions further comprises surfactants, such as for example but not limited to Triton X-100, SDS, CTAB, X-114, CHAPS, DOC, and/or NP-40. In some embodiments such surfactants are in the range of from about 1% to about 5% w/w, about 1% to about 4% w/w, or about 1% to about 3% w/w.
- In embodiments, the lysis solution further comprises chaotropes, such as for example but not limited to urea, sodium dodecyl sulfate and/or thiourea. In some embodiments, the chaotrope is used at a concentration in the range of from about 0.5 M to 8 M, about 1 M to about 6 M, about 2 M to about 6 M or about 1 M to 3 M.
- In some embodiments, the lysis solution further comprises one or more additional lysis reagents and such lysis reagents are well known in the art. In some embodiments, such lysis reagents include cell wall lytic enzymes, such as for example but not limited to lysozyme. In some embodiments, lysis reagents comprise alkaline detergent solutions, such as 0.1 aqueous sodium hydroxide containing 0.5% sodium dodecyl sulphate.
- In some embodiments, the lysis solution further comprises aqueous sugar solutions, such as sucrose solution and chelating agents such as EDTA, for example the STET buffer. In certain embodiments, the lysis reagent is prepared by mixing the cell suspension with an equal volume of lysis solution having twice the desired concentration (for example 0.2 sodium hydroxide, 1.0% sodium dodecyl sulphate).
- In some embodiments, after the desired extent of lysis has been achieved, the mixture comprising lysis solution and lysed cells is contacted with a neutralizing or quenching reagent to adjust the conditions such that the lysis reagent does not adversely affect the desired product. In some embodiments, the pH is adjusted to a pH of from about 5 to about 9, about 6 to about 8, about 5 to about 7, about 6 to about 7 or about 6.5 to 7.5 to minimize and/or prevent degradation of the cell contents, including for example but not limited to the nucleic acids. In some embodiments, when the lysis reagent comprises an alkaline solution, the neutralizing reagent comprises an acidic buffer, for example an alkali metal acetate/acetic acid buffer. In some embodiments, lysis conditions, such as temperature and composition of the lysis reagent are chosen such that lysis is substantially completed while minimizing degradation of the desired product, including for example but not limited to nucleic acids.
- In some embodiments, a first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth or twentieth lysis solution is employed with the methods. In some embodiments, the volume of lysis buffer used is about 10 μL, about 20 μL, about 30 μL, about 40 μL, about 50 μL, about 60 μL, about 70 μL, about 80 μL, about 90 μL, about 100 μL, about 120 μL, about 130 μL, about 140 μL, about 150 μL, 160 μL, about 170 μL, about 180 μL, about 190 μL, about 200 μL, about 220 μL, about 230 μL, about 240 μL, about 250 μL, about 260 μL, about 270 μL, about 280 μL, about 290 μL, about 300 μL, about 320 μL, about 330 μL, about 340 μL, about 350 μL, about 360 μL, about 370 μL, about 380 μL, about 390 μL, about 400 μL, about 450 μL, about 500 μL, about 550 μL, about 600 μL, about 650 μL, about 700 μL, about 750 μL, about 800 μL, about 850 μL, 900 μL, 950 μL, 1000 μL, 1500 μL or 2000 μL. In some embodiments, the lysis buffer is between about 10 μL and about 1000 μL, about 10 μL and about 800 μL, about 10 μL and about 600 μL, about 10 μL and about 400 μL, about 20 μL and about 400 μL, about 50 μL and about 300 μL, about 50 μL and about 200 μL, about 50 μL and about 400 μL, about 100 μL and about 400 μL, about 10 μL and about 300 μL or about 100 μL and about 200 μL.
- Any combination of the above can be employed by one of skill, as well as combined with other known and routine methods, and such combinations are contemplated by the present invention.
- V. Purification of Nucleic Acids from Lysis Buffer
- In some embodiments, the nucleic acids, including for example but not limited to genomic DNA, are isolated from lysis buffer prior to performing subsequent analysis. In some embodiments, the nucleic acids are isolated from the lysis buffer prior to the performance of additional analyses, such as for example but not limited to real-time PCR analyses. Any of a variety of methods useful in the isolation of small quantities of nucleic acids are used by various embodiments of the disclosed methods. These include but are not limited to precipitation, gel filtration, density gradients and solid phase binding. Such methods have also been described in for example, Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013), incorporated herein by reference for all purposes.
- Nucleic Acid precipitation is a well know method for isolation that is known by those of skill in the art. A variety of solid phase binding methods are also known in the art including but not limited to solid phase binding methods that make use of solid phases in the form of beads (e.g., silica, magnetic), columns, membranes or any of a variety other physical forms known in the art. In some embodiments, solid phases used in the disclosed methods reversibly bind nucleic acids. Examples of such solid phases include so-called “mixed-bed” solid phases are mixtures of at least two different solid phases, each of which has a capacity to nucleic acids under different solution conditions, and the ability and/or capacity to release the nucleic acid under different conditions; such as those described in US Patent Application No. 2002/0001812, incorporated by reference herein in its entirety for all purposes. Solid phase affinity for nucleic acids according to the disclosed methods can be through any one of a number of means typically used to bind a solute to a substrate. Examples of such means include but are not limited to, ionic interactions (e.g., anion-exchange chromatography) and hydrophobic interactions (e.g., reversed-phase chromatography), pH differentials and changes, salt differentials and changes (e.g., concentration changes, use of chaotropic salts/agents). Exemplary pH based solid phases include but are not limited to those used in the INVITROGEN ChargeSwitch Normalized Buccal Kit magnetic beads, to which bind nucleic acids at low pH (<6.5) and releases nucleic acids at high pH (>8.5) and mono-amino-N-aminoethyl (MANAE) which binds nucleic acids at a pH of less than 7.5 and release nucleic acids at a pH of greater than 8. Exemplary ion exchange based substrates include but are not limited to DEA-SEPHAROSE™, Q-SEPHAROSE™, and DEAE-SEPHADEX™ from PHARMACIA (Piscataway, N.J.), DOWEX® I from The Dow Chemical Company (Midland, Mich.), AMBERLITE® from Rohm & Haas (Philadelphia, Pa.), DUOLITE® from Duolite International, In. (Cleveland, Ohio), DIALON TI and DIALON TII.
- Any individual method is contemplated for use alone or in combination with other methods, and such useful combination are well known and appreciated by those of skill in the art.
- VI. Nucleic Acid Analyses
- The disclosed methods are used to isolate nucleic acids, such as genomic DNA (gDNA) for a variety of nucleic acid analyses, including genomic analyses. In some embodiments, such analysis includes detection of variety of genetic mutations, which include but are not limited to one or more deletions, insertions, transitions and transversions. In some embodiments, the mutation is a single-nucleotide polymorphism (SNP).
- A variety of methods for analyzing such isolated nucleic acids, for example but not limited to genomic DNA (gDNA) are known in the art and include PCR methods, such as real-time PCR analysis, microarray analysis, hybridization analysis and nucleic acid sequence analysis, as well as a variety of other methods where nucleic acid compositions are analyzed and which are known to those of skill in the art. See, for example, Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013).
- a. Real-Time PCR
- For the design of Real-Time PCR assays, several parts are coordinated, including the DNA fragment that is flanked by the two primers and subsequently amplified, often referred to as the amplicon, the two primers and the detection probe or probes to be used.
- Real-time PCR relies on the visual emission of fluorescent dyes conjugated to short polynucleotides (termed “detection probes”) that associate with genomic alleles in a sequence-specific fashion. Real-time PCR probes differing by a single nucleotide can be differentiated in a real-time PCR assay by the conjugation and detection of probes that fluoresce at different wavelengths. Real-Time PCR finds use in detection applications (diagnostic applications), quantification applications and genotyping applications.
- Several related methods for performing real-time PCR are disclosed in the art, including assays that rely on TAQMAN® probes (U.S. Pat. Nos. 5,210,015 and 5,487,972, and Lee et al., Nucleic Acids Res. 21:3761-6, 1993), molecular beacon probes (U.S. Pat. Nos. 5,925,517 and 6,103,476, and Tyagi and Kramer, Nat. Biotechnol. 14:303-8, 1996), self-probing amplicons (scorpions) (U.S. Pat. No. 6,326,145, and Whitcombe et al., Nat. Biotechnol. 17:804-7, 1999), Amplisensor (Chen et al., Appl. Environ. Microbiol. 64:4210-6, 1998), Amplifluor (U.S. Pat. No. 6,117,635, and Nazarenko et al., Nucleic Acids Res. 25:2516-21, 1997, displacement hybridization probes (Li et al., Nucleic Acids Res. 30:E5, 2002), DzyNA-PCR (Todd et al., Clin. Chem. 46:625-30, 2000), fluorescent restriction enzyme detection (Cairns et al., Biochem. Biophys. Res. Commun. 318:684-90, 2004) and adjacent hybridization probes (U.S. Pat. No. 6,174,670 and Wittwer et al., Biotechniques 22:130-1, 134-8, 1997).
- In some instances, real-time PCR can result in detection of a variety of gene mutations, including for example but not limited to SNPs. In some embodiments, detection of SNPs in specific gene candidates is performed using real-time PCR, based on the use of intramolecular quenching of a fluorescent molecule by use of a tethered quenching moiety. Thus, according to exemplary embodiments, real-time PCR methods also include the use of molecular beacon technology. The molecular beacon technology utilizes hairpin-shaped molecules with an internally-quenched fluorophore whose fluorescence is restored by binding to a DNA target of interest (See, e.g., Kramer, R. et al. Nat. Biotechnol. 14:303-308, 1996). In some embodiments, increased binding of the molecular beacon probe to the accumulating PCR product is used to specifically detect SNPs present in genomic DNA.
- One of the many suitable genotyping procedures is the TAQMAN® allelic discrimination assay. In some instances of this assay, an oligonucleotide probe labeled with a fluorescent reporter dye at the 5′ end of the probe and a quencher dye at the 3′ end of the probe is utilized. The proximity of the quencher to the intact probe maintains a low fluorescence for the reporter. During the PCR reaction, the 5′ nuclease activity of DNA polymerase cleaves the probe, and separates the dye and quencher. This results in an increase in fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye. The 5′ nuclease activity of DNA polymerase cleaves the probe between the reporter and the quencher only if the probe hybridizes to the target and is amplified during PCR. The probe is designed to straddle a target SNP position and hybridize to the nucleic acid molecule only if a particular SNP allele is present.
- By way of example, to amplify the Avellino corneal dystrophy associated SNP located in
exon 4 of the TGFβI gene, forward and reverse PCR primer pairs (SEQ ID NOs:1 to 24 inFIG. 2 ) were constructed as described in U.S. Patent Publication No. 2012/0077200. In some embodiments, any of the forward and reverse primer pairs disclosed therein are used in the improved methods disclosed herein. In a preferred embodiment, the forward and reverse primer pair of SEQ ID NO:1 (forward) and SEQ ID NO:2 (reverse) are used in the improved methods provided herein. - In order to detect the guanine-to-adenine mutation in
exon 4 of TGFβI gene, fluorescently labeled real-time PCR probe pairs for the detection of the wild type (“G”) and Avellino corneal dystrophy-associated mutant (“A”) allele having nucleotide sequences according to SEQ ID NOs: 25 to 42, as shown inFIG. 3 , were constructed as described in U.S. Patent Publication 2012/0077200. In some embodiments, any of the wild type and mutant probes are used in the improved methods disclosed herein. In a preferred embodiment, the wild type and mutant probe pair of SEQ ID NO:25 (wild type) and SEQ ID NO:26 (mutant) are used in the improved methods provided herein. To differentiate the wild type allele from the disease-associated allele, the wild type probes were labeled with VIC, and the mutant probes were labeled with FAM. The minor groove binder (MGB) was attached to the probe so as to facilitate binding to a complementary gene fragment. - b. Real-Time PCR Cycles
- Real-time PCR methods include a variety of steps or cycles as part of the methods for amplification. These cycles include denaturing double-stranded nucleic acids, annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence and synthesizing (i.e., replicating) second-strand DNA from the annealed forward primer and the reverse primer. This three step process is referred to herein as a cycle.
- In some embodiments, about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 cycles are employed. In some embodiments, about 10 to about 60 cycles, about 20 to about 50 or about 30 to about 40 cycles are employed. In some embodiments, 40 cycles are employed.
- In some embodiments, the denaturing double-stranded nucleic acids step occurs at a temperature of about 80° C. to 100° C., about 85° C. to about 99° C., about 90° C. to about 95° C. for about 1 second to about 5 seconds, about 2 seconds to about 5 seconds, or about 3 seconds to about 4 seconds. In some embodiments, the denaturing double-stranded nucleic acids step occurs at a temperature of 95° C. for about 3 seconds.
- In some embodiments, the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 40° C. to about 80° C., about 50° C. to about 70° C., about 55° C. to about 65° C. for about 15 seconds to about 45 seconds, about 20 seconds to about 40 seconds, about 25 seconds to about 35 seconds. In some embodiments, the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 60° C. for about 30 seconds.
- In some embodiments, the synthesizing (i.e., replicating) second-strand DNA from the annealed forward primer and the reverse primer occurs at about 40° C. to about 80° C., about 50° C. to about 70° C., about 55° C. to about 65° C. for about 15 seconds to about 45 seconds, about 20 seconds to about 40 seconds, about 25 seconds to about 35 seconds. In some embodiments, the annealing a forward primer, a reverse primer and a detection probe to the target genomic DNA sequence step occurs at about 60° C. for about 30 seconds.
- In some embodiments, it was found that about 1 μL, about 2 μL, about 3 μL, about 4 μL or about 5 μL of a genomic DNA sample prepared according to the present methods described herein, are combined with only about 0.05 μL, about 0.10 μL about 0.15 μL, about 0.20 μL, about 0.25 μL or about 0.25 μL of a 30×, 35×, 40×, 45×, 50× or 100× real-time PCR assay mix and distilled water to form the PCR master mix. In some embodiments, the PCR master mix has a final volume of about 5 μL, about 6 μL, about 7 μL, about 8 μL, about 9 μL, about 0 μL, about 11 μL, about 12 μL, about 13 μL, about 14 μL, about 15 μL, about 16 μL, about 17 μL, about 18 μL, about 19 μL or about 20 μL or more. In some embodiments, it was found that 2 μL of a genomic DNA sample prepared as described above, are combined with only about 0.15 μL of a 40× real-time PCR assay mix and 2.85 μL of distilled water in order to form the PCR master mix.
- While exemplary reactions are described herein, one of skill would understand how to modify the temperatures and times based on the probe design. Moreover, the present methods contemplate any combination of the above times and temperatures.
- c. PCR Primers and Primer Design
- In some embodiments, primers are tested and designed in a laboratory setting. In some embodiments, primers are designed by computer based in silico methods. Primer sequences are based on the sequence of the amplicon or target nucleic acid sequence that is to be amplified. Shorter amplicons typically replicate more efficiently and lead to more efficient amplification as compared to longer amplicons.
- In designing primers, one of skill would understand the need to take into account melting temperature (Tm; the temperature at which half of the primer-target duplex is dissociated and becomes single stranded and is an indication of duplex stability; increased Tm indicates increased stability) based on GC and AT content of the primers being designed as well as secondary structure considerations (increased GC content can lead to increased secondary structure). TM's can be calculated using a variety of methods known in the art and those of skill would readily understand such various methods for calculating TM; such methods include for example but are not limited to those available in online tools such as the TM calculators available on the World Wide Web at promega.com/techserv/tools/biomath/calc11.htm. Primer specificity is defined by its complete sequence in combination with the 3′ end sequence, which is the portion elongated by Taq polymerase. In some embodiments, the 3′ end should have at least 5 to 7 unique nucleotides not found anywhere else in the target sequence, in order to help reduce false-priming and creation of incorrect amplification products. Forward and reverse primers typically bind with similar efficiency to the target. In some instances, tools such as NCBI BLAST (located on the World Wide Web at ncbi.nlm.nih.gov) are employed to performed alignments and assist in primer design.
- Those of skill in the art would be well aware of the basics regarding primer design for a target nucleic acid sequence and a variety of reference manuals and texts have extensive teachings on such methods, including for example, Molecular Cloning (three volume set, Cold Spring Harbor Laboratory Press, 2012) and Current Protocols (Genetics and Genomics; Molecular Biology; 2003-2013) and Real-Time PCR in Microbiology: From Diagnostics to Characterization (Ian M. MacKay, Calster Academic Press; 2007); PrimerAnalyser Java tool available on the World Wide Web at primerdigital.com/tools/PrimerAnalyser.html and Kalendar R, et al. (Genomics, 98(2): 137-144 (2011)), all of which are incorporated herein in their entireties for all purposes.
- An additional aspect of primer design is primer complexity or linguistic sequence complexity (see, Kalendar R, et al. (Genomics, 98(2): 137-144 (2011)). Primers with greater linguistic sequence complexity (e.g., nucleotide arrangement and composition) are typically more efficient. In some embodiments, the linguistic sequence complexity calculation method is used to search for conserved regions between compared sequences for the detection of low-complexity regions including simple sequence repeats, imperfect direct or inverted repeats, polypurine and polypyrimidine triple-stranded cDNA structures, and four-stranded structures (such as G-quadruplexes). In some embodiments, linguistic complexity (LC) measurements are performed using the alphabet-capacity L-gram method (see, A. Gabrielian, A. Bolshoy, Computer & Chemistry 23:263-274 (1999) and Y. L. Orlov, V. N. Potapov, Complexity: an internet resource for analysis of DNA sequence complexity, Nucleic Acids Res. 32: W628-W633(2004)) along the whole sequence length and calculated as the sum of the observed range (xi) from 1 to L size words in the sequence divided by the sum of the expected (E) value for this sequence length. Some G-rich (and C-rich) nucleic acid sequences fold into four-stranded DNA structures that contain stacks of G-quartets (see, the World Wide Web at quadruplex.org). In some instances, these quadruplexes are formed by the intermolecular association of two or four DNA molecules, dimerization of sequences that contain two G-bases, or by the intermolecular folding of a single strand containing four blocks of guanines (see, P. S. Ho, PNAS, 91:9549-9553 (1994); I. A. Il'icheva, V. L. Florent'ev, Russian Journal of Molecular Biology 26:512-531(1992); D. Sen, W. Gilbert, Methods Enzymol. 211:191-199 (1992); P. A. Rachwal, K. R. Fox, Methods 43:291-301 (2007); S. Burge, G. N. Parkinson, P. Hazel, A. K. Todd, K. Neidle, Nucleic Acids Res. 34:5402-5415 (2006); A. Guédin, J. Gros, P. Alberti, J. Mergny, Nucleic Acids Res. 38:7858-7868 (2010); O. Stegle, L. Payet, J. L. Mergny, D. J. MacKay, J. H. Leon, Bioinformatics 25:i374-i382 (2009); in some instances, these are eliminated from primer design because of their low linguistic complexity, LC=32% for (TTAGGG)4.
- These methods include various bioinformatics tools for pattern analysis in sequences having GC skew, (G−C)/(G+C), AT skew, (A−T)/(A+T), CG−AT skew, (S−W)/(S+W), or purine-pyrimidine (R−Y)/(R+Y) skew regarding CG content and melting temperature and provide tools for determining linguistic sequence complexity profiles. For example the GC skew in a sliding window of n, where n is a positive integer, bases is calculated with a step of one base, according to the formula, (G−C)/(G+C), in which G is the total number of guanines and C is the total number of cytosines for all sequences in the windows (Y. Benita, et al., Nucleic Acids Res. 31:e99 (2003)). Positive GC-skew values indicated an overabundance of G bases, whereas negative GC-skew values represented an overabundance of C bases. Similarly, other skews are calculated in the sequence. Such methods, as well as others, are employed to determine primer complexity in some embodiments.
- According to non-limiting example embodiments, real-time PCR is performed using exonuclease primers (TAQMAN® probes). In such embodiments, the primers utilize the 5′ exonuclease activity of thermostable polymerases such as Taq to cleave dual-labeled probes present in the amplification reaction (See, e.g., Wittwer, C. et al. Biotechniques 22:130-138, 1997). While complementary to the PCR product, the primer probes used in this assay are distinct from the PCR primer and are dually-labeled with both a molecule capable of fluorescence and a molecule capable of quenching fluorescence. When the probes are intact, intramolecular quenching of the fluorescent signal within the DNA probe leads to little signal. When the fluorescent molecule is liberated by the exonuclease activity of Taq during amplification, the quenching is greatly reduced leading to increased fluorescent signal. Non-limiting examples of fluorescent probes include the 6-carboxy-floruescein moiety and the like. Exemplary quenchers include
Black Hole Quencher 1 moiety and the like. - A variety of PCR primers can find use with the disclosed methods. Exemplary primers include but are not limited to those described herein. Primers for use in the disclosed methods are also found in U.S. Patent Publication No. 20120077200, which is hereby incorporated by reference for all purposes. In some embodiments, the PCR primers for use in the methods of the present disclosure include but are not limited to the following listed in Table 1 and find use in the detection of the TGFβI gene. Tables 2 and 3 provide biophysical parameters for each primer, as calculated using the World Wide Web at primerdigital.com/tools/PrimerAnalyser.html.
-
TABLE 1 Exemplary Primers for the TGFβI gene Primer Name SEQ ID NO: Primer Sequence ACD Fw primer SEQ ID NO: 1 5′-TCC ACC ACC ACT CAG CTG TA ACD Re primer SEQ ID NO: 2 5′-CCA TCT CAG GCC TCA GCT T (60 bp) AV Fw primer SEQ ID NO: 3 5′-TGC AGC CCT ACC ACT CTC AA AV Re primer SEQ ID NO: 4 5′-AGG CCT CGT TGC TAG G (150 bp) Real Fw primer SEQ ID NO: 5 5′-TAG TCT CTT ATT CTA ATA GA Real Re primer SEQ ID NO: 6 5′-GCT GCA GAC TCT GTG TTT AA (860 bp) ACD Fw2 primer SEQ ID NO: 7 5′-CCA TCC CTC CTT CTG TCT TCT G ACD Re2 primer SEQ ID NO: 8 5′-CGG GCC CCT CCA TCT C (140 bp) ACD Fw3 primer SEQ ID NO: 9 5′-CAG AGA AGG GAG GGT GTG GTT ACD Re3 primer SEQ ID NO: 10 5′-GGG CGA AGA TGG TGA AGC T (190 bp) ACD Fw4 primer SEQ ID NO: 11 5′-TCC TCG TCC TCT CCA CCT GTA ACD Re4 primer SEQ ID NO: 12 5′-AGC TGG CAA GGA GGC CC ACD Fw5 primer SEQ ID NO: 13 5′-TTT GGG CTT TCC CAC ATG C ACD Re5 primer SEQ ID NO: 14 5′-GGC AGA CGG AGG TCA TCT CA ACD Fw6 primer SEQ ID NO: 15 5′-GTA GTA CCG TGC TCT CTG ACD Re6 primer SEQ ID NO: 16 5′-AGT TCC CCA TAA GAA TCC CCC ACD Fw7 primer SEQ ID NO: 17 5′-GGC TGG ACC CCC AGA GG ACD Re7 primer SEQ ID NO: 18 5′-ACC CCT CGG GGA AGT AAG G ACD Fw8 primer SEQ ID NO: 19 5′-AAC CTT TAC GAG ACC CTG GGA ACD Re8 primer SEQ ID NO: 20 5′-GAC TCC CAT CCA TCA TGC CC ACD Fw9 primer SEQ ID NO: 21 5′-AGT CGT TGG ATC CAC CAC CA ACD Re9 primer SEQ ID NO: 22 5′-GAC GTC ATT TCC TAC TGT TTC AGG ACD Fw10 primer SEQ ID NO: 23 5′-CCC CCC AGA AAC AGC CTG ACD Re10 primer SEQ ID NO: 24 5′-TTC TAA GGG GTT AAG GAG AAA GCT T GCD1 Fw primer SEQ ID NO: 43 5′-ACA CAG TCT TTG CTC CCA CAA A GCD1 Re primer SEQ ID NO: 44 5′-ACT TAA GTT GGT CTT TAC CCA AGA GTC T -
TABLE 2 Biophysical Parameters for Forward Primers GC % PCR Forward Primer Length Tm1 Tm2 Content Complexity Effic. SEQ ID NO: 1 19 55.4 57.8 57.9 70 70 SEQ ID NO: 3 20 57.1 58 55 81 66 SEQ ID NO: 5 20 40.2 45.7 25 73 38 SEQ ID NO: 7 22 55.9 60.2 54.5 62 43 SEQ ID NO: 9 21 57.5 60.2 57.1 64 40 SEQ ID NO: 11 21 57.6 60.2 57.1 66 57 SEQ ID NO: 13 19 55.4 55.7 52.6 81 80 SEQ ID NO: 15 18 50.6 55.3 55.6 75 66 SEQ ID NO: 17 17 57.8 62.2 76.5 74 60 SEQ ID NO: 19 21 56.6 58.2 52.4 82 73 SEQ ID NO: 21 20 57.4 58 55 78 46 SEQ ID NO: 23 18 56.5 59.9 66.7 69 69 Avg 19.67 54.96 57.80 56.05 72.69 59.85 Median 20 56.55 58.1 55.3 73.5 63 Std Dev 1.50 5.00 4.24 11.78 6.84 14.10 -
TABLE 3 Biophysical Parameters for Reverse Primers GC % PCR Reverse Primer Length Tm1 Tm2 Content Complexity Effic. SEQ ID NO: 2 19 55.5 57.8 57.9 72 52 SEQ ID NO: 4 16 52.1 54.5 62.5 78 78 SEQ ID NO: 6 20 52.4 53.9 45 84 41 SEQ ID NO: 8 16 55.2 59.6 75 63 53 SEQ ID NO: 10 19 56.5 57.8 57.9 78 69 SEQ ID NO: 12 17 58.5 59.8 70.6 74 66 SEQ ID NO: 14 20 57.6 60.1 60 84 74 SEQ ID NO: 16 21 54.9 58.2 52.4 71 51 SEQ ID NO: 18 19 56.6 60 63.2 78 60 SEQ ID NO: 20 20 56.5 60.1 60 65 65 SEQ ID NO: 22 24 55.5 58.7 45.8 88 67 SEQ ID NO: 24 25 55.3 57.2 40 74 40 Avg 19.69 55.61 58.13 57.33 76.54 60.69 Median 19.5 55.5 58.45 58.95 76 62.5 Std Dev 2.77 1.86 2.10 10.33 7.52 12.30 - In some embodiments, the real-time PCR primers for use with the disclosed methods have a linguistic sequence complexity of at least 70%, at least 72%, at least 75%, at least 77%, at least 80%, at least 82%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 97% or at least 99%.
- d. Detection Probe Design and Detection Probes
- A variety of detection probes can find use with the disclosed methods and are employed for genotyping and or for quantification. Detection probes commonly employed by those of skill in the art include but are not limited to hydrolysis probes (also known as TAQMAN® probes, 5′ nuclease probes or dual-labeled probes), hybridization probes, and Scorpion primers (which combine primer and detection probe in one molecule). In some embodiments, detection probe design is determined by one of skill in the art based on the desired probe target such that the probe is compatible with the PCR primers employed (e.g., primers and probes should not interfere with one another's functions in the real-time PCR assay). In some embodiments, probes are designed to have higher Tm's than the primers in order to promote efficient signal production. Tm's are calculated using any of a variety of methods known in the art and those of skill would readily understand such various methods for calculating Tm; such methods include for example those available in online tools such as the calculators available on the World Wide Web at promega.com/techserv/tools/biomath/calc11.htm. In some embodiments, the increased Tm of the detection probe provides that the detection probe has bound before the primers are elongated by the polymerase.
- In some embodiments, detection probes contain various modifications. In some embodiments, detection probes include modified nucleic acid residues, such as but not limited to 2′-O-methyl ribonucleotide modifications, phosphorothioate backbone modifications, phosphorodithioate backbone modifications, phosphoramidate backbone modifications, methylphosphonate backbone modifications, 3′ terminal phosphate modifications and/or 3′ alkyl substitutions.
- In some embodiments, the detection probe has increased affinity for a target sequence due to modifications. Such detection probes include detection probes with increased length, as well as detection probes containing chemical modifications. Such modifications include but are not limited to 2′-fluoro (2′-deoxy-2′-fluoro-nucleosides) modifications, LNAs (locked nucleic acids), PNAs (peptide nucleic acids), ZNAs (zip nucleic acids), morpholinos, methylphosphonates, phosphoramidates, polycationic conjugates and 2′-pyrene modifications. In some embodiments, the detector probes contains one or more modifications including 2′ fluoro modifications (aka, 2′-Deoxy-2′-fluoro-nucleosides), LNAs (locked nucleic acids), PNAs (peptide nucleic acids), ZNAs (zip nucleic acids), morpholinos, methylphosphonates, phosphoramidates, and/or polycationic conjugates.
- In some embodiments, the detection probes contain detectable moieties, such as those described herein as well as any detectable moieties known to those of skill in the art. Such detectable moieties include for example but are not limited to fluorescent labels and chemiluminescent labels. Examples of such detectable moieties can also include members of FRET pairs. In some embodiments, the detection probe contains a detectable entity.
- Examples of fluorescent labels include but are not limited to AMCA, DEAC (7-Diethylaminocoumarin-3-carboxylic acid); 7-Hydroxy-4-methylcoumarin-3; 7-Hydroxycoumarin-3; MCA (7-Methoxycoumarin-4-acetic acid); 7-Methoxycoumarin-3; AMF (4′-(Aminomethyl)fluorescein); 5-DTAF (5-(4,6-Dichlorotriazinyl)aminofluorescein); 6-DTAF (6-(4,6-Dichlorotriazinyl)aminofluorescein); 6-FAM (6-Carboxyfluorescein; aka FAM; including TAQMAN® FAM™); TAQMAN VIC®; 5(6)-FAM cadaverine; 5-FAM cadaverine; 5(6)-FAM ethylenediamme; 5-FAM ethylenediamme; 5-FITC (FITC Isomer I; fluorescein-5-isothiocyanate); 5-FITC cadaverin; Fluorescein-5-maleimide; 5-IAF (5-Iodoacetamidofluorescein); 6-JOE (6-Carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein); 5-CR11O (5-Carboxyrhodamine 110); 6-CR11O (6-Carboxyrhodamine 110); 5-CR6G (5-Carboxyrhodamine 6G); 6-CR6G (6-Carboxyrhodamine 6G); 5(6)-Caroxyrhodamine 6G cadaverine; 5(6)-Caroxyrhodamine 6G ethylenediamme; 5-ROX (5-Carboxy-X-rhodamine); 6-ROX (6-Carboxy-X-rhodamine); 5-TAMRA (5-Carboxytetramethylrhodamine); 6-TAMRA (6-Carboxytetramethylrhodamine); 5-TAMRA cadaverine; 6-TAMRA cadaverine; 5-TAMRA ethylenediamme; 6-TAMRA ethylenediamme; 5-TMR C6 maleimide; 6-TMR C6 maleimide; TR C2 maleimide; TR cadaverine; 5-TRITC; G isomer (Tetramethylrhodamine-5-isothiocyanate); 6-TRITC; R isomer (Tetramethylrhodamine-6-isothiocyanate); Dansyl cadaverine (5-Dimethylaminonaphthalene-1-(N-(5-aminopentyl))sulfonamide); EDANS C2 maleimide; fluorescamine; NBD; and pyrromethene and derivatives thereof.
- Examples of chemiluminescent labels include but are not limited to those labels used with Southern Blot and Western Blot protocols (see, for e.g., Sambrook and Russell, Molecular Cloning: A Laboratory Manual, (3rd ed.) (2001); incorporated by reference herein in its entirety). Examples include but are not limited to -(2′-spiroadamantane)-4-methoxy-4-(3″-phosphoryloxy)phenyl-1,2-dioxetane (AMPPD); acridinium esters and adamantyl-stabilized 1,2-dioxetanes, and derivatives thereof.
- The labeling of probes is known in the art. The labeled probes are used to hybridize within the amplified region during amplification. The probes are modified so as to avoid them from acting as primers for amplification. The detection probe is labeled with two fluorescent dyes, one capable of quenching the fluorescence of the other dye. One dye is attached to the 5′ terminus of the probe and the other is attached to an internal site, so that quenching occurs when the probe is in a non-hybridized state.
- Typically, real-time PCR probes consist of a pair of dyes (a reporter dye and an acceptor dye) that are involved in fluorescence resonance energy transfer (FRET), whereby the acceptor dye quenches the emission of the reporter dye. In general, the fluorescence-labeled probes increase the specificity of amplicon quantification.
- Real-time PCR that are used in some embodiments of the disclosed methods also include the use of one or more hybridization probes (i.e., detection probes), as determined by those skilled in the art, in view of this disclosure. By way of non-limiting example, such hybridization probes include but are not limited to one or more of those provided in the described methods. Exemplary probes, such as the HEX channel and/or FAM channel probes, are understood by one skilled in the art.
- According to example embodiments, detection probes and primers are conveniently selected e.g., using an in silico analysis using primer design software and cross-referencing against the available nucleotide database of genes and genomes deposited at the National Center for Biotechnology Information (NCBI). Some additional guidelines may be used for selection of primers and/or probes in some embodiments. For example, in some embodiments, the primers and probes are selected such that they are close together, but not overlapping. In some embodiments, the primers may have the same (or close TM) (e.g., between about 58° C. and about 60° C.). In some embodiments, the TM of the probe is approximately 10° C. higher than that selected for the TM of the primers. In some embodiments, the length of the probes and primers is selected to be between about 17 and 39 base pairs, etc. These and other guidelines are used in some instances by those skilled in the art in selecting appropriate primers and/or probes.
- Probes for use in the methods of the present invention include but are not limited to the following exemplary probes listed in Table 4.
-
TABLE 4 Exemplary Probes for the TGFβI gene Probe Name SEQ ID NO: Probe Sequence Normal probe 1 SEQ ID NO: 25 VIC-CAC GGA CCG CAC GGA-NFQ (15 bp) Mutant probe 1 SEQ ID NO: 26 FAM-CAC GGA CCA CAC GGA-NFQ Normal probe 2 SEQ ID NO: 27 VIC-ACA CGG ACC GCA CG-NFQ Mutant probe 2 SEQ ID NO: 28 FAM-ACA CGG ACC ACA CG-NFQ (14 bp) Normal probe 3 SEQ ID NO: 29 VIC-TAC ACG GAC CGC A-NFQ Mutant probe 3 SEQ ID NO: 30 FAM-TAC ACG GAC CAC A-NFQ (13 bp) Normal probe 4 SEQ ID NO: 31 VIC-CTG TAC ACG GAC CGC ACG-NFQ Mutant probe 4 SEQ ID NO: 32 FAM-CTG TAC ACG GAC CAC ACG-NFQ (18 bp) Normal probe 5 SEQ ID NO: 33 VIC-CTG TAC ACG GAC CGC ACG GAG-NFQ Mutant probe 5 SEQ ID NO: 34 FAM-CTG TAC ACG GAC CAC ACG GAG-NFQ (21 bp) Normal probe 6 SEQ ID NO: 35 VIC-GCT GTA CAC GGA CCG CAC GGA GAA- NFQ Mutant probe 6 SEQ ID NO: 36 FAM-GCT GTA CAC GGA CCA CAC GGA GM- NFQ Normal probe 7 SEQ ID NO: 37 VIC-ACC GCA CGG AGA AGC-NFQ Mutant probe 7 SEQ ID NO: 38 FAM-ACC ACA CGG AGA AGC-NFQ Normal probe 8 SEQ ID NO: 39 VIC-ACC GCA CGG AGA AGC TGA GGC-NFQ Mutant probe 8 SEQ ID NO: 40 FAM-ACC ACA CGG AGA AGC TGA GGC-NFQ Normal probe 9 SEQ ID NO: 41 VIC-ACC GCA CGG AGA AGC TGA GGC CTG- NFQ Mutant probe 9 SEQ ID NO: 42 FAM-ACC ACA CGG AGA AGC TGA GGC CTG- NFQ Normal Probe 10 SEQ ID NO: 45 VIC-CAC CAA GAG AAC GGA-NFQ Mutant Probe 10 SEQ ID NO: 46 FAM-CAC CAA GAG AAT GG-NFQ Normal Probe 10a SEQ ID NO: 47 VIC-CAC CAA GAG AAC GGA G-MGB NFQ #TGFBI R124C SEQ ID NO: 48 FAM-CAC GGA CTG CAC GGA-MGB NFQ #TGFBI R124L SEQ ID NO: 49 FAM-CAC GGA CCT CAC GGA-MGB NFQ #TGFBI R555Q-1 SEQ ID NO: 50 FAM-AC CAA GAG AACA GA G--MGB NFQ - VII. Diagnostic Tests
- In some embodiments, diagnostic testing is employed to determine one or more genetic conditions by detection of any of a variety of mutations. In some embodiments, diagnostic testing is used to confirm a diagnosis when a particular condition is suspected based on for example physical manifestations, signs and/or symptoms as well as family history information. In some embodiments, the results of a diagnostic test assist those of skill in the medical arts in determining an appropriate treatment regimen for a given patient and allow for more personalized and more effective treatment regimens. In some embodiments, a treatment regimen include any of a variety of pharmaceutical treatments, surgical treatments, lifestyles changes or a combination thereof as determined by one of skill in the art.
- The nucleic acids obtained by the disclosed methods are useful in a variety of diagnostic tests, including tests for detecting mutations such as deletions, insertions, transversions and transitions. In some embodiments, such diagnostics are useful for identifying unaffected individuals who carry one copy of a gene for a disease that requires two copies for the disease to be expressed, identifying unaffected individuals who carry one copy of a gene for a disease in which the information could find use in developing a treatment regimen, preimplantation genetic diagnosis, prenatal diagnostic testing, newborn screening, genealogical DNA test (for genetic genealogy purposes), presymptomatic testing for predicting adult-onset disorders such as Huntington's disease, presymptomatic testing for estimating the risk of developing adult-onset cancers and Alzheimer's disease, confirmational diagnosis of a symptomatic individual, and/or forensic/identity testing. In some embodiments, the present methods find use in the detection of corneal dystrophy. In some embodiments, corneal dystrophy is detected for example through detection of Avellino corneal dystrophy-related SNPs, such as those that result in R124 mutations in the TGFβI gene (including for example but not limited to an R124H mutation caused by a G to A transition at nucleotide 418 of TGFβI gene also referred to as a C(G/A)C SNP). In some embodiments, corneal dystrophy is detected for example through detection of granular corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGFβI gene (including for example but not limited to an R555W mutation caused by a C to T transition at nucleotide 1663 of TGFβI gene also referred to as a (C/T)GG SNP). In some embodiments, corneal dystrophy is detected for example through detection of lattice dystrophy-related SNPs, such as those that result in R124 and/or 626 mutations in the TGFβI gene (including for example but not limited to an R124C mutation caused by a C to T transition at nucleotide 417 of TGFβI gene also referred to as a (C/T)GC SNP or a H626P mutation caused by an A to C transition at nucleotide 1924 of TGFβI gene. In some embodiments, corneal dystrophy is detected for example through detection of Reis-Buckler corneal dystrophy-related SNPs, such as those that result in R124 mutations in the TGFβI gene (including for example but not limited to an R124L mutation caused by a G to T transition at nucleotide 418 of TGFβI gene also referred to as a C(G/T)C SNP). In some embodiments, corneal dystrophy is detected for example through detection of Thiel-Behnke corneal dystrophy-related SNPs, such as those that result in R555 mutations in the TGFβI gene (including for example but not limited to an R555Q mutation caused by a G to A transition at nucleotide 1664 of TGFβI gene also referred to as a C(G/A)G SNP).
- In some embodiments, newborn screening includes any genetic screening employed just after birth in order to identify genetic disorders. In some embodiments, newborn screening finds use in the identification of genetic disorders so that a treatment regimen is determined early in life. Such tests include but are not limited to testing infants for phenylketonuria and congenital hypothyroidism.
- In some embodiments, carrier testing is employed to identify people who carry a single copy of a gene mutation. In some cases, when present in two copies, the mutation can cause a genetic disorder. In some cases, one copy is sufficient to cause a genetic disorder. In some cases, the presence of two copies is contra-indicated for a particular treatment regimen, such as the presence of the Avellino mutation and pre-screening prior to performing surgical procedures in order to ensure the appropriate treatment regiment is pursued for a given patient. In some embodiments, such information is also useful for individual contemplating procreation and assists individuals with making informed decisions as well as assisting those skilled in the medical arts in providing important advice to individual patients as well as patients' relatives.
- In some embodiments, predictive and/or presymptomatic types of testing are used to detect gene mutations associated with a variety of disorders. In some cases, these tests are helpful to people who have a family member with a genetic disorder, but who may exhibit no features of the disorder at the time of testing. In some embodiments, predictive testing identifies mutations that increase a person's chances of developing disorders with a genetic basis, including for example but not limited to certain types of cancer. In some embodiments, presymptomatic testing is useful in determining whether a person will develop a genetic disorder, before any physical signs or symptoms appear. The results of predictive and presymptomatic testing provides information about a person's risk of developing a specific disorder and help with making decisions about an appropriate medical treatment regimen for a patient as well as for a patient's relatives. Predictive testing is also employed, in some embodiments, to detect mutations which are contra-indicated with certain treatment regimens, such as the presence of the Avellino mutation being contra-indicated with performing LASIK surgery and/or other refractive procedures, such as but not limited to Phototherapeutic keratectomy (PTK) and/or Photorefractive keratectomy (PRK). For example, patients exhibiting the Avellino mutation should not undergo LASIK surgery or other refractive procedures.
- In some embodiments, diagnostic testing also includes pharmacogenomics which includes genetic testing that determines the influence of genetic variation on drug response. Information from such pharmacogenomic analyses finds use in determining and developing an appropriate treatment regimen. Those of skill in the medical arts employ information regarding the presence and/or absence of a genetic variation in designing appropriate treatment regimen.
- In some embodiments, diseases whose genetic profiles are determined using the methods of the present disclosure include but are not limited to ophthalmic disorders, cancer, diabetes mellitus, hypertension, schizophrenia, and most common congenital malformations, such as cleft lip, cleft palate, neural tube defects, Achondroplasia, Alpha-1 Antitrypsin Deficiency, Antiphospholipid Syndrome, Autism, Autosomal Dominant Polycystic Kidney Disease, Charcot-Marie-Tooth, Colon cancer, Cri du chat, Crohn's Disease, Cystic fibrosis, Dercum Disease, Down Syndrome, Duane Syndrome, Duchenne Muscular Dystrophy, Factor V Leiden Thrombophilia, Familial Hypercholesterolemia, Familial Mediterranean Fever, Fragile X Syndrome, Gaucher Disease, Hemochromatosis, Hemophilia, Holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, Myotonic Dystrophy, Neurofibromatosis, Noonan Syndrome, Osteogenesis imperfecta, Parkinson's disease, Phenylketonuria, Poland Anomaly, Porphyria, Progeria, Retinitis Pigmentosa, Severe Combined Immunodeficiency (SCID), Sickle cell disease, Spinal Muscular Atrophy, Tay-Sachs, Thalassemia, Trimethylaminuria, Turner Syndrome, Velocardiofacial Syndrome, WAGR Syndrome, Wilson Disease, as well as any other disease with a genetic component. Ophthalmic disorders and/or disorders that include an ophthalmic component include but are not limited to chalazion, stye, trichiasis, entropion, ectropion, lagophthalmos, bleharitis, dacryocystitis, orbital cellulitis, ptergium, pterygiumcorneal dystrophy, conjuctivitis, ophtalmia neonatorum, bacterial corneal ulcer, fungal corneal ulcer, glaucoma, Fuchs Dystrophy, keratoconus, Advanced Macular Degeneration, Retinitis pigmentosa, cataracts, retinal disorecers, macular degeneration, diabetic eye problems (for example, diabetic retinopathy), blepharophimosis-ptosis-epicanthus-inversus syndrome (BPES), oculocutaneous albinism, Marfan syndrome, Stickler syndrome, and CHARGE (coloboma, heart anomalies, atresia of the choanae, retardation of growth and development, genital/urinary anomalies, ear abnormalities or deafness) syndrome. Corneal dystrophies include but are not limited to Avellino corneal dystrophy, granular corneal dystrophy, lattice type I corneal dystrophy, Fuchs Dystrophy, Thiel-Behnke and Reis-bucklers corneal dystrophy. Cancers include but are not limited to carcinoma, sarcoma, blastoma, lymphoma, leukemia germ cell tumors, and cancers of unknown origin. In some embodiments, the cancer include but is not limited to head and neck, skin, colon, oral, glioblastoma, breast, laryngeal, esophageal, endothelial, endometrial, ovarian, lung, urogenital, rectal, prostate, kidney, melanoma, renal, pancreatic, gastrointestinal, blood, liver, uterine and brain as well as viral induced cancers such as papilloma virus-induced cancer.
- In some embodiments, the present methods find use in development of personalized medicine treatment regimens by providing the genomic DNA which is used in determining the genetic profile for an individual. In some embodiments, such genetic profile information is employed by those skilled in the art in order determine and/or develop a treatment regimen. In some embodiments, the presence and/or absence of various genetic variations and mutations identified in nucleic acids isolated by the described methods are used by those of skill in the art as part of a personalized medicine treatment regimen or plan. For example, in some embodiments, information obtained using the disclosed methods is compared to databases or other established information in order to determine a diagnosis for a specified disease and or determine a treatment regimen. In some cases, the information regarding the presence or absence of a genetic mutation in a particular patient is compared to a database or other standard source of information in order to make a determination regarding a proposed treatment regimen. In some cases, the presence of a genetic mutation indicates pursuing a particular treatment regimen. In some cases the absence of a genetic mutation indicates not pursuing a particular treatment regimen.
- In some embodiments, information regarding the presence and/or absence of a particular genetic mutation is used to determine the treatment efficacy of treatment with the therapeutic entity, as well as to tailor treatment regimens for treatment with therapeutic entity. In some embodiments, information regarding the presence and/or absence of a genetic mutation is employed to determine whether to pursue a treatment regimen. In some embodiments, information regarding the presence and/or absence of a genetic mutation is employed to determine whether to continue a treatment regimen. In some embodiments, the presence and/or absence of a genetic mutation is employed to determine whether to discontinue a treatment regimen. In other embodiments, the presence and/or absence of a genetic mutation is employed to determine whether to modify a treatment regimen. In some embodiments the presence and/or absence of a genetic mutation is used to determine whether to increase or decrease the dosage of a treatment that is being administered as part of a treatment regimen. In other embodiments, the presence and/or absence of a genetic mutation is used to determine whether to change the dosing frequency of a treatment administered as part of a treatment regimen. In some embodiments, the presence and/or absence of a genetic mutation is used to determine whether to change the number of dosages per day, per week, times per day of a treatment. In some embodiments the presence and/or absence of a genetic mutation is used to determine whether to change the dosage amount of a treatment. In some embodiments, the presence and/or absence of a genetic mutation is determined prior to initiating a treatment regiment and/or after a treatment regimen has begun. In some embodiments, the presence and/or absence of a genetic mutation is determined and compared to predetermined standard information regarding the presence or absence of a genetic mutation.
- In some embodiments, a composite of the presence and/or absence of more than one genetic mutation is generated using the disclosed methods and such composite includes any collection of information regarding the presence and/or absence of more than one genetic mutation. In some embodiments, the presence or absence of 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 20 or more, 30 or more or 40 or more genetic mutations is examined and used for generation of a composite. Exemplary information in some embodiments includes nucleic acid or protein information, or a combination of information regarding both nucleic acid and/or protein genetic mutations. Generally, the composite includes information regarding the presence and/or absence of a genetic mutation. In some embodiments, these composites are used for comparison with predetermined standard information in order to pursue, maintain or discontinue a treatment regimen.
- In some embodiments, corneal dystrophy is detected for example through detection of 2, 3, 4 or 5 SNPs selected from but not limited to Avellino corneal dystrophy-related SNPs, granular corneal dystrophy-related SNPs, lattice dystrophy-related SNPs, Reis-Buckler corneal dystrophy-related SNPs, and/or Thiel-Behnke corneal dystrophy-related SNPs. In some embodiments, corneal dystrophy is detected for example through detection of an Avellino corneal dystrophy-related SNP, in combination with a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP, a Reis-Buckler corneal dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP. In some embodiments, corneal dystrophy is detected for example through detection of a granular corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a lattice dystrophy-related SNPs, a Reis-Buckler corneal dystrophy-related SNPs, and/or a Thiel-Behnke corneal dystrophy-related SNP. In some embodiments, corneal dystrophy is detected for example through detection of a lattice dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a Reis-Buckler corneal dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP. In some embodiments, corneal dystrophy is detected for example through detection of a Reis-Buckler corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP, and/or a Thiel-Behnke corneal dystrophy-related SNP. In some embodiments, corneal dystrophy is detected for example through detection of a Thiel-Behnke corneal dystrophy-related SNP in combination with an Avellino corneal dystrophy-related SNP, a granular corneal dystrophy-related SNP, a lattice dystrophy-related SNP and/or a Reis-Buckler corneal dystrophy-related SNP.
- In some embodiments, corneal dystrophy is detected for example through detection of 2, 3, 4, 5 and/or 6 SNPs selected from Avellino corneal dystrophy-related SNPs. In some embodiments, the SNPs include SNPs that result in mutations at
positions - In some embodiments, corneal dystrophy is detected for example through detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, corneal dystrophy is detected for example through detection of 2, 3, 4 and/or 5 of R124C, R124H, R124L, R555W, and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R124C in combination with one or more of R124H, R124L, R555W and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R124H in combination with one or more of R124C, R124L, R555W and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R555W in combination with one or more of R124C, R124H, R124L and/or R555Q. In some embodiments, corneal dystrophy is detected for example through detection of R555Q in combination with one or more of R124C, R124H, R124L and/or R555W. In some embodiments, R124H is detected in combination with R555W. In some embodiments, corneal dystrophy is detected for example through detection of H262P in combination with one or more of R124C, R124H, R124L, R555W and/or R555Q. In some embodiments, R124C, R124H, R124L, R555W and/or R555Q are all detected. In some embodiments, R124C, R124H, R124L, R555W, R555Q and/or H626P are all detected.
- VIII. Diagnostic Kits
- In some embodiments, any or all of the reagents described above are packaged into a diagnostic kit. Such kits include any and/or all of the primers, probes, buffers and/or other reagents described herein in any combination. In some embodiments, the kit includes reagents for detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, the kit includes reagents for detection of 2, 3, 4, and/or 5 of R124C, R124H, R124L, R555W and R555Q. In some embodiments, the kit includes reagents for detection of R124C, R124H, and R124L. In some embodiments, the kit includes reagents for detection of R555W and R555Q. In some embodiments, the kit includes reagents for detection of R124C. In some embodiments, the kit includes reagents for detection of R124H. In some embodiments, the kit includes reagents for detection of R124L. In some embodiments, the kit includes reagents for detection of R555W. In some embodiments, the kit includes reagents for detection of R555Q.
- In some embodiments, the kit includes primers and probes for detection of 2, 3, 4, 5 and/or 6 of R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, the kit includes primers and probes for detection of 2, 3, 4, and/or 5 of R124C, R124H, R124L, R555W and R555Q. In some embodiments, the kit includes primers and probes for detection of R124C, R124H, and R124L. In some embodiments, the kit includes primers and probes for detection of R555W and R555Q. In some embodiments, the kit includes primers and probes for detection of R124C. In some embodiments, the kit includes primers and probes for detection of R124H. In some embodiments, the kit includes primers and probes for detection of R124L. In some embodiments, the kit includes primers and probes for detection of R555W. In some embodiments, the kit includes primers and probes for detection of R555Q. In some embodiments, the kit includes primers and probes for detection of H626P.
- In some embodiments, the reagents in the kit are included as lyophilized powders. In some embodiments, the reagents in the kit are included as lyophilized powders with instructions for reconstitution. In some embodiments, the reagents in the kit are included as liquids. In some embodiments, the reagents are included in plastic and/or glass vials or other appropriate containers. In some embodiments the primers and probes are all contained in individual containers in the kit. In some embodiments, the primers are packaged together in one container, and the probes are packaged together in another container. In some embodiments, the primers and probes are packaged together in a single container.
- In some embodiments, the kit further includes control gDNA and/or DNA samples. In some embodiments the control DNA sample included is TGFBI R124 normal. In some embodiments the control DNA sample included corresponds to the mutation being detected, including R124C, R124H, R124L, R555W, R555Q and/or H626P. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H, R124L, R555W, R555Q and/or H626P are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H, R124L, R555W and/or R555Q are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C, R124H and/or R124L are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R555W and/or R555Q are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124C are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal DNA and a mutant DNA sample corresponding to R124H are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and a mutant DNA sample corresponding to R124L are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal DNA and a mutant DNA sample corresponding to R555W are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and mutant DNA sample corresponding to R555Q are included. In some embodiments, a control DNA sample corresponding to TGFBI R124 normal and mutant DNA sample corresponding to H626P are included. In some embodiments, the concentration of the control DNA sample is 5 ng/μL, 10 ng/μL, 20 ng/μL, 30 ng/μL, 40 ng/μL, 50 ng/μL, 60 ng/μL, 70 ng/μL, 80 ng/μL, 90 ng/μL, 100 ng/μL, 110 ng/μL, 120 ng/μL, 130 ng/μL, 140 ng/μL, 150 ng/μL, 160 ng/μL, 170 ng/μL, 180 ng/μL, 190 ng/μL or 200 ng/μL. In some embodiments, the concentration of the control DNA sample is 50 ng/μL, 100 ng/μL, 150 ng/μL or 200 ng/μL. In some embodiments, the concentration of the control DNA sample is 100 ng/μL. In some embodiments, the control DNA samples have the same concentration. In some embodiments, the control DNA samples have different concentrations.
- In some embodiments, the kit can further include buffers, for example, GTXpress TAQMAN® reagent mixture, or any equivalent buffer. In some embodiments, the buffer includes any buffer described herein.
- In some embodiments, the kit can further include reagents for use in cloning, such as vectors (including, e.g., M13 vector).
- In some embodiments, the kit further includes reagents for use in purification of DNA.
- In some embodiments, the kit further includes instructions for using the kit for the detection of corneal dystrophy in a subject. In some embodiments, these instructions include various aspects of the protocols described herein.
- DNA was extracted from oral epithelium or hair root or whole blood as described below and in line with the disclosures provided herein.
- For DNA extraction from oral epithelium or hair root, the sample was first pre-treated in 1×PBS 300 μL. Next, 30 μL Lysis solution was added to tube and the mixture vortexed. The mixture was then incubated at 95° C. for 3 min. Next, 30 μL of DNA Stabilizing Solution (from Life Technologies/Thermo Scientific, USA) was added and the mixture vortexed. The mixture was then centrifuged at 13,000 RPM for 1 min.
- For DNA extraction from whole blood, the sample was first pre-treated in 1×PBS 300 μL starting with 3 μL of whole blood. Next, 30 μL of lysis solution was added to tube and the mixture vortexed. The mixture was then incubated at 95° C. for 3 min. Next, 30 μL of DNA Stabilizing Solution (from Life Technologies/Thermo Scientific, USA) was added and the mixture vortexed. The mixture was then centrifuged at 13,000 RPM for 1 min.
- After the above procedures were completed, the DNA concentration was read using a commercially available Tecan® Infinite® 200 PRO NanoQuant. For quantitation, 100 μL of eluents were pipetted into a clear 96 well plate. Next, 100 μL of prepared blank solution was added to well H12. Concentrations were then read using the manufacturer's instructions provided with the NanoQuant.
- Reaction mixtures were prepared using the probes and primers described below in Tables 5 and 6.
-
TABLE 5 Probe Sequences PROBE SEQUENCE TGFBI R124Normal VIC-CAC GGA CCG (SEQ ID NO: 25) CAC GGA-MGB NFQ TGFBI R124H FAM-CAC GGA CCA (SEQ ID NO: 26) CAC GGA-MGB NFQ TGFBI R124C FAM-CAC GGA CTG (SEQ ID NO: 48) CAC GGA-MGB NFQ TGFBI R124L FAM-CAC GGA CCT (SEQ ID NO: 49) CAC GGA-MGB NFQ TGFBI R555Normal VIC-CAC CAA GAG (SEQ ID NO: 45) AAC GGA-MGB NFQ TGFBI R555W FAM-CAC CAA GAG (SEQ ID NO: 46) AAT GG-MGB NFQ TGFBI R555Q FAM-AC CAA GAG (SEQ ID NO: 50) AAC AGA G-MGB NFQ -
TABLE 6 Primer Sequences PRIMER SEQUENCE TGFBI 124 F TCC ACC ACC ACT CAG (SEQ ID NO: 1) CTG TA TGFBI 124 R CCA TCT CAG GCC TCA (SEQ ID NO: 2) GCT T TGFBI 555 F ACA CAG TCT TTG CTC (SEQ ID NO: 43) CCA CAA A TGFBI 555 R ACT TAA GTT GGT CTT (SEQ ID NO: 44) TAC CCA AGA GTC T - The components and ratios used in an exemplary reaction mixture are shown below in Table 7.
-
TABLE 7 Reaction Mixture All reagent extract (whole blood) 3.00 μl GTXpress TaqMan ® 10.00 μl Primer (124R) (reverse) 10 pMol 0.50 μl Primer (124F) (forward) 10 pMol 0.50 μl Primer (555R) (reverse) 10 pMol 0.50 μl Primer (555F) (forward) 10 pMol 0.50 μl Probe (NL/VIC) 10 pMol 0.20 μl Probe (R124H/FAM) 10 pMol 0.30 μl Probe (R124C/FAM) 10 pMol 0.20 μl Probe (R124L/FAM) 10 pMol 0.50 μl Probe (R555N/VIC) 10 pMol 0.20 μl Probe (R555Q-1/FAM) 10 pMol 0.20 μl Probe (R555W/FAM) 10 pMol 0.20 μl DW 3.20 μl - Exemplary PCR cycling conditions are shown below in Table 8.
-
TABLE 8 PCR Cycling Pre-read Hold stage Cycling Stage 40 Cycle Post-read 60° C. 95° C. 95° C. 64° C. 60° C. 1 min 20 sec 3 sec 30 sec 1 min - The above protocols were used to generate the Real-Time PCR data provided in
FIGS. 4-8 . - All headings and section designations are used for clarity and reference purposes only and are not to be considered limiting in any way. For example, those of skill in the art will appreciate the usefulness of combining various aspects from different headings as appropriate according to the spirit and scope of the invention described herein.
- All references cited herein are hereby incorporated by reference herein in their entireties and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
- Many modifications and variations of this application can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments and examples described herein are offered by way of example only, and the application is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which the claims are entitled.
-
1 gcttgcccgt cggtcgctag ctcgctcggt gcgcgtcgtc ccgctccatg gcgctcttcg 61 tgcggctgct ggctctcgcc ctggctctgg ccctgggccc cgccgcgacc ctggcgggtc 121 ccgccaagtc gccctaccag ctggtgctgc agcacagcag gctccggggc cgccagcacg 181 ggtaagccga gccgcctggc caggggctgc ggaaggtcag gtagtcgggg ctcggagcgc 241 aagccgctgg gggcattgaa ctgggctggg ggcgcagggg acaaagcccg aactaaaaac 301 cttgcagcat ggagcgctcg gacaccagcc ctgcacgcgg tggaaggaga gagggaggga 361 ggtggaggac catggaggga aagcgggagg ccgccgcttt gtagaaggga gtggggaagt 421 ggaccagaga ctttcgacgc aggccaagag cctgagacgg acagcgcttt cagcttctcc 481 tcccagccac tgcagaaagg gggaaatggc aactctttgg ccataatcac cgtgggaggg 541 tcccaagggc aaagcccacc cagcagtaca cctattccaa cccagccagg cccccggcca 601 gcgactccag acaagaacct gggccacaca cggtggcagc atctaaggtg ccccaggctc 661 ctgtgctcct ggccaggccc tgcactcaga cactgctggc acccgacact gctctctggg 721 tacagcaagg gcaatgtggc acttcttgtc ctgcccgatg aagagcagga gaatgcactg 781 ggccctcaca cacactgttc aaatggggaa actgagtcct gagtggttcc actttcccac 841 agtcctgaag tgtgcactgg agccaggatt ggagtctgtc ttaaagtaat agctgggttt 901 gtaaatgtag gacactatca ttgcaggaat tcctttgaga ccctgaagat gtgttggctt 961 taggagacaa actcaagcag aaggtctggt ctgatagtgg ccctaatact gacccaggca 1021 gaggcaggca acatttctac ctcaaaaacc aggccatacc tgcgtcacaa atacccaggc 1081 tttgctgcag cttccagcct acctggttgc accaacttct ttttcataac taggtaaaac 1141 tatatatgag tagaatcttg tagtgactcc tcagaggaag cctaaatacc atcggggtct 1201 ggcgttcaca cccacaagca atgcccaaac ctccaagaga ctgggcagat ctgtgctcaa 1261 atcaaaactc attgttgggg gtgatagagt tgacttcaca ggccctgaaa gtcttggctc 1321 cttgcactag gagtgctctg ggtacgggta caggctgccc cttgtagggc atagttgctc 1381 ttgtttcctc tacttgtggc tttatggtct aggcctttca ggagtttggg gctctggcgg 1441 agagggcctg ctgggagcac atctggccac cctgcagagt gaaatcaaac caggcctggc 1501 tccaacctca acaccctcct ggaaagagga gaatactggg gatatcctgg ggtctttctg 1561 gaagtgggag aatcagcttt gacttgggca gtgtgcagaa tagagtgagg ggggatgtca 1621 gaaagatgag agggatatga ggcctcaaca tcaaaatgca agcacctggc atttttatta 1681 tctctgccca cctctccgtt ggtctctctg cctttcctgc caatgaattg tgttatgttt 1741 gggtgcctca atttgcctag gagggttcta tttcttctgt atcttcgcca ctaagtcagg 1801 agaagatcct tatagcatgc cctgcaacag tgtcacctgt aagggcatct ctctgcacag 1861 ccacagtgaa ggatcctcaa aggtattgag ggctttccat caagagccat ctttacagca 1921 aacctctttc ccttcagagc ccagaagagt gctgaccagc tggaaaacag ggtttttttc 1981 ttaaatgcag atgctcttga ttatgagttc cagatattag atcaacttcc ccaccatacc 2041 cctgcaggca aagcctctta attagcttcc tgcagcacag ctggaaaggc ctattgtaat 2101 ctgtgatggg cagagtaatc taagaagtca caggagcacc cctgtcccag tagaatctgg 2161 atgcgcaggc acatgaacca tggcaaaatg gttgcaggca cagttgtatt tactctgatc 2221 taactgtccc tcttaatgcc acagggctgc ctggcctggc acacagggct gtggcgcctt 2281 gtgcaaatgg ataacgttgt tctagctcca gcctttcatt caaagtgaaa actgttagaa 2341 agggaaggaa aactttgcta ttttaaggaa ttgtagcgtg ctgcctgata tgaaggaaga 2401 aataacagct gtgccttgct tgtgcgcagc actcgattgc cgcttttgct ttcgacctca 2461 ccacaacaca gtgagatcta ctgttcatgt tcccatttta caggaggtga aactgcagct 2521 tagtgaggta gagagtgact tagttcagac acagaatgct gttgggagag taataactat 2581 gatatggtct cttgactccc agctatatct gtgttgctat agggaagggg aaaaataata 2641 ctgaaagaga agtaaaaata caatcacact tccaaacatc aaccaccaaa aactgaactg 2701 aatttcctga agcacttggt tttcaaatct aagctgaaca tcaatgctgt tattcttgag 2761 gcccagaagc aacttgctca tttcaattaa gcttcagcat gaacttccta tgtacacagc 2821 ccacccacac tccccgatgt gagaaggaga gggtcacagc cgcccccagc ctctgctgct 2881 gccacaagga cagcagcagt ggaaacattc agcaaaggaa tcttggagcc acatccacaa 2941 gagactcact gaagattcgc caaacgccta cggaaagtgg cagggaattc attgacagta 3001 attgtttcct gcttgatcag attgaagagc ttctgggatt ctgtaacaat aaataggacc 3061 gggggctgga gtatggccag caaggactct tcaggggtta ttcagggact gtctaacctg 3121 tgaatcctag gcagcaaaca gaaaccaggt attcagaaat ctggaggatt tggtcaggcc 3181 cagctaggac tagggaggca tgggcctctg ctggctgtgg tcccttctcc agccttcact 3241 tctcttgtcc ctagatcctt acatggattc attaatgctc attgtccctc ctgggcccac 3301 tcactttcac ctgttgaaca aaaaactggc caagaggtga cagtcatatc accgcagaag 3361 agacagggca gagaaatgaa ggggcagaat ggactcccac ccaaaagcct gactctgaat 3421 atttgagaat tgttcaagtt cctgcagagg aatcatgatg gggacagtag gtgtagtttt 3481 tactgcaata ttggtgtctt cttaacaaat acgctgcaca tcaagtgatg tctgtggatg 3541 gcattcttaa agtaacaggg aaattgatgt taaagaaata cttcatcctt tgggtgatac 3601 ctgaagttct ctgagcttgg aggtcttgtg aaagccctca gtattgtttg ttttatttgc 3661 tttcctctga cttgtgattc agtcagatgc atgcctgcct ctggctcagg aagatcaacc 3721 ctctcctgac tgaccacgcc tctcctgact gaccacgtag cacagcagct tcctttccct 3781 aggggctcct aatgaagctt tcacaatcac ctggcctgag cacagtttgg gtcaggactt 3841 ggtatacttg aaaaaaacat gcaaaaccaa aatcctgtgg ttctggaaaa ggcttcttag 3901 cagaaccccc agacatttac actctgcttt ttcacagggt ccctgaggat tctttggatc 3961 tgggtagttt ggggagcagt attttcaaca agttcatttc gtgctccttc tacaccctgc 4021 ctggatgcta ggccccatct agaatgtgaa caacagaaca aggcagaaca cttgtcctca 4081 aggttctgtt gagtgttaga tccagagaag agacaccccc cacctccccg catcacttac 4141 aggaattctg tttggaaccc aacatcaaat aaggaccgta tccactgtca gaggatggga 4201 agcagcatgt catctgggac attggagaaa ggctcctggg ggaagtggga cttgagctgt 4261 gatctaagta atgaacaact gagagttaaa tcggagagca tcccctatca gggtcctgag 4321 agcaaccagc catggtttaa accagctata aagcctcggg tttataggat agacagtaac 4381 aatggcttgt ctttgggagc caagcagctg gtccaggcat gcagagcatg tctgtatgga 4441 gagctgcctg agagatgctt ttgtttacac ttatcaattg cccatgtcaa agaaggatat 4501 gtacatgaag ttacatcagt atgtaagaga gattttaaca atttttgcag gggaagcttt 4561 catgggggct gatgggaatc taggtaaaca gaaccaaagt ctaaacccaa gatatcccca 4621 gtaccaagac tgaaatgact ctctcctcta tctctagaaa gttccagtga cccaaggagg 4681 caaacacgat gggagtcatt aaagtggggt ggacgtgctg atcatcttcc taattctgct 4741 gcttttgttt tcagccccaa cgtgtgtgct gtgcagaagg ttattggcac taataggaag 4801 tacttcacca actgcaagca gtggtaccaa aggaaaatct gtggcaaatc aacgtgagta 4861 tctgtaacca gccaggagac caagctgtat gcacgctggc tgcagttccc cagggcctgg 4921 gccagccttc tagaaggtca ggttgcctaa aaagccatga agatgcatgt gcgaacatgt 4981 ctgggacctg cgtgctaggg agtggcattt ttaggaagct ggccaatttt gttttgcatt 5041 tttaaggctg ctgacaagac ttggagacat ttttcagggc tggtttgggt ttgcaagaaa 5101 catgaaacac tgcgtgtgtg tgtgtgtgtg tgtgtttctc aatcctcata aaataataca 5161 gatatgcagt ggagaagcca ccagcatgtg actctggaaa agaaagccca ttggtgaatc 5221 tgtactaaag aatgccatcc ctatcttaca gtcctaaggt aaacacccca aaaagactta 5281 gagcactaaa catatgcaga ttatgagaca gcatagcata taatatttgc acagacttcc 5341 tcattcaaac cctagctcta cctgggccag tcgattcatc tttagaaccc tccattgctt 5401 tacctgaaaa gttcgtataa caaaaggacc caccttatgg ggttgttaca aggattgaat 5461 gaaataatgt acataagaga ctgaatatgg tgcccagcat atatcagtgc tcaataaatg 5521 ctagctacta ttattattat caccctagat ttgcaaatct agaccacaca agcagaagta 5581 agagtgccaa cggggtgtgg accagtgtgg ttacaatagg gcttgttgat gtctgtttca 5641 gcaaggaggg aggcagcttt taccccactg cccagctccc tggtggaatc aggtgcatgt 5701 tctaacaatt ctggggaaac ctaatctgtt ttggcactgt caacagatct caaagctggc 5761 tgtctcctat agctaggaag atgtgtatga caaatctcct gagccacttg tgaaggcctg 5821 accttcctcc tgtctccata cataatggga tgattaagaa actctaagcc actctcttaa 5881 gcacttttca atgttaggga tttttaagtt tattgttgtg acattgcttt tgagcagaca 5941 tctcctccaa tttaatagcc aactgaaaga agagaaaatg ctctttcctt aaactgtatg 6001 tcgaaataaa tattccaatg tgtgaccctg attatgttag gcaattagca atcctaatat 6061 gaattgaggg aagttgggat tcatggcaca gctggggaga taccagcagt ccctgggagc 6121 ctgtccaggg caggtccatg gcagcttgct ccatgcctga ttgacagccc agcctgcaag 6181 ctaaaagttg agtgagctag gaggacacac tcccaagatt cagctaacag acacccagcg 6241 atattcttgc tgctatgaac aaaaggagac tatgcaaatt atacaccacc cattcttcca 6301 ggatgcctga cttaaaaaat aagaaaaaag atgggccggg cacagtggct cacgcctgta 6361 atcccaacac tttgggaggc cgaggtgggc ggatcacaag gtcaggagac agagaccatc 6421 ctggctaaca tcgtgaaacc ccgtctctac taaaaaaata caaaaatatt agcgggcgtg 6481 gtggcgggca cctgtagtcc cagctactcg ggaggctgag gcaggagaat ggcgtgaacc 6541 tgggaggcgg agcttgcagt gagccaagat cgtgccactg cagtccagcc tgggtgacag 6601 agtgagacac cgtctcaaaa aaaaaaaaaa aaaaagaaaa gaaaaccttt agtactgatt 6661 gattttttcc catgtgtgta tattatctac tcaaattaac aattaattac ttaattaaac 6721 acaaagccag gcctcaccta attgcttctt ggaaggtgac cagagtgcta gtgccaagca 6781 aacaactctt ctatatctca agagccctgg gcttcagagg gccatctttt ttgttaattc 6841 aagtttctct gaaaatggag acccgtttat gatgacaagc tggctacagg gtagcatctg 6901 ccacactgtt tcgggggtgc cgctgggctg aagcatttgc ccagctagtt aacaatagct 6961 cgataacatt ccctatcagt gtccaggctg agaatactgt cagtgatgag tcgccttggc 7021 tcttgtacct gtatctttgt gtgccaggac aaggcacaag caacagagct gtgtgttgcc 7081 aaaatgttcc tgatgagcag gtcaacccct cgggggcagg tttggatatg ataatgtggt 7141 gatgtggtgg cgcagctccc ttacccagtg agcacaaggg gagtcctcta ggaaaaggaa 7201 gaaatgtctg gatgaggtgg ggagatgggg ttcagagtgg actcaggcaa agcccgatgc 7261 ccagtcccag ctgttggcct agtctcacaa agccagaagg atatgacatt tacattcaac 7321 tcttgaattt gtggccactg ctttgggcaa cttcaaagag agaaaatgaa gatagaaaaa 7381 tattatttga tataaaactt ctaggacaag agaggccctt cctggaacat tacatgtagt 7441 attaggaagg tggagctgcc ctggaaaaga tccagagaac tcagagagag gaagaggtgg 7501 aacccatctc tcttcttgta gagagctcag taagagtggc ttggcagggc tcctgtgtac 7561 ctgagaccaa gaccagtgag gaggctactg tctgaccacc atacggtcag aattcagtgc 7621 catgggtggt caggtgggaa ggggagagga ctgtgctggc tggagttgat gttatcctgg 7681 ggaaagtagg tccctagatg cctttagttg agtgaggagc agactgggaa atgggagcac 7741 agtagtggtt ggggcaaaaa ggactgtctc tgcatgaggt ccataggcag ttggaatttt 7801 ctcagcaaga ctccagagaa ggaggctgga gcagaggtgt atgttgggat gaaaaggagt 7861 aaagtatcat gggggaggag gcagctcagg ttgtcaaggg tcaagaaacc agaaggagaa 7921 tttcaccttg gaagcagaca acgggtacca agcatacagg ggaatacttt gtggtgagag 7981 gtcacacaga gatacaggag ccgacctggt gagacaggag cctggagcca cctgcctgct 8041 tttgtgaggc cccagactcc actgctatca tcaggtgaag ctctgttgcc tgcacacaaa 8101 agcttttctg catttacaaa gagagaaggg cctgagtttc tggtgcaatg cgtcaagctg 8161 acatatggac tttattacag gaagtggtta ccagtgggtc cctatttagt ggctgttatt 8221 gtgaatttta ttgttcggaa attcacttta gcatttattt cagatcctaa atagcaccgg 8281 agtgatacaa tcgctaatca aacaaagagg gctgtgggga gcagacagtc agcatccccc 8341 tctgtgattt caggccctgg tttgattagt agccataaaa ttttttacgt gtggcacttt 8401 gagcaaaggt gcaggaaatt gtggtcagga agcctggctg cctctcgaca ggcttccttt 8461 gtgctagccc cagggagagg aggcctattt aacagccaag tccaagttga catcatggga 8521 ctggaatagt catagcagga gctcagacat cataaacgtg gcatagggag ggctggtgga 8581 ggagctagcg ggtatgggtg gcagctattc attccaaaag tcttgaaatt gtttcacgag 8641 caacacattt cacaagtgcg aagcccttct ctggagccaa gatgagctgg cagagcactc 8701 ctgtttctct agtagcaagt gttcctttgc ccaggggcaa aaatattaat actccttcag 8761 cactgcatta atgcttaaag atttaacttt taaagagatc agctggtgca tggtcgagct 8821 tttccatcag ctggcagggc tttttcagta ggtgtccttc tgggcagggc actggggaca 8881 gctgacgtga aggtgaagaa gagctgtcgt tttcctccct tatatcccac aaccttggtc 8941 ccaagaggaa aaaaaagaag atggtgagaa gtcatccaag cagaccccag acccatacta 9001 gtgcctcctt tcctgtttca tatccctgtg cagccagctg ggatctcttg aataatctgc 9061 tctgggggca ctgagattgg acatacacca aacagcggag atcgaccaaa cgcctctgtt 9121 gggcagtgtt tcctgagggt tctgtcccat tctgtaaact aggaggctga ctagctgaca 9181 aggaatttta ttctgttggg tatttacatg aacctatgtg ccacctgggg taagaccctg 9241 tcgtaggtag aaacatgact tcccaaaaat gtccacatcc taatctctaa ttctgtaaat 9301 atattccctt actggaaaaa gagactttgc aggtgtgatt aaattaagga tcataagagg 9361 gagagattat ccaggattat ttgatgagtc taatataatc atcagggtac ttaaaagagg 9421 gaggcaggct gtgcctggtg gttcacgcct ttaatcccag cactttggga gactgaggcg 9481 agcgggtcac gaggacagga gttggagacc agcctgacca acatggtgaa actccccctc 9541 tagtaaaaaa aaaaatacaa aaattagcca ggcatggtgg tacacacctg taatcccagc 9601 tactcaggag gctgaggcgg gagaattgct tgaacccagg aggcagaggt tgtggtgagc 9661 tgagatcgca ccactgccct ccagcctggg caacagagca agactccatc tcaaaaaaaa 9721 aaaaagaggg aggcagtggg atcagagtca gagaaggcaa cgtgatgatg aaagctgaca 9781 tttgagtgat gcaaccacaa gccaaggaat gcaggcagct tctcaaagct ggaaaggacg 9841 agcaatggat tcttccctac agcctctgtg aggaatgcag cctttgattt taaccccata 9901 aggccgattt ctgactctag cctctggaat tgtaagataa tttgcatgat ctcaagccac 9961 taaatttgtg gtaatttgtc acagaaagca atgggaagcc aacacaggcc ttatttgttg 10021 acttatagat gcatttttct ttatttcaat gtacttttat caatggtctc atgtagggta 10081 ttgctttcaa tgaagatatt aacatagttt caactttaag gtttatatct ggagtttctt 10141 tagaagcttc acaactgacc acttagtaaa cagtaagcat ctgttaagtg cttctcatat 10201 gtaagttcat tcaattctca caatcacact ataagataaa tatgattatt agcccattta 10261 cagatgagga gacaggctca aaagactttt atgcaacctg gtcaaagtca ttcactggta 10321 agctgaggag gtctgtccac ttccttttgc tgcccccagg gggtatcaag cctggcagtt 10381 agtgtcagcg acttaggagg tgaacaagtg agcaggcctg taggacctgg ctaaactgcc 10441 ccaggtctct gtctacagcc tcaaacctgt ggctgtgggt cccagagaca aggcctcctc 10501 agcatcagag aaggatgcct ttgtctcagg gtcatcaacc ttctccaggt tgctcacccc 10561 ctgctgtaaa ggggatcccc aagaccgctc atcagacaag gagcttggga actgaggaga 10621 cacagtcagc ctccaggagt gcccaaaatg ccctcacatg ctgcatacag attgccacaa 10681 ataaagtaca tccacattct gaagactctg tcctcatcac caaccaggct ggcccctggt 10741 gagggctgta gtggttgagg cctttgttgg tagacagtag gttaaagcaa gccatgattt 10801 tctattggga ggcttcagaa tcagctcagc tgtgtttcca agaccaggag ggcagaaagc 10861 aaaccatccc aggcaagcag tccatgggcc atgtcagatg tctagacgtt atgggtctgt 10921 gtttgctctg ccattcctct cggaaactat gatgccctgt atggtttacc ttcagtcaca 10981 ggtgactggc ctacagggcc attccttgtt ccaacgactt ctcgagtata attaatcccc 11041 aggcatttac ggccagagca gccggccaaa tccgtgaagt gcagtggttg ttttaaatta 11101 tattaacttc ttggaaactt attttaggga gagaaaactc agtacttctc tctatccaat 11161 cttgagtaaa aatgttagaa gggactggtg gagagcctcc cagacatccc tacacataga 11221 ctttgggttg acattatctc tttgcacctt ccttgaaact ttcttctaaa ttaggtgcct 11281 tccctaattt aggcaccttc ccagtactag tctgtgacct gttaggaacc aggccacaca 11341 gcaggagttg agtggcaggg agtgagcatt attgcctgag ctccgcctcc tgtcagatca 11401 gcagtggcat tagattctca tagcagtccg aatactattg tgaactgtgc gtgtaaggga 11461 tctagcttgt gcattcctta tgagaatcta atgcccgatg gtctgagatg gaagagtttc 11521 ataccaaaac caccccttcc ccctgccacc atctggggaa atattgtcta ccacgaaact 11581 gatccctggt gccaaaaagg ttggggaccg ctgtcctaag ggatctgctt tttctgacct 11641 gaggtttttc tttattagac tgtatctggc tgaggagaag cctgaagcct ttaatcggaa 11701 cagctttggc tgatgagatt agattcagaa accaacagat tggtcttttc tatgcaggga 11761 agcctaggaa ctggggggct atggctggga agccccctat tgtttccatc ctttcctatg 11821 ttcatcctgg aggaatggca tcagacccat gcctctgtga ttgctcccag cccatccaac 11881 cacagcatct atgttctgcc tgggaccagg gccagggagc atggcacact gagctgagta 11941 taaggagagt ggagcaggcc actgccagcc cagaaaattt tggtcaaagt tgcctgaaat 12001 cttctcagcc ttcgattcac agctgctctc tgctgctctg gggccatgca gaccagttca 12061 gaaaagagtt aatttgttgg ggcagttgga ggcaggtgga ctgccagctt tgacaccttc 12121 ccagcccaca ggctgctgca ctggggctga aggcgtggct aacccctgca cacctagaga 12181 gtgacagaga tcccagactg ggcagcagga aggcaagagg attaagagag agcttcctgg 12241 ctgaaagcca cactcggtta accaggaaaa agcccttggc acgagaagac tcagtggcct 12301 gagggactga gccttggttg ttgggcatgt gctgcataag ccatccatgt gtgacagtag 12361 agtgtagtcc agccactgtg ggacatgggt gctgaaagac cacatggaga ggaacagtga 12421 gtgctgacaa gggctagcct tgatcacttt ggagacaccc cctgtgtctt ctagatgtca 12481 gactttccaa atctgtctgc tatcctccaa acgtgcattt tcaagagcaa tggaaaaagg 12541 attggacttg atggaatgca gcaagagtcc taggtctgtt actacctacc tatgacctta 12601 agaaactcct tcacccctca gaacccttac agctttcttt ctgattctat cctgagttac 12661 tctactccaa gctgagactt ttctgcttag atctatccct tcctcctaaa cccccaacct 12721 ccatttctcc tggtgtcttt ctttacacac ccctcagcat acacacacac ctagccacag 12781 gaaccaatga gttaatattt gaggagttgg ttttcttttg tcctcaatga gatcctggtg 12841 aggccacttg agctgttcag ctcccttgcg gtattttggg gatggaactc agaagccaac 12901 aatatagaaa aagagtcttt ggccagcttt cccaggggct ccatgccata gagagtactg 12961 cacccgtgtg cacagggggc cctgacatga ggactttgag gataacacta ttcctccaac 13021 tctgcttcag catctccatg gattttcaca cagacacttt aggaaagaaa ctaagtttgg 13081 ggggacttga cctaatccca catcacagcc ccagtaatac agccctggaa tttatcacag 13141 aaagcctaga atcccatgca tatcccatgc atatgcatcc ctagtcctat gggttcaagg 13201 cttggagctc tccctggatt tagctgggaa aagttggcag acagttcttc tctgtcttct 13261 agaaatatgg actagaatcg tgagtgtgag attgcaagta acttttaaaa tcatctagtt 13321 taacttcacc ccatttcata gaccaagaaa ctgagaccag agagagaaat ggactttcaa 13381 gttcaccctg ctagttactg atggatcaca agtcaaatct cctgattcta gcactgtttc 13441 tcttacacca caccaccttt gaaagtgtgt caatcaaatc ttactttagt tgcagaggat 13501 gactttagtt tctgaagata aaattgtgag tcaatcaaga tgagtcccaa gacaatagcc 13561 tctttagccc ttataagttc agggatgaaa ggttagaaag aaacaggatg gaaggaggac 13621 tggagaaaaa aacaaaagag gaaggaagga ggaggaagca aacaggaaaa aaaaagaatg 13681 tgcatagctt gtcactcctc agtcatttcc tgggagccca tttctagcaa agtgacagct 13741 gcaactccct ggccacctga gcatcttagc tgatctgtct ctgaaacacc ccctggagaa 13801 cagatgaatc aggcttcatc ttcgcttaac taagtcttcc ctgagacgac tccatttaaa 13861 tgaacaagag caggatttcc tgggcacact gagagcacct tccagaggcc cctccagagc 13921 cctaaagcct gtatttcttc cagtcggcct gtttctttcc tggtgatgtc attaaacgcc 13981 ctttgagagt cccacagtga gcagttctgc ggtaaaaccc gctgcaatta aagtctgagt 14041 cctttcctgt ctcaaagggc atattcatat agaagaaagg aaaaggaagg actggctgtt 14101 tgcatttggt tccaggcctg ttgagtagag gtcgtgctca ctccaccgaa ggtacagggt 14161 agccttcagc agaacctggg gatttggttt taagcaagtc tttcttaggt gtgggctttc 14221 agaacacttc cttccttgca atattatttg aaattctcag tgttttagcc gtccccagaa 14281 tattggttcg ttaaagctgt gtatttcaga tctccagaca gtggtcactg tttgtatatt 14341 ttcaatttca aaccagaaaa caaaagttct tattgattac tttttttatt taaaaaataa 14401 aaagtaagta tcttcgtaag aggagctttg ttttaatttt aaagtttaaa atttgattgt 14461 gaagacagag aaaaacttga tgattgtaga tatattcccc tctttggcta ttcaatcaga 14521 gaactagaaa atcatgagag atttaatgac cactgcctga tacacatatg tcttttacag 14581 atgaggaaac tgagacccag agagatgatg aaattggctg aggatggccc agctggtcag 14641 tgaaagactc agagccagag ctggtgcagg gctctttcta ttccttcctg ttccctttca 14701 ggaacactca ccatcggctt tcctgtgaat aatgttgaga taaaatcctt ggtgcattat 14761 gttttctagt cacaacattg actaggctgc cagagtcctc tgttctccca gttggttggc 14821 tgtaggtgtt ggcagccgcc aggagcattc tacagaacag aggaggagtg agactctcct 14881 tgctcaggaa aggcagacct atgacttagc aaataactcc taagaggaga gtgtttcacc 14941 caccattcct cttccttggc tgtggaggca acttagtgga gaggggccag atgacctgtg 15001 aggaacagtg aagccctgcc taacacaatg tatggttgtc ttgttacaga gtcatcagct 15061 acgagtgctg tcctggatat gaaaaggtcc ctggggagaa gggctgtcca gcaggtgaat 15121 gaatcctccg ggccttgcct gttggtgtgg gtggaaggga atggtgggag agaggagtac 15181 ccacataaaa ggcagcagag tgtgaatggg ggcagtggca caaggacatg gcattctccc 15241 cacgtgccca ctggccccag gctctatgcg aggggctgag gaatggaagc tggaaacagc 15301 gcatttcctg agctgctcct cctggcctcc ttaccacact ggtggagtag actccaactg 15361 tggcctgtcc atgcccttcc cagcaggcac aggctcaggc tcaggctctt ggcctctgcc 15421 tctggctggg agtgattcta aacacatcca gcagggtcag cctgatagcc catcagtttc 15481 cgatcagctc tgctagagag ccgatgggat gtgggaggag ggggtcactg gtgggctggc 15541 aaccccaagc catccccatc tccctctgtg tctaaacttg gccctttgga gttcggtagg 15601 gagaagagcc ataggccagg tgggctcacc cagagtcagc agagagtccc acaaatggtt 15661 gcactgggcg aaagacagca tggcacctgt gaattttatt agagcttttc ttttagtgct 15721 acacacaagt gactgtacag gggagttagt attttgtttt aattttgaaa tagagtcatc 15781 ttttggtatc tgcgggggat tgattctagg acccattcta ggatgccata tcctcagatg 15841 ttcaagtccc tgatataaag tggtatagta tttgcatgta atctatgcat attcttccat 15901 gtactttaaa tcatctcaag attacttata ataccaaata taatgtaaat cctatgtaag 15961 tagttgttat accctctttt aaatttttgt attatctttt attgtatttc aaaaaatatt 16021 tttggtccat gtttagttga atctgtgggt gaagaaccca cagatacgaa gggccaactg 16081 tattggctat ttttttagtt aagaatgtga gactgaggcc aggcgcagtg gctcatgcct 16141 ttgattccag cactttggga ggccaagagg ggacgatcac ctgagccaag aattcgagac 16201 cagcagcccg tccaacatag tgagaccttg tctcttaaag attgtgagac tgggctgggc 16261 acggtggctc acgcctgtaa tcctagcact ttgggaggcc aaggcaggtg gatcaactga 16321 ggtcaggagt ttgagatcag cctggctaac atagtgaaac tctgtctcta ctaaaaatac 16381 aaaaaaatta gctgggtgtg gtggtgggcg cctataatcc cagctactca ggaggctgag 16441 gcaggagaat cgcttgtatc caggaggcgg aggttgcagt gagctgagat agggccgttg 16501 cactccagcc tgggcaagaa gagcaaaact ccatctcaaa aataaataaa taaataaata 16561 aataaatcat gagactgaga cataacagga aggagggcaa tttggttggt tccaaggttc 16621 ctagagtaty tgatgggaga ggttggtgcg ggtggggcca tggaggtact gactcaagtg 16681 gagggacagg tggggaaatg ggatgggaaa agaagattga ccttagaagg ggagctcaac 16741 ctctgaaccc taatttcaga cccttcaaaa tgaatattaa gctcattttg gtctaagaaa 16801 caaaaaacaa atgaacatga aactcatttt ggtcttataa ggtctgagaa accccttcta 16861 aacttcaagc tgctttaaga aataacattt tattacctgc aaatacacac agtactttgg 16921 agatttataa tagtctctta ttctaataga agccattagg gaaccagttt caataaacag 16981 gtaaatctgt aagactagtt tgtaattagg atatctgttt ccagtgtcca ttcctgcctc 17041 tcttatctaa atgtctggga acaagagctg tgctctgctg tctttaaaat gattaaaaat 17101 caccaattag ttgagttcac gtagacaggc atttgactta ttgagttgtt ttaagaagac 17161 tataacaagc cttaagcccc ccagaaacag cctgtctttg ggctttccca catgcctcct 17221 cgtcctctcc acctgtagat gtaccgtgct ctctgtcaga gaagggaggg tgtggttggg 17281 ctggaccccc agaggccatc cctccttctg tcttctgctc ctgcagccct accactctca 17341 aacctttacg agaccctggg agtcgttgga tccaccacca ctcagctgta cacggaccgc 17401 acggagaagc tgaggcctga gatggagggg cccggcagct tcaccatctt cgcccctagc 17461 aacgaggcct gggcctcctt gccagctgtg agatgacctc cgtctgcccg ggggactctt 17521 atggggaact gccttacttc cccgaggggt gggcatgatg aatgggagtc tgcagtcatt 17581 tcctactgtt tcaggaagct ttctccttaa ccccttagaa aaggctgtgg aacttgagct 17641 aaaatatgtc ttaccaggtt gcgtctaatg ccccccgttc cctactgggc agaaagactt 17701 gggtgcttcc tgaggaggga tccttggcag aagagaggcc tgggctcacg agggctgaga 17761 acatgtttcc cagagttgca aggacccatc tcttaaacac agagtctgca gcccctaact 17821 gacaccctgt ccttcctcct aggaagtgct ggactccctg gtcagcaatg tcaacattga 17881 gctgctcaat gccctccgct accatatggt gggcaggcga gtcctgactg atgagctgaa 17941 acacggcatg accctcacct ctatgtacca gaattccaac atccagatcc accactatcc 18001 taatggggta ggggatcccc agccatactg catggccctt ggtgcataat gaacccattt 18061 ctgttccatg tgtgggctgg tttctggggt ttaagctgta gacaacccac cctctttgtg 18121 cctgcttctc cttgggccct ctattccaca gcttgtggaa cccacatttt gctactgtgt 18181 ttgaaaacac tgttttctcc tcccggggct ttgggactat gcctctgttg tgttgactgc 18241 tcatccttgc tgcttctctg ggcagattgt aactgtgaac tgtgcccggc tgctgaaagc 18301 cgaccaccat gcaaccaacg gggtggtgca cctcatcgat aaggtcatct ccaccatcac 18361 caacaacatc cagcagatca ttgagatcga ggacaccttt gagacccttc gggtaaggga 18421 ctgccctggg tggaggccca ggcttgggac acattgcctc ccaagagggg cctagcagga 18481 actcttctgc aggagaggta gaggatggct cctgtagggg aacatagagc aggttcccct 18541 gaatgccctt gaacatggag aattcattga ccagacattc agcttgacct aacctgtgaa 18601 attctccatc ttctttataa agtgttccct tccttgcctc ccctggaaag gtcagtggtg 18661 tgtggctgca gcagcacagt gtcctctgag ccctggacct gcactgtggc ttccagaggt 18721 ggcagttccc acatggggta ctagaataaa tggcctatca ggctgtgtgt gctttgggat 18781 cacatgtccc caccctagga ccctggttcc aaccatacgc atgttctctt ggagcccaga 18841 acagcagaga agccaccagt gtggacacag aagtcaaggg tctgatttcc agcctggctt 18901 ctgactgctc tggggccgca ggaatacggt tccttccccc atgcccagca ggcatttgtc 18961 ttacaactgg aggggaaggc atgttcctct tggcaaggac tgctcaggag gaagtggagg 19021 caggctgccc tgtcagggtt tttgccttga ttcaaggaga acttcctaac cacaaaggat 19081 acaagtggga gtgaggcgga ccctccctag agatctccaa cacagagaga caaacacgct 19141 ggggctggct ggcactgaca ggcctcgcag gtgtggatgg ctgttagctg ggagcttcgc 19201 tgtctaagct cctctcccat gcttttcttc tgggttgctc gaaggacggg ggtctgcaag 19261 aaaatgatgt tcccacatag ttggcagcac gtgaacagca attgatccct ttgcatcacc 19321 tcctcttact gtttagattt ggtaaatatt tcttccttcc ctcttctgac cctccatttt 19381 gccgatcttt ccttcttata acacatactt actaggtacc tgctacttcc cgggtgggcc 19441 tatgtgccag gagtatagag gtgaacaagg aaggcaaagt tctattctca gtagagctaa 19501 tactctatct ggagagagac aacaaacaaa tcaacaaggt agccaggggc tgtgataatt 19561 tatgtcaagt gggcaggtaa atcgggagtg acagtagtgc agggaggatt ggaaagtcag 19621 ggagttctct ctggaggagg tggcttttga tctgcagcct aaaggatgag aatgggtcca 19681 ttatacaaaa tgctggggca agagcacacc cagtagaggg gagagtaata gcaaaggctc 19741 agggcaggaa gggcaaggga gaggccagtg ggtgaggtca catgtgaagg gcatacaatg 19801 ggcaaagaca aggccagagt ggccaggccc aatcctccag gacttgcaga cctgggaaag 19861 agtgcatctc catcctggga gcagcaggaa accactcagg cctttagaag atccttctgg 19921 cagctgtgta gagaatgggt ggtgtgatcc ttccatgcat gggctcatgt acgtgattac 19981 cagtaactgt cgagtgacag tgtgaggagg gctgcaagcc atgagtgtag gcacagcaga 20041 cagactcacc tttgtctggc ggtgagatgg ggtgggaagt gtgccaagtt gacctcccaa 20101 agaaatgata ttttagtgga agaatgaata gaatcagaga agcaaagtaa gagggaagag 20161 cagagaggac agcagggaca aggacttggg ggcaggaaga ggaaaggcag gttaaggaca 20221 tgaaagatgg ccaggctggc tggagctcag gcccagcaag gccccctggg ggccatggtc 20281 atgggtgagc ttgggtttgg cttctgtttt cgtcttgggc ttctgtgaaa gcctcgagcc 20341 cttgcgggga accagtgaag ctgtgtgtgc atcttctgtg gggagtgcca gagtcttcag 20401 ggagcactcc atcttctctc ctccccacag gctgctgtgg ctgcatcagg gctcaacacg 20461 atgcttgaag gtaacggcca gtacacgctt ttggccccga ccaatgaggc cttcgagaag 20521 atccctagtg agactttgaa ccgtatcctg ggcgacccag aagccctgag aggtgagcat 20581 cctttggctc ctgctgctgc ctcatttgtg cagctagatt gagcccaaga cctgctctgg 20641 tccaagatga acataccacc tgccatgagg tgaccctcag gatatccact gcagccatgg 20701 gctggggtca tcctgtcctg ttgcttcagc taaccgtgtc tctagcagcc acactactct 20761 gagggctgac tacagaatcc agcagctttt gtctgggaga gctggactga agagaggcat 20821 agctggagac ccatagctgg ccctggccag aaacagggag agtgaaaggc tggaatagcc 20881 aaggccagag caaggctaat aggtagagca acagcttaca ggtgtggggg tggcagatac 20941 tcgcaccctt gaaatggatt cctcatgccc acgcttcact attcttctct gtggctaggg 21001 gatttatgga taaaccaaaa ttacagttaa aaaccagcca taggccaggc acagtgactc 21061 acgcctttaa tatcagcact ttgggaggac aaggtgggcg gatcacctga gatctggaat 21121 ttgagaccag cctggccaac atggcgaaac cccatctcta ctaaaaatac aaaaattagc 21181 tgggcatggt ggtgggcacc tgtaatccca gttactcagg ggctgaggca ggagaaccac 21241 ttgaacccag gaggtggagg ttgcagtgag ccaagcttgc accactgcac tccagcctgg 21301 gtgacacagc gacactccgt ctcaagaaaa aaaaaaaaaa aaacagttat agtagtcaac 21361 ttttgactct ccatttcaga tttcgtcatg ccctcctcaa tgagctgcta agttaggcag 21421 tgcattgatt attgctgcag gagagggaag gaaggagcta acgtgttttc acatgttttc 21481 cttttggaga tgagaaagga ggactctgcc ttccccctac cctgcccctt tctactccag 21541 gacctctgaa aggccatgag cacaaagctg ctgcctgagt cccctgaaat gcagggtacg 21601 ccccaggtct ctgatgtacc ccaccacact tttcctctca aacatattcc aggatcactt 21661 gatttctttt gaatctattt aaacccaccg tgtcaatgtg ctatataaaa tgtctaatgc 21721 atttcagaca ccctatacat ctatacattt aaagtgttct ccttctatct gtgcagggat 21781 gggaaagggc atatttctga aagcacagat gggaagacgg gatttgttcc gtgtccaggt 21841 gattatggta cctctatgcg cctggccggc actggggaca gaggccatga aaatgaatac 21901 agcacagcct ttgcctccaa gaaacttaag acctagtaga aatggcaggc tttaaaacag 21961 gttgttggga tctgatttgg tgagtgcaat gacagagata ctcacagcac aaaatgggga 22021 atgagggcgg gcattgggac acacatagcc ttaaggggcc caaaggcttt tagaactgta 22081 ttccctatta aaacatgatt tgcacagagc acattctttg ctttggagac ctcagaactc 22141 cttactatag gccgggcatg gttataatcc cagcactttg ggaagccaag gcgggcagat 22201 cacttgaggc tgagagttca agaccagcct ggccaacatg gtaaaacccc gtctctacta 22261 aaaatacaaa aattagctgg gtgtggtggt ggccacctgt aatcccagct actcaggagg 22321 ctgaggtagg agaatcactt gaacctggga ggcagaagtt gcaataagcc cagatcatgc 22381 cactgcactc cagcctgggc aacaaagcta gactctctca aaagaaaaaa acaaaacaaa 22441 acaaaacaaa acaaaaaaaa ctccttatta taaactgtaa gaaaaaaaag gcccctactt 22501 cgtccctttt gcaaatctgc cttttcctac tcactaacca gctggttcag agcaaggaca 22561 ctctgtttgg tgccatcgct gcagactgga aggaagaggt ccttgcccca cacccaacag 22621 tctcctgctg ttaccggcag gttggcaggc aggcaggcga gaagcagcca gggctggtgg 22681 tgtgtccagt ttgaagacta gtttccagcc ctggccctgc tcaccctcca agtggccctg 22741 gcaggttcct ctaccacatc gtggacttca ccttccttct ctaagaagct caatccccaa 22801 ggcctcattc ccataggcct tctcaccctt tttctttccc tctggctgaa tgtggccagc 22861 acgggcttcc aaggccatca actcgtctgc agcagcccca tgccttgcag ggcctcagag 22921 cttcctcctg cctatgacag tgtggttttg gttcccacac ttgggatcag attgaaactc 22981 gcctccgtgg tgagaatatg ggacatagag cctcggtgac cttggtgagc agcagtccag 23041 gccacctgct cagcctgggg ttgggggggg ctcctcctcc ttgactggtc cttgcatttg 23101 cctccatcca gcctgtctgg gctctccgag gcaatggaga ccagcaggag tcacgatggg 23161 tcaggagccc cctttgggcc tcagccctgc cctgccccct aaagtagcac ttggataagc 23221 aaataaatta ttatacttac tatttatggg tgtggtgaat gggatggcaa aggccaagtc 23281 ttactgatca ccaaacctta agatatatcc tggcagctag tagacccttg ggctaaatga 23341 acagaaaact ggacaaataa agtgtacaca aataactcaa agctgtcatt tgtacacttt 23401 tcgtcttttc ctactacagt ttacattttt ataaaggtga gtagatttct aaaatcccgt 23461 ggtaggctct cttgagtttt tcttgtatcc ctgaagttca gctacaaata agctaatcac 23521 taacatttgt tgagcattta ctctgttgtc aggccccgtg ccgagtgctt taggttcaga 23581 atttcatgtc atccccacag cagccctagg agatgaatgc aattcttatg tccacttgac 23641 tgataaggaa gttgaggttc aaagaggcta aatgactctc ccagggtccc acagctggaa 23701 agtggccaca gggccccagc tggttttcta gggcagcagg cagaaggcga ggaggatctg 23761 ggccctgtgg tgccccagcc tcatctgagg gtcctcatct gagagaacag gatcctcaca 23821 gcatgggcag gctgcaagtg gtccctgagg ttatcgtgga gtggaccctg acttgacctg 23881 agtctgtttg gaccccagac ctgctgaaca accacatctt gaagtcagct atgtgtgctg 23941 aagccatcgt tgcggggctg tctgtagaga ccctggaggg cacgacactg gaggtgggct 24001 gcagcgggga catgctcact atcaacggga aggcgatcat ctccaataaa gacatcctag 24061 ccaccaacgg ggtgatccac tacattgatg agctactcat cccagactca ggtaggccag 24121 gcctccgggg gccttggccc tgcctggccc accatctctt ctgccatcct ttgtggcggg 24181 ggaggggaaa ttcagagatc tttgggcgac ttccctgcct ggacccagct cacagcttct 24241 cggccactgc aaatgtgtgg gttgtgacca gactgatgtg tcttgagctt caggcttgca 24301 agtgcagtgg agaggcagtg gggagctatt gaaggggtct ggggacagac tcaatcacag 24361 aggcctttca gaagatctgc ctgctgtgca tgggcaaaga gggccacttg ctgacctcag 24421 agcatgtgct ttctcagtag tgcccaagct gtcccatggt cactgaccca gttagaatga 24481 ctgaatggac tttggcttgt gtctcattag gaatcctagc cccattctag tcttccagtg 24541 agatctgtcc atgagtgaag gaatctcaca ggaaaaaaca aaatgcttct atgggtgtgg 24601 ttgctggcct tatctacacc acagaagcca tcacacagac tgtctttctt cccattgtta 24661 gaatgtgccc tgaccaagca gcccacaggg cctgggacag aggctgatct ctgcctaact 24721 gagctcacct ctcctccctc tcctcctgac tggttagatt ttctaggtga ctgttcccct 24781 gatgacacaa gcccgctggg ccccagcagt gtttagaggg gttgttgact cacgagatga 24841 cattcctgct gatgtgtgtc atgccctggg gtggatgaat gataaatgaa aacagcgctt 24901 ttaacttttg aacccacttt ctccttcctt gtagccaaga cactatttga attggctgca 24961 gagtctgatg tgtccacagc cattgacctt ttcagacaag ccggcctcgg caatcatctc 25021 tctggaagtg agcggttgac cctcctggct cccctgaatt ctgtattcaa aggtaacatg 25081 gggaaggcat ccctgttaga ttgtccctgg aggcagcttc cccacccctg tcacctccac 25141 aacactctcc gatttacagc accccatggg acattagaac ttccactcag ctcaaccaaa 25201 agcagatgtg acttcagcag aaacttcaga ggctctgttg tttcattagg cagtgcagag 25261 aatgcctttg gggagccgtt cctcagaact caagacttga catctgggag gcagccgttc 25321 ctcagaactc aagacttgac atctgggaga gcagagcatt cccttgcctt tctatttgca 25381 gggtcacttg ccaatgtata gtcaagaggt cagagtgagg gtacagctga gctgcagccc 25441 caggaaggca gagaaggggg ccaagttgtg tgcgtgcctg cccttccctc ttagggcaaa 25501 actccaaaca cccttgatta tctggatctt ctttaattct ccatagaaga taccagatgt 25561 taaggaatat tcgcagcttc acttggtttc tcaatccctg tttccaaact caaggaggga 25621 tgggcttttt cactgtattt atctctcatc actctcttca ttgcaggagc acatctctct 25681 ggacctaacc atcacccttt cttgtagatg gaacccctcc aattgatgcc catacaagga 25741 atttgcttcg gaaccacata attaaagacc agctggcctc taagtatctg taccatggac 25801 agaccctgga aactctgggc ggcaaaaaac tgagagtttt ttttatcgt aatgtaagtt 25861 ctgggtccta aatcatgctc ctgggaagct ccttactgtg ggacttgtat tagtgtaaaa 25921 aaaaatgtcc tcaataagca ggagtttgca tgagaactgg ttgctgacaa ggaaggaaat 25981 aatttctgga aaatatagat aacaaaatga gatcctgcag aaggattgga atctcttttt 26041 ctggaggcct ttgagaataa accacacaat tatccaacct gtattgtgaa ggaataagtc 26101 cttcttgaat tcaggaatta acacctggga ggagggatgg agttcagact ctttctgagc 26161 ttatgagaag agaagccccc taaactaaaa tacagccctc cttggtccaa aaggtgcctt 26221 ctctcttctg ctgtatcttc tttgttttca aacccaacag ttaccctgga aatcaaaaag 26281 gaagtacaac tcaacatagc tcttgcctgg gaccaaccag caccatttgg ctaaagatgg 26341 ttatcatctg ttaaacaaag aaataaataa atgggttcaa cgtatttatt tcaacattgt 26401 caatggacct catgtgtaac tgatattctc attatgggac ctctgtgtga ctttattggg 26461 gcctctctaa ccgttctttc cttaaggaag accatttatt gttttatttc ctggagaaaa 26521 tacatcattt tatcccagcc ttaataaccc atcccagtgt atactccttc atcttcatgg 26581 ataatgaccc tcctacatgc tctgaacaaa tcaggaggcc cctcgtggaa gtataaccag 26641 tcctttcttt ctctgtccct cttctgtgca gagcctctgc attgagaaca gctgcatcgc 26701 ggcccacgac aagaggggga ggtacgggac cctgttcacg atggaccggg tgctgacccc 26761 cccaatgggg actgtcatgg atgtcctgaa gggagacaat cgctttaggt aattagttcc 26821 atccccgggt ggagcttctg cccagtggtc atgctggagt gggatgtggg gccccagcta 26881 tttgtcaagc tttcttctac cttggggatt caattaacac tagcagtgca ctgctgcgac 26941 cttccagact tgggatgggg aaaaggcaag ggtcgccttg aaagcttaca ttgggaagaa 27001 gggttacttc taagagtgta atcttcacat gcatgggaag cagggagggg ggactacatt 27061 tttatgactg aagtgcaagg aaaacatcac cctctcattg taaagctcca agtgagccaa 27121 gagcacatag tttacagtgc acgatgagcc tctcactctc tgcgcagtat ctgtttattg 27181 caactgaagc acccttgtga gtttgtttt ttgcccggct atctccattt ctgacttgct 27241 cattcacctt ggggtgctgt catattgaat gtttccctgt cactgacttc agccacctgc 27301 acaagggctt ggagaccaca cccctctgcc ctcccagaat catatccctg gaggctcagc 27361 tagtctctgg gtcagccata cctctgccct ttcttttccc tcctttctcc tgtggcctct 27421 gacgtctggc catttaacag agcttagcat ttttgctggg tggagagagc tggagcctgg 27481 aatcactccc tctttgtgca tacggagggc atgaaaacca aggtgtgtgc attccagtgg 27541 cctggactct actatcctca gtggtgaggt atttaaggaa aatacctctc agcgtggtga 27601 ggtatttaag gaaaatacct gttgacaggt gacattttct gtgtgtgtat ctacagcatg 27661 ctggtagctg ccatccagtc tgcaggactg acggagaccc tcaaccggga aggagtctac 27721 acagtctttg ctcccacaaa tgaagccttc cgagccctgc caccaagaga acggagcaga 27781 ctcttgggta aagaccaact taagtacacg tctccatttt tctaaagtag tgatccctca 27841 gggccccagc agcaaacagt tcgcacatca aggattgact tgaagggatt ttatgacaag 27901 actattagtg aaagagtggg cgggactaaa ggaactagca aaggatgagg ccaaccaggg 27961 actagcaacc ctgggaagcc tttactaccc ctaggcctgg gggaatggga ggatgagagc 28021 aggaaccagg gaggtcatga gccttggaca agggcacaga acagcagcca gagccatgtg 28081 cagccagcca ctgtcagaac catgcaaggg ggaccactca gcgccccagc ctccctctca 28141 gacagttgcc atctgggtct cttgttggct gatgcgagag caggagggag cccactgatg 28201 cagttcatag agctcagcct cctgggcagg aaaccgggca gagaggagta gaaaagaatt 28261 aagggtggct gcgaccagcc cagtcactga ggcacgtttc ccactggaga cctatgagca 28321 cagtgataat aaagccagtt acctgcactg actatccctc cagacaaaag ctttcccaag 28381 aagttagtca tggctctgag agatctagtt gaggatgttt ggcaggggat ctagtggtta 28441 cgggtggcta agaaaaatga ggaaggtaag agtatcttgc agcctgtgtt gggaggatta 28501 aataggatgc cacacacagg gccaggcaga cagcctggtc agtaatagcc atgacgatgg 28561 gggcgggggg agcaggaatg ggagttgcag tctttagctc agatgcatgc ctgtgagaga 28621 tgcttccact ctcacagaaa gatgagacca aggaaaagga ggaggaagag gaaggacctt 28681 gacaaacctt ggggcccaca ttgtctacac ctcccttcct gctctagagc agaatagaaa 28741 gttcaggttg caggcagctc taagttgaat tcgtgtcctg tttaattttc tttattgcta 28801 aatgaatgcc tgtgtctgtg atgctgacgt atgttcctaa ggagagggga gaagttcatt 28861 ctgaacataa acttttcatc ctctctctgt ccagcaagaa tggaatattc cccaagtggc 28921 ctgagccagc ttggctttct ttttgttttc aattatgtgg gagttgagga gggggatggg 28981 aaaagcttcc caaacacacc ctcccccagg cctgaggcac ccctggggga cagagagtgt 29041 tagaggttgg tacaggtgtt agagatattg aaaggacatc ccatgcaccc caggggctgg 29101 tgtggctctg tacttccagg caatattttg tggaagggga accttgtcag ctccaggttg 29161 tggatgtttg aaaatcagtt ggtacccagt ggctccatcc tctggcaggc atgtggattt 29221 gtcaataacc aagtgaactc tccaaaataa gttaaaactt cctcccttct cagtttcaag 29281 atgctggaaa tagctgttca taagccctgg ggaaatttag ccctttggct ggtaatggga 29341 gtatccgaga tgagagggca gctggaaact ttcggaatga cctcccacac ttaatttggg 29401 aaatgcctct gcacctttat gggcaaccag atgcctgccc cagttgctgg agacactgat 29461 gtgggctgaa aggaatgctg agacgtgacg aggagagatg ctgcggaggg aatatccccc 29521 tcagccctga cctcatcggc tccatggctc ctccacagta cagctgtcta ctcttttaag 29581 ttctcccttc aggaaatagc catctcaaac agaatgtgca tttgagggca gaatgtgtaa 29641 atattgcact actgtgttat aaccgtcagg agccatgctg atgatgaaac gtcccagatg 29701 ccggtgctgg aaaggtccct ggctttccaa gcaaatattt atctcatgga aacatgagtc 29761 atactcacag aggagtatgg attaactcct tctcagcagc cagggagccc agcatcccag 29821 acagcatatt taacccagag gccaactgac tgctggggca gatttgtggt catgaacatg 29881 tgctttgtgt cctctgacca ttagacagat tgtgggtcac aacgttgagt atacagtggg 29941 agcttaataa gtgcttattc cctgggcagg gagttcttca tttcaggggt gaccacttac 30001 atcttctcct ctgggccctc cttgaccagg ctaattacca ttcttgggat taactctatc 30061 tccttttccc gcaacctgca ggagatgcca aggaacttgc caacatcctg aaataccaca 30121 ttggtgatga aatcctggtt agcggaggca tcggggccct ggtgcggcta aagtctctcc 30181 aaggtgacaa gctggaagtc agcttggtaa gtgtcctgca aatcaaaggc tggctaaatt 30241 tccccagggc agggctccag gacatatctc acccccagga tggaattata cacacacaac 30301 cttcaagttg cagcccgaat ctctgagtgt aattcgtcca aagaaaaaga gaaaagagaa 30361 gagggtcttc agggaaatca agtgagatca tagttagaca tgagtaagaa cttccagatt 30421 tacaagggaa tagagcatct gatttggcat ctgagagagg ctattagatc ttccttctct 30481 taaggaggtt gtaggcaact agttatgtga ctgaagagat cagtctgtac tcacaccatc 30541 ccacccccca aacccagggc ttcactgagt tgtaccatga accagaccat cccaagaggc 30601 tttttgagtt ctgacacttg ctctgtgagc cttcccttgc tctgcacatt gatgatataa 30661 ctttgtaact gcactaagag tgttcctaaa gcagatagcc agccgagctc cagaaatctc 30721 cctggctgca cctgcagagg ccactgaccc ctctgtggag ggaccgctct tcagtgtgtg 30781 gctggcttct actctctgct cctctctctt ggtcttcagc catccattgc tcaccagttt 30841 ctcacgagga gcataggaag atatgcatgt agggaggtag gcacggggat gacttgtttg 30901 actttagcag gtcattcaag aatctcctcg cacctggttt cagatgctgg ggtcctgtct 30961 gtcacaggct tctgtgcctc ctaccccctt gagtttgtca catggccctt caggaaggcc 31021 tgagatagat ttgccctggg tgggcctcct atgagaaaat cttaagtgag gcacccaggc 31081 aaaatggaaa gagccttttg cccagagcag gaagcctgtc ttccatttcc agctgttcca 31141 cctacttagc ttaaaagagg cacttcgcct gtcttcagtc tcagtctcag tctcctcttc 31201 tgtggaatgg gacaataata tctactctcc ttatcataca ctgctgtgag gactgagtgg 31261 atcacacaaa aaagcattat gtaaattgca aagtgctaaa tccacacagg agatttgaat 31321 taatccacca cactgaaggt ctgtcaaggg cagggactgt ttcattcacc agagtatccc 31381 cagtctaaca caggacttgg catatgaaaa gtgttcagta ggccgggtgc agtggctcat 31441 gcctgtaatc ccagcacttt gggaggccaa agtgggcgga tcatctgagg tcaggagttc 31501 aagtccagcc tcgccaacgt ggtgaaacca catctctact aaaaatacaa aattagctgg 31561 gcgtggtggc acatgcctgt aatcacagct actctggagg ctgaggcagg agaatcactt 31621 gaacccagga ggcggaggtt gcagtgagtc gagatcatgc cactgcactc cagcctgggc 31681 gacaagattg aaactccatc tcaaaaacaa agaacaagga aaaaaacgaa aactgttcag 31741 taaacacttg ctgaatgaat aaaataaata tataaatgta taaataaatg ctctactttc 31801 aaccactact ctgtttttct tttagaaaaa caatgtggtg agtgtcaaca aggagcctgt 31861 tgccgagcct gacatcatgg ccacaaatgg cgtggtccat gtcatcacca atgttctgca 31921 gcctccaggt aagtgtcgca tccccactga ctctgcagcc agtccttttc ttcatgtggc 31981 agttggtgga gagaagaaaa actgttctaa acaatgatga gaataacatg taattgtgat 32041 agttaaactg tgcctatgtg actgattgca gagtgaattg ggagctgttg gttttgaatg 32101 caccacacta aggaatgtga ggacacattg ctctttgcgg agttgcccag ctatattagc 32161 tcccctcgga cacagcccag ttttctgtat tcgcgtggat gctgtccgcg cgattcccag 32221 cactcctctt acagcatctc acctcagtgt atgttccttg cctccagtgc agttgaacct 32281 cagtcctgcc tctcctcatg tgtgcattca cctttcttgg tgctctctcc ccatgggcca 32341 agttctacca tgagttatga aacattatgg agaaaacatg tctttggaaa tgtgagccag 32401 aaagcccacc agtgcccctc agtcacggtt gttatgaatg acatgctaat ggtttcactc 32461 tcgtcaaacc tgccttttct ttcctcttca gccaacagac ctcaggaaag aggggatgaa 32521 cttgcagact ctgcgcttga gatcttcaaa caagcatcag cgttttccag ggtaagatgc 32581 ctgctaggtt tgcgcctagc ctgagcagcc tcaggtcctc tgtttgggcc atagaggagc 32641 ctctccagcc cctgtcttcc ttggctgctc cccagggctc tcttaaaact tctccccact 32701 cccactgagg catcctcagc cccagcctgt gtcaaattca gagtaaagaa ccaaggcaac 32761 tccctggctt tcatgggcca aagcgcaggc tttcacaccg aggcctctga gcctcagatc 32821 atggggaagt cactgctgga gagaacagac atagctctgg aagccatctg cccaagaggg 32881 cagcccatcc caagttcatc ttacagtggc caggcctgcc ctgagccggg gcctctgggt 32941 cactcttctg ctgtccatgg cattgcccat cctgggtgag gctggggctc tcctgggcac 33001 tgtatgtatt ctggatacag ggatactggg ctcgctatgt gtgtggagcc atcccttcct 33061 tgccccagcc ccacctccct ctcaaaccct ctctggctct ttctgagctt cctttcctgc 33121 tccccagctt gcccagtgct cagtgcccca cttggctctt ttgctacttc gggtcaggtg 33181 gagcctcttg ggaatgtgaa gtgccttaca gaaagattgc acttcaagag gagaggctgc 33241 agggagccat cctaaaccca gaggcctgga gcttactgtg tcactttact tttgtacaca 33301 ggggtctcct tagtgccctc gagaaggatt cttggccctg agcttctact cctgaggcca 33361 cctctgtgca gccccagctc cctcaactct aggctgtagt ctcagtggga aagcctggct 33421 tgggggtctc ctaggaatgt ccacctgaag gcacacttga taggggcttg cacaacttat 33481 gtctgccaag gccacctgag gaactccctg gtgcctataa gttccacctt ccccttcctc 33541 ttcctcgccc cagcattttt tctgagtagg ggtggcaatg ggcaaagcca ttgtcataag 33601 cagttgcagg tataactttc actagaaaac ctgacacctt gtgttttctt tcaggcttcc 33661 cagaggtctg tgcgactagg tgagtctggt ctgggtttga agtcattgca gacctgttta 33721 ggccttaccc ccaagcaagc ccaagcctgc catctgctgt atatagataa gaacatcatg 33781 gtgcagtaaa agaagcctgg cctttggagt cagaacagca gggtgacttg gggtcagacc 33841 cagagcaccc catttccttc tctgtaagat gaggataata agagtaacaa ccttttaggg 33901 ttaaggtgag ttttcagctt aggaagtctg ggaatattgc aaagggcttg gcaggaaccc 33961 atggtgagga tctagttcca agttgatagg tacagaaaac cagaacatcg ggccttgagt 34021 aaagagtgaa gtttcacaaa ccacaaagca cctgctatgt gcaggagagc atggcagaag 34081 gaggctgctt ggccctggtc cttgagattc tgacagtgtc ctagacagac atggggagat 34141 ctgcacctat ttgacgttac caacttctct ttttcagccc ctgtctatca aaagttatta 34201 gagaggatga agcattagct tgaagcacta caggaggaat gcaccacggc agctctccgc 34261 caatttctct cagatttcca cagagactgt ttgaatgttt tcaaaaccaa gtatcacact 34321 ttaatgtaca tgggccgcac cataatgaga tgtgagcctt gtgcatgtgg gggaggaggg 34381 agagagatgt actttttaaa tcatgttccc cctaaacatg gctgttaacc cactgcatgc 34441 agaaacttgg atgtcactgc ctgacattca cttccagaga ggacctatcc caaatgtgga 34501 attgactgcc tatgccaagt ccctggaaaa ggagcttcag tattgtgggg ctcataaaac 34801 aagaaacata caatccagcc tcatgggaag tcctggcaca gtttttgtaa agcccttgca 34561 atgaatcaag aatggcatca ttataagcta tgagttgaaa tgttctgtca aatgtgtctc 34621 cagctggaga gtggcttgga ggcttttatg gggccctgtc caggtagaaa agaaatggta 34681 acatctacac agatttccct attgtgacag agccatggtg tgtttgtaat aataaaacca 34741 tgtagagctt TGFβI gene protein product (βIG-H3 protein sequence; NCBI Reference number NG 012646.1): MALFVRLLALALALALGPAATLAGPAKSPYQLVLQHSRLRGRQH GPNVCAVQKVIGTNRKYFTNCKQWYQRKICGKSTVISYECCPGYEKVPGEKGCPAALP LSNLYETLGVVGSTTTQLYTDRTEKLRPEMEGPGSFTIFAPSNEAWASLPAEVLDSLV SNVNIELLNALRYHMVGRRVLTDELKHGMTLTSMYQNSNIQIHHYPNGIVTVNCARLL KADHHATNGVVHLIDKVISTITNNIQQIIEIEDTFETLRAAVAASGLNTMLEGNGQYT LLAPTNEAFEKIPSETLNRILGDPEALRDLLNNHILKSAMCAEAIVAGLSVETLEGTT LEVGCSGDMLTINGKAIISNKDILATNGVIHYIDELLIPDSAKTLFELAAESDVSTAI DLFRQAGLGNHLSGSERLTLLAPLNSVFKDGTPPIDAHTRNLLRNHIIKDQLASKYLY HGQTLETLGGKKLRVFVYRNSLCIENSCIAAHDKRGRYGTLFTMDRVLTPPMGTVMDV LKGDNRFSMLVAAIQSAGLTETLNREGVYTVFAPTNEAFRALPPRERSRLLGDAKELA NILKYHIGDEILVSGGIGALVRLKSLQGDKLEVSLKNNVVSVNKEPVAEPDIMATNGV VHVITNVLQPPANRPQERGDELADSALEIFKQASAFSRASQRSVRLAPVYQKLLERMK H
Claims (11)
1.-19. (canceled)
20. A reaction mixture for detecting corneal dystrophy in a human subject, the reaction mixture comprising:
(A) at least a first amplification primer pair for amplifying and determining a first TGFβI gene sequence from a biological sample from the subject; and
(B) a first set of at least three detection probes including a first detection probe comprising the sequence of SEQ ID NO:45 or 47, a second detection probe comprising the sequence of SEQ ID NO:46 and a third detection probe comprising the sequence of SEQ ID NO:50.
21. The reaction mixture according to claim 20 , further comprising a second set of detection probes including a fourth detection probe comprising the sequence of SEQ ID NO:25 and one or two detection probes selected from a group consisting of a fifth detection probe comprising the sequence of SEQ ID NO:26, a sixth detection probe comprising the sequence of SEQ ID NO:48 and a seventh detection probe comprising the sequence of SEQ ID NO:49, and at least a second amplification primer pair for amplifying and determining a second TGFβI gene sequence from the biological sample from the subject.
22. The reaction mixture according to claim 20 , wherein the first amplification primer pair comprises a first amplification primer and a second amplification primer, the first amplification primer comprises nucleotide sequence SEQ ID NO:43, and the second amplification primer comprises nucleotide sequence SEQ ID NO:44.
23. The reaction mixture according to claim 20 , wherein the first TGFβI gene sequence comprises nucleotides encoding amino acid residue 555 from the biological sample from the subject.
24. The reaction mixture according to claim 21 , wherein the first TGFβI gene sequence comprises nucleotides encoding amino acid residue 555 from the biological sample from the subject and the second TGFβI gene sequence comprises nucleotides encoding amino acid residue 124 from the biological sample from the subject.
25. The reaction mixture according to claim 24 , wherein the first amplification primer pair comprises a first amplification primer and a second amplification primer, the first amplification primer comprises nucleotide sequence SEQ ID NO:43, and the second amplification primer comprises nucleotide sequence SEQ ID NO:44, and the second amplification primer pair comprises a third amplification primer and a fourth amplification primer, the third amplification primer comprises a nucleotide sequence SEQ ID NO:1, and the fourth amplification primer comprises a nucleotide sequence SEQ ID NO:2.
26. A method for detecting whether or not a human subject carries a mutation that causes corneal dystrophy comprising:
(A) amplifying a first TGFβI gene sequence from a biological sample from the subject using a reaction mixture comprising at least a first amplification primer pair for amplifying a TGFβI gene sequence and a set of at least three detection probes including a first detection probe comprising the sequence of SEQ ID NO:45 or 47, a second detection probe comprising the sequence of SEQ ID NO:46 and a third detection probe comprising the sequence of SEQ ID NO:50;
(B) hybridizing one detection probe of the set of at least three detection probes to the first TGFβI gene sequence; and
(C) detecting whether or not a mutation in the first TGFβI gene sequence based on (i) the hybridization of the one detection probe of the set of at least three detection probes that has hybridized in step (B) to the first TGFβI gene sequence and (ii) the failure of the other two detection probes of the set of at least three detection probes to hybridize to the first TGFβI gene sequence.
27. The method according to claim 26 , wherein the reaction mixture comprises:
(A) at least a first amplification primer pair for amplifying and determining a first TGFβI gene sequence from a biological sample from the subject; and
(B) a first set of at least three detection probes including a first detection probe comprising the sequence of SEQ ID NO:45 or 47, a second detection probe comprising the sequence of SEQ ID NO:46 and a third detection probe comprising the sequence of SEQ ID NO:5
28. A method for detecting whether or not a human subject carries a genomic mutation associated with corneal dystrophy in a sample from the subject, the method comprising:
(A) using epithelial cells of the subject adhered to a tip of a substrate;
(B) agitating the tip of the substrate in a lysis solution that lyses cells adhered to the substrate;
(C) removing the substrate from the lysis solution upon completion of the agitating (B);
(D) incubating the lysis solution after the removing (C);
(E) isolating genomic DNA from the lysis solution to form a gDNA solution; and
(F) determining an identity of at least a nucleotide present in the TGFβI gene using at least a first primer pair for amplifying a TGFβI gene sequence, a first set of at least three detection probes including a first detection probe comprising the sequence of SEQ ID NO:45 or 47, a second detection probe comprising the sequence of SEQ ID NO:46 and a third detection probe comprising the sequence of SEQ ID NO:50, and the gDNA solution by concurrently exposing the gDNA solution to the first set of at least three detection probes, wherein:
the at least a nucleotide is located at a particular position of the TGFβI gene corresponding to a single nucleotide polymorphism (SNP) associated with corneal dystrophy.
29. The method according to claim 28 , further comprising:
(G) determining an identity of at least a second nucleotide present in the TGFβI gene using at least a second primer pair, a second set of detection probes including a fourth detection probe comprising the sequence of SEQ ID NO:25 and one or two detection probes selected from a group consisting of a fifth detection probe comprising the sequence of SEQ ID NO:26, a sixth detection probe comprising the sequence of SEQ ID NO:48 and a seventh detection probe consisting of the sequence of SEQ ID NO:49, and the gDNA solution by concurrently exposing the gDNA solution to the second set of detection probes, wherein:
the at least second nucleotide is located at a second particular position, independent of the position of the at least a nucleotide, of the TGFβI gene corresponding to a second single nucleotide polymorphism (SNP) associated with corneal dystrophy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/064,444 US20230348984A1 (en) | 2013-11-15 | 2022-12-12 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361905051P | 2013-11-15 | 2013-11-15 | |
PCT/US2014/065975 WO2015073978A2 (en) | 2013-11-15 | 2014-11-17 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
US15/154,895 US11525160B2 (en) | 2013-11-15 | 2016-05-13 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
US18/064,444 US20230348984A1 (en) | 2013-11-15 | 2022-12-12 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/154,895 Continuation US11525160B2 (en) | 2013-11-15 | 2016-05-13 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230348984A1 true US20230348984A1 (en) | 2023-11-02 |
Family
ID=53058284
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/154,895 Active US11525160B2 (en) | 2013-11-15 | 2016-05-13 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
US18/064,444 Abandoned US20230348984A1 (en) | 2013-11-15 | 2022-12-12 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/154,895 Active US11525160B2 (en) | 2013-11-15 | 2016-05-13 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
Country Status (9)
Country | Link |
---|---|
US (2) | US11525160B2 (en) |
EP (2) | EP3068908B1 (en) |
JP (2) | JP6672147B2 (en) |
KR (3) | KR102293785B1 (en) |
CN (2) | CN113604551A (en) |
AU (2) | AU2014348279B2 (en) |
SG (1) | SG10201804076RA (en) |
TW (3) | TWI755350B (en) |
WO (1) | WO2015073978A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101251538B1 (en) | 2009-04-17 | 2013-04-08 | (주)아벨리노 | Primer for Avellino Corneal Dystrophy |
KR101125212B1 (en) | 2010-10-01 | 2012-03-21 | (주)아벨리노 | System for diagnosis of avellino corneal dystrophy |
KR20210037750A (en) * | 2013-03-15 | 2021-04-06 | 아벨리노 랩 유에스에이, 인크. | Methods for improved isolation of genomic dna templates for allele detection |
US10889850B2 (en) | 2013-03-15 | 2021-01-12 | Avellino Lab Usa, Inc. | Methods for improved isolation of genomic DNA templates for allele detection |
AU2014348279B2 (en) | 2013-11-15 | 2021-02-18 | Avellino Lab Usa, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
EP4036228A1 (en) * | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
CN106480200A (en) * | 2016-10-25 | 2017-03-08 | 北京亿昊基因技术有限公司 | A kind of detection method with corneal dystrophy associated gene mutation site rapidly and efficiently |
CN108085375B (en) * | 2016-11-07 | 2020-10-16 | 北京华大通瀛科技有限公司 | Method for detecting genotype of corneal dystrophy gene polymorphism site and kit thereof |
WO2018191304A1 (en) * | 2017-04-10 | 2018-10-18 | Avellino Lab Usa, Inc. | Methods for multiplex detection of alleles associated with corneal dystrophy |
CN107523635A (en) * | 2017-10-09 | 2017-12-29 | 湖南大地同年生物科技有限公司 | A kind of TGFBI gene pleiomorphisms quick detection kit and its detection method |
CN107858420A (en) * | 2017-11-17 | 2018-03-30 | 奥斯汀生命科学技术公司 | Cause the primed probe and detection method of corneal dystrophy for diagnosing the Mutation of people TGF β I genes 124 |
KR200487603Y1 (en) | 2018-02-01 | 2018-12-05 | 백병하 | Air Filter Apparatus For Electric Fan |
CN108796062A (en) * | 2018-06-06 | 2018-11-13 | 无锡正则精准医学检验有限公司 | A kind of kit of detection TGFBI gene pleiomorphisms |
CN109406469B (en) * | 2018-10-24 | 2021-04-09 | 中国医科大学 | Method for detecting tryptophan based on protein binding induced DNA double-strand allosteric |
KR102241836B1 (en) * | 2019-06-14 | 2021-04-21 | 솔젠트 (주) | Genetic polymorphism testing using dual check oligo |
CN113999899A (en) * | 2020-07-28 | 2022-02-01 | 首都医科大学附属北京同仁医院 | Kit for detecting TGFBI gene mutation |
CN115820837A (en) * | 2022-11-04 | 2023-03-21 | 温州谱希基因科技有限公司 | PCR (polymerase chain reaction) detection kit for corneal dystrophy and application thereof |
CN117417997A (en) * | 2023-10-26 | 2024-01-19 | 上海谱希和光基因科技有限公司 | Genome biomarker combination for diagnosing keratoconus |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
ATE295427T1 (en) | 1996-06-04 | 2005-05-15 | Univ Utah Res Found | MONITORING HYBRIDIZATION DURING PCR |
US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
US6018713A (en) | 1997-04-09 | 2000-01-25 | Coli; Robert D. | Integrated system and method for ordering and cumulative results reporting of medical tests |
JP3380744B2 (en) | 1998-05-19 | 2003-02-24 | 株式会社日立製作所 | Sensor and measuring device using the same |
GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
US6171112B1 (en) | 1998-09-18 | 2001-01-09 | Wyngate, Inc. | Methods and apparatus for authenticating informed consent |
WO2000058509A2 (en) | 1999-03-29 | 2000-10-05 | Genset | Prostate cancer associated human fibronectin gene and biallelic markers |
US6270970B1 (en) | 1999-05-14 | 2001-08-07 | Promega Corporation | Mixed-bed solid phase and its use in the isolation of nucleic acids |
ATE381626T1 (en) | 2000-04-13 | 2008-01-15 | Univ Georgetown | GENETIC DIAGNOSIS TO DETERMINE QT PROLONGATION AS AN ADVERSE REACTION TO DRUGS |
US8438042B2 (en) | 2002-04-25 | 2013-05-07 | National Biomedical Research Foundation | Instruments and methods for obtaining informed consent to genetic tests |
JP2005511013A (en) | 2001-08-09 | 2005-04-28 | キュラジェン コーポレイション | Nucleic acids, polypeptides, single nucleotide polymorphisms, and methods of use thereof |
WO2003046526A1 (en) | 2001-11-28 | 2003-06-05 | Graffinity Pharmaceuticals Ag | Surface plasmon resonance (spr) sensor surface support |
US6943417B2 (en) | 2003-05-01 | 2005-09-13 | Clemson University | DNA-based memory device and method of reading and writing same |
US20050019757A1 (en) | 2003-06-12 | 2005-01-27 | Stolarchuk Danylo J. | Contaminant detection apparatus |
JP4229394B2 (en) | 2003-08-06 | 2009-02-25 | 日本電信電話株式会社 | Molecule detection method using porous material, porous material and method for producing porous material |
CA2544129A1 (en) | 2003-10-22 | 2005-05-06 | The Regents Of The University Of California | Methods for preparing and functionalizing nanoparticles |
JP2007512807A (en) | 2003-10-28 | 2007-05-24 | バイエル ヘルスケア アーゲー | Methods and compositions for predicting response to treatment of malignant tumors |
EP1541528A1 (en) | 2003-12-08 | 2005-06-15 | Institut Jozef Stefan | Quasi-one-dimensional polymers based on the metal-chalcogen-halogen system |
US20060057604A1 (en) | 2004-03-15 | 2006-03-16 | Thinkfar Nanotechnology Corporation | Method for electrically detecting oligo-nucleotides with nano-particles |
AU2005246415B8 (en) | 2004-05-19 | 2011-09-01 | Vp Holding, Llc | Optical sensor with layered plasmon structure for enhanced detection of chemical groups by SERS |
US7713849B2 (en) | 2004-08-20 | 2010-05-11 | Illuminex Corporation | Metallic nanowire arrays and methods for making and using same |
US7332329B2 (en) | 2004-09-24 | 2008-02-19 | Wisconsin Alumni Research Foundation | Versatile substrate for SPR detection |
JP2008533000A (en) | 2005-03-08 | 2008-08-21 | メディジーンズ カンパニー リミテッド | Pharmaceutical composition for treating Avellino corneal dystrophy comprising an antibody against TGF-β |
JP2006250668A (en) | 2005-03-10 | 2006-09-21 | Tatsuro Endo | Non-labelled biochip |
EP1715326A1 (en) | 2005-04-22 | 2006-10-25 | Universität Heidelberg | Sensor chip with connected non-metallic particles comprising a metallic coating |
US20070154903A1 (en) | 2005-06-23 | 2007-07-05 | Nanosphere, Inc. | Selective isolation and concentration of nucleic acids from complex samples |
KR20070076532A (en) * | 2006-01-18 | 2007-07-24 | 메디제네스(주) | Dna chip for diagnosis of corneal dystrophy |
CN101374850A (en) * | 2006-01-18 | 2009-02-25 | 株式会社美迪基尼斯 | DNA chip for diagnosis of corneal dystrophy |
MX2008012026A (en) | 2006-03-21 | 2008-11-04 | Univ Washington | Genetic polymorphisms in the corticotropin-releasing hormone(crh) gene as markers for improving beef marbling score and/or subcutaneous fat depth. |
EP1932922A1 (en) | 2006-12-13 | 2008-06-18 | Desitin Arzneimittel GmbH | In situ hybridisation detection of DNA squences |
WO2008089280A2 (en) * | 2007-01-16 | 2008-07-24 | Applied Biosystems, Llc | Selective lysis of sperm cells |
US7898658B2 (en) | 2007-01-23 | 2011-03-01 | The Regents Of The University Of California | Platform for chemical and biological sensing by surface-enhanced Raman spectroscopy |
KR100891096B1 (en) | 2007-02-13 | 2009-03-31 | 삼성전자주식회사 | Oligomer probe array and method of fabricating the same |
JP5222599B2 (en) | 2007-07-20 | 2013-06-26 | 株式会社日立ハイテクノロジーズ | Nucleic acid analysis device and nucleic acid analysis apparatus using the same |
CN101144812B (en) | 2007-10-17 | 2012-02-22 | 中国科学院光电技术研究所 | Method for manufacturing local surface plasma biochemical sensor |
US20120231537A1 (en) | 2008-04-30 | 2012-09-13 | Gradalis, Inc. | Highly Pure Plasmid DNA Preparations |
KR101251538B1 (en) * | 2009-04-17 | 2013-04-08 | (주)아벨리노 | Primer for Avellino Corneal Dystrophy |
KR101041606B1 (en) * | 2009-08-18 | 2011-06-15 | (주)아벨리노 | Multi-Spot Metal-Capped Nanostructure Array Nucleic Acid Chip for Diagnosis of Corneal Dystrophy and Preparing Method Thereof |
US8865402B2 (en) | 2009-08-26 | 2014-10-21 | Clemson University Research Foundation | Nanostructured substrates for surface enhanced raman spectroscopy (SERS) and detection of biological and chemical analytes by electrical double layer (EDL) capacitance |
KR20110037379A (en) * | 2009-10-06 | 2011-04-13 | 주식회사 크라운진 | Method and kit for detecting avellino corneal dystrophy using real-time pcr and high resolution melting analysis |
KR101125212B1 (en) * | 2010-10-01 | 2012-03-21 | (주)아벨리노 | System for diagnosis of avellino corneal dystrophy |
AU2014348279B2 (en) | 2013-11-15 | 2021-02-18 | Avellino Lab Usa, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
CN111206032A (en) | 2013-12-12 | 2020-05-29 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing |
-
2014
- 2014-11-17 AU AU2014348279A patent/AU2014348279B2/en active Active
- 2014-11-17 KR KR1020167015852A patent/KR102293785B1/en active IP Right Grant
- 2014-11-17 CN CN202110622983.2A patent/CN113604551A/en active Pending
- 2014-11-17 KR KR1020217024701A patent/KR102483783B1/en active IP Right Grant
- 2014-11-17 CN CN201480072417.7A patent/CN105899681B/en active Active
- 2014-11-17 SG SG10201804076RA patent/SG10201804076RA/en unknown
- 2014-11-17 TW TW103139861A patent/TWI755350B/en active
- 2014-11-17 WO PCT/US2014/065975 patent/WO2015073978A2/en active Application Filing
- 2014-11-17 JP JP2016531678A patent/JP6672147B2/en active Active
- 2014-11-17 KR KR1020227046070A patent/KR20230007558A/en not_active Application Discontinuation
- 2014-11-17 EP EP14862501.5A patent/EP3068908B1/en active Active
- 2014-11-17 TW TW112128794A patent/TW202346604A/en unknown
- 2014-11-17 TW TW111108208A patent/TWI812047B/en active
- 2014-11-17 EP EP21150206.7A patent/EP3872192A1/en active Pending
-
2016
- 2016-05-13 US US15/154,895 patent/US11525160B2/en active Active
-
2019
- 2019-10-04 JP JP2019183365A patent/JP7077289B2/en active Active
-
2021
- 2021-05-06 AU AU2021202884A patent/AU2021202884B2/en active Active
-
2022
- 2022-12-12 US US18/064,444 patent/US20230348984A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201610167A (en) | 2016-03-16 |
KR102293785B1 (en) | 2021-08-26 |
CN105899681B (en) | 2021-06-22 |
JP6672147B2 (en) | 2020-03-25 |
KR20210099204A (en) | 2021-08-11 |
US11525160B2 (en) | 2022-12-13 |
WO2015073978A2 (en) | 2015-05-21 |
JP7077289B2 (en) | 2022-05-30 |
TW202346604A (en) | 2023-12-01 |
EP3872192A1 (en) | 2021-09-01 |
KR20160079117A (en) | 2016-07-05 |
TW202223098A (en) | 2022-06-16 |
AU2014348279A9 (en) | 2016-07-28 |
KR102483783B1 (en) | 2022-12-30 |
TWI812047B (en) | 2023-08-11 |
CN105899681A (en) | 2016-08-24 |
EP3068908B1 (en) | 2021-01-06 |
AU2014348279B2 (en) | 2021-02-18 |
US20160319357A1 (en) | 2016-11-03 |
SG10201804076RA (en) | 2018-06-28 |
WO2015073978A9 (en) | 2016-06-23 |
AU2021202884B2 (en) | 2023-04-06 |
CN113604551A (en) | 2021-11-05 |
EP3068908A2 (en) | 2016-09-21 |
JP2017501685A (en) | 2017-01-19 |
JP2020039339A (en) | 2020-03-19 |
AU2021202884A1 (en) | 2021-06-03 |
KR20230007558A (en) | 2023-01-12 |
AU2014348279A1 (en) | 2016-06-09 |
EP3068908A4 (en) | 2017-08-23 |
WO2015073978A3 (en) | 2015-07-16 |
TWI755350B (en) | 2022-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230348984A1 (en) | Methods for multiplex detection of alleles associated with ophthalmic conditions | |
US11905560B2 (en) | Methods for multiplex detection of alleles associated with corneal dystrophy | |
US20210115499A1 (en) | Methods for Improved Isolation of Genomic DNA Templates for Allele Detection | |
US9856516B2 (en) | Methods for improved isolation of genomic DNA templates for allele detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVELLINO LAB USA, INC.,, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAO-SHERN, CONNIE;CHO, SUN-YOUNG;LEE, GENE;SIGNING DATES FROM 20141113 TO 20141115;REEL/FRAME:067308/0761 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION) |